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A B S T R A C T
Background
Parenteral opioids are used for pain relief in labour in many countries throughout the world.
Objectives
To assess the acceptability, effectiveness and safety of different types, doses and modes of administration of parenteral opioids given to
women in labour.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 April 2011) and reference lists of retrieved studies.
Selection criteria
We included randomised controlled trials examining the use of intramuscular or intravenous opioids (including patient controlled
analgesia) for women in labour. We looked at studies comparing an opioid with another opioid, placebo, other non-pharmacological
interventions (TENS) or inhaled analgesia.
Data collection and analysis
At least two review authors independently assessed study eligibility, collected data and assessed risk of bias.
Main results
We included 57 studies involving more than 7000 women that compared an opioid with placebo, another opioid administered
intramuscularly or intravenously or compared with TENS to the back. The 57 studies reported on 29 different comparisons, and for
many outcomes only one study contributed data. Overall, the evidence was of poor quality regarding the analgesic effect of opioids,
satisfaction with analgesia, adverse effects and harm to women and babies. There were few statistically significant results. Many of the
studies had small sample sizes, and low statistical power. Overall findings indicated that parenteral opioids provided some pain relief
and moderate satisfaction with analgesia in labour, although up to two-thirds of women who received opioids reported moderate or
severe pain and/or poor or moderate pain relief one or two hours after administration. Opioid drugs were associated with maternal
nausea, vomiting and drowsiness, although different opioid drugs were associated with different adverse effects. There was no clear
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evidence of adverse effects of opioids on the newborn. We did not have sufficient evidence to assess which opioid drug provided the
best pain relief with the least adverse effects.
Authors’ conclusions
Parenteral opioids provide some relief from pain in labour but are associated with adverse effects. Maternal satisfaction with opioid
analgesia was largely unreported but appeared moderate at best. This review needs to be examined alongside related Cochrane reviews
examining pain management in labour. More research is needed to determine which analgesic intervention is most effective, and
provides greatest satisfaction to women with acceptable adverse effects for mothers and their newborn.
P L A I N L A N G U A G E S U M M A R Y
The use of opioid intramuscular and intravenous pain relieving drugs in labour
Pain during labour is normal and its management is influenced by an interaction between a woman’s mental and emotional state and
the physiological changes that occur during labour. The use of pain-relieving drugs during labour is now part of standard care in many
countries throughout the world. In recent years, many women in Western countries have chosen to have epidural analgesia to relieve
pain. However, some women prefer not to have an epidural, or in some settings an epidural is not available. In many maternity units
intramuscular injections of opioid drugs are widely used for pain relief in labour and options for intravenous infusions may also be
available. The opioid drugs used include pethidine (also known as meperidine or demerol), diamorphine, nalbuphine, butorphanol,
meptazinol, pentazocine, fentanyl and tramadol, and are relatively inexpensive. It is not clear how effective these drugs are, which opioid
is best, and how unpleasant side effects (such as vomiting or sleepiness) or harm to women or their babies can be avoided.
We included 57 randomised controlled trials involving more than 7000 women that compared an opioid with placebo, another opioid
or transcutaneous electrical nerve stimulation (TENS). Overall, our findings indicated that opioids provided some pain relief during
labour, although substantial proportions of women still reported moderate or severe pain. Opioid drugs were associated with nausea,
vomiting and drowsiness, and different types of opioids were associated with different side effects. There was no clear evidence of
adverse effects of opioids on the newborn. Maternal satisfaction with opioid analgesia was largely unreported but appeared moderate.
We did not have sufficient evidence to assess which opioid drug women were most satisfied with, or which provided the best pain relief
with the least side effects for mothers and babies.
In this review the 57 studies reported on 29 different comparisons, and for many outcomes only one study contributed data. We did
not examine the effectiveness and safety of intramuscular or intravenous (parenteral) opioids compared with other pharmacological
methods of pain relief in labour (such as epidural analgesia) and this review needs to be examined alongside related Cochrane reviews.
As parenteral opioid drugs are so widely used it is important that more research is carried out so that women can make informed choices
about these forms of pain relief.
B A C K G R O U N D
This review is one in a series of Cochrane reviews examining pain
management in labour. These reviews contribute to an overview
of systematic reviews of pain management for women in labour
(Jones 2011b) and share a generic protocol (Jones 2011a).
Description of the condition
Pain during labour is normal, being one of the few examples of
pain which does not signal pathology or harm. This does not make
the experience of pain any less, but it may alter the way pain is
perceived, both by the woman in labour and those providing care.
Characteristics of labour pain
Pain during labour is intermittent, accompanying uterine con-
tractions (Findley 1999). Characteristically the pain intensifies as
the contraction increases, reaching a peak when the contraction
is at its strongest, then diminishing as the uterus relaxes. Between
contractions the uterus is at rest and there is usually no associated
pain. As labour progresses the uterine contractions grow stronger,
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more frequent and longer lasting; at the same time they become
more painful. Typically the strongest, most frequent, and most
painful, uterine contractions occur at the end of the first stage of
labour as the cervix reaches full dilatation. While the vast majority
of women will describe at least some stages of labour as painful,
the severity of reported pain varies considerably (Findley 1999).
Pain relief in labour - physiology and pain perceptions
Labour pain as perceived by women is a unique, subjective and
complex neuro-hormonal phenomenon, which involves the inter-
action of physiological and psychological factors (Genesi 1998a;
Genesi 1998b; Trout 2004). Several factors have been shown to
reduce pain experienced by women in labour. These include con-
tinuous support of a caregiver, attendance of a birth companion
and a relaxed birth environment (Hodnett 2002). Two other key
determinants that may influence the pain level that a woman ex-
periences are feeling in control of her behaviour, and the care she
receives. The extent to which a woman can actively participate in
negotiating the care she receives has also been linked to overall
maternal satisfaction with the childbirth experience (Green 2003;
Hodnett 2002). The degree to which a woman is satisfied with the
birth experience is not, therefore, solely associated with the pain
felt. Having more control will foster a woman’s sense of self-belief
and confidence in her capacity to labour and give birth, which will
also affect her pain perception (Lowe 1993; Lowe 1996). From
the clinical point of view, the management of pain during labour
involves much more than simply the provision of a pharmacologi-
cal intervention. Related Cochrane reviews have demonstrated the
value of continuous support, midwifery models and non-phar-
macological approaches to managing pain in labour (Barragán
2011; Cluett 2009; Dowswell 2009; Hatem 2008; Hodnett 2007;
Hunter 2007).
A caregiver’s perception of a woman’s labour pain may be different
from what the woman is actually experiencing (Callister 1995).
A large UK survey that collected maternal and midwifery assess-
ments of pain relief found that midwives rated pethidine more
positively than the women who received it (Chamberlain 1993).
Practitioners’ attitudes tomaternal pain vary (Leap 2004), wherein
some adopt a rescue position to relieve the pain and recommend
the use of analgesia, whilst others facilitate the woman to optimise
coping mechanisms, using strategies involving breathing and/or
relaxation techniques and positions that offer her more comfort.
Women’s attitudes towards, and preferences for, intrapartum pain
relief vary widely.Whilst somewomen prefer to labour without the
use of pharmacological analgesia, others opt, for example, to use
epidural analgesia throughout labour. Good communication and
sensitive support from caregivers improves a woman’s experience
of labour, and her overall satisfaction with care, regardless of her
choice of pain relief or levels of reported pain (Hodnett 2002). It
is important that decisions for coping with the pain of labour are
based on informed choice (Green 2003; Hawkins 2003).
Pain relief in labour - the use of opioids
The use of pain-relieving drugs during labour is now standard care
in many countries throughout the world (Findley 1999; Reynolds
2000). The extent of usage of parenteral opioids during labour is
unclear; however,most obstetric units in developed countries offer
intramuscular opioids, along with facilities for epidural analgesia.
Opioids are relatively inexpensive, and use of the opioid drugs
pethidine, meptazinol or diamorphine during labour is common
midwifery and obstetric practice in some countries. In other parts
of the world, parenteral opioids commonly used in labour include
morphine, nalbuphine, fentanyl and more recently remifentanil
(Evron 2007). Worldwide, pethidine is the most commonly used
opioid (Bricker 2002). In the UK, a midwife can take respon-
sibility for giving a woman an intramuscular injection of either
pethidine or diamorphine, without a prescription from a medical
practitioner, whether she is working in the hospital or community
care setting (MHRA 2007).
In the UK, estimates for opioid use showed that 34% of women
overall used pethidine or another opioid during labour, with
variation between NHS Hospital Trusts between 5% and 66%
(Healthcare Commission 2007). A survey of 4800 women re-
ported that 32.9%used pethidine or another opioid, and 10.5%of
these women also had an epidural (Redshaw 2007). The use of an
opioid varied by parity, with more nulliparae reporting use (with
or without an epidural) compared with multiparous women. Use
of pethidine in the UK has declined from 42% in 1995 to 33%
in 2006, yet the proportion of women who received an epidural
has changed little over this time period: 27% in 1995 and 28%
in 2006 (Redshaw 2007). In the USA, 39% to 56% of women
received an opioid during labour (Hawkins 1999). Studies in New
Zealand and the UK have revealed that more than 95% of hospi-
tals surveyed routinely offered intramuscular pethidine (Lee 2004;
Saravanakumar 2007). In theUK study, approximately half (49%)
of the units surveyed offered patient-controlled intravenous opi-
oid analgesia for use in labour (Saravanakumar 2007).
Some maternity practitioners have voiced concerns about the use
of parenteral opioid analgesia during labour. These centre ondoubt
about analgesic effectiveness, and anxiety about the sedative effects
on women and babies. Concerns relating to maternal outcomes
include an impaired capacity to engage in decision making about
care, nausea and/or vomiting, and the slowing down of gastric
emptying, which increases the risk of inhalation of gastric contents
should a general anaesthetic be required in an emergency situation.
If a woman feels drowsy or sedated, she is less likely to mobilise
and adopt an upright position, and as a result this may lengthen
her labour, and make it more painful (Lawrence 2009).
Effects on the baby
Opioids readily cross the placenta by passive diffusion. It is es-
timated that it can take a newborn three to six days to elimi-
nate pethidine, and its metabolite, norpethidine, from its system
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(Hogg 1977). Pethidine has been shown to significantly affect fetal
heart rate variability, accelerations and decelerations during labour
(Sekhavat 2009; Solt 2002). Changes in normal fetal heart indices
have consequences for the woman. She will be required to have
electronic fetal heart rate monitoring (EFM) if she is in hospital,
and transfer to hospital if she is in a community setting. Results
from observational studies have reported effects of opioids on the
newborn that include inhibited sucking at the breast and decreased
alertness, resulting in delayed effective breastfeeding (Nissen1995;
Ransjo-Arvidson 2001; Righard 1990).
Why it is important to do this review
This review evaluates effects of parenteral opioids for analgesia in
labour. The use of intramuscular injection of opioid analgesia in
labour became a traditional part of midwifery practice without
evidence from randomised controlled trials for its analgesic effec-
tiveness, impact on labour outcomes or acceptability to women.
It is thought its perceived analgesic efficacy may be due, at least
in part, to its sedative effects rather than a true reduction in per-
ceived pain (NICE 2007). There remains uncertainty amongst
practitioners as to which opioid provides the most effective pain
relief, and whether opioids used during labour are acceptable to
women. The most effective and acceptable mode of administra-
tion also remains unknown. In addition, there are concerns about
the potential adverse effects associated with the use of opioids in
labour, particularly the effects on the newborn in relation to infant
feeding.
At present, the choice of opioid for analgesia in labour depends on
what is available in different hospitals. However, no matter what
facilities and drugs are available, women often have no choice as to
which drug is used, and healthcare professionals have little infor-
mation to guide decision-making. Whilst there have been previous
reviews on this topic (Bricker 2002; Elbourne 2006) this review
provides an up-to-date summary of existing knowledge. We aim
to provide best evidence to facilitate discussions between mater-
nity practitioners and women to enable them to make informed
decisions about their choice of analgesia during labour.
O B J E C T I V E S
To assess the effectiveness, safety and acceptability to women of
different types, doses and modes of administration of parenteral
opioid analgesia in labour. A second objective is to assess the effects
of opioids in labour on the baby in terms of safety, condition at
birth and early feeding.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials. We did not include quasi-ran-
domised trials. We included studies presented only in abstracts
provided that there was enough information to allow us to assess
eligibility and risk of bias; if there was insufficient information we
attempted to contact study authors.
Types of participants
Women in labour. We have excluded studies focusing specifically
and exclusively on women in high-risk groups, or women in pre-
mature labour (before 37 weeks’ gestation), but have included
studies which include such women as part of a broader sample.
Types of interventions
Parenteral opioids (intramuscular and intravenous drugs, includ-
ing patient controlled analgesia).
Drugs for comparison include pethidine or meperidine, nal-
buphine, butorphanol, diamorphine, buprenorphine, meptazinol,
pentazocine, tramadol, alfentanil, sufentanil, remifentanil and fen-
tanyl.
The following comparisons were eligible for the review.
• An opioid versus placebo using the same route of
administration.
• An opioid versus another opioid using the same route of
administration.
• An opioid plus an add-on drug versus another opioid plus
the same add-on drug using the same route of administration.
• One opioid versus the same opioid but a different dose.
We planned to use trialists’ definitions of higher and lower doses
of the same drugs, as high and low doses are different for different
opioids.
Where different doses of the same drug were compared with the
same comparator (e.g. 40 mg pethidine versus placebo, and 80 mg
pethidine versus placebo), we planned to use subgroup analyses to
examine findings.
This review is one in a series of Cochrane reviews examining pain
management in labour. These reviews contribute to an overview
of systematic reviews of interventions for pain management in
labour (Jones 2011b), and share a generic protocol (Jones 2011a).
To avoid duplication, the different methods of pain management
have been listed in a specific order, from one to 15. Individual
reviews focusing on particular interventions include comparisons
with only the intervention above it on the list. Methods of pain
management identified in the future will be added to the end of
the list. The current list is as follows.
1. Placebo/no treatment
2. Hypnosis
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3. Biofeedback (Barragán 2011)
4. Intracutaneous or subcutaneous sterile water injection
(Derry 2011)
5. Immersion in water (Cluett 2009)
6. Aromatherapy (Smith 2011b)
7. Relaxation techniques (yoga, music, audio)
8. Acupuncture or acupressure (Smith 2011a)
9. Manual methods (massage, reflexology)
10. Transcutaneous electrical nerve stimulation (TENS)
(Dowswell 2009)
11. Inhaled analgesia
12. Opioids (this review)
13. Non-opioid drugs (Othman 2011)
14. Local anaesthetic nerve blocks (Novikova 2011)
15. Epidural (including combined spinal epidural)
(Anim-Somuah 2005; Simmons 2007)
Accordingly, this review includes comparisons of an opioid with:
1. placebo/no treatment; 2. hypnosis; 3. biofeedback; 4. intracu-
taneous or subcutaneous sterile water injection; 5. immersion in
water; 6. aromatherapy; 7. relaxation techniques (yoga, music, au-
dio); 8. acupuncture or acupressure; 9. manual methods (massage,
reflexology); 10. TENS; 11. inhaled analgesia; or 12. another opi-
oid (as specified above).
Types of outcome measures
Primary outcomes
1. Maternal satisfaction with analgesia measured during
labour.
2. Maternal satisfaction with analgesia in labour measured
during the postnatal period.
Secondary outcomes
For women
1. Maternal pain score or pain measured in labour.
2. Additional analgesia required: epidural.
3. Maternal sleepiness during labour.
4. Nausea and vomiting in labour.
5. Caesarean section.
6. Assisted vaginal birth.
7. Postpartum haemorrhage (as defined by the trial authors).
8. Breastfeeding at discharge.
9. Breastfeeding in the postnatal period (four to six weeks).
10. Sense of control in labour (as defined by trialists).
11. Satisfaction with childbirth experience (as defined by
trialists).
12. Effect (negative) on mother/baby interaction.
For babies
1. Fetal heart rate changes in labour (persistent decelerations
or tachycardia).
2. Naloxone administration.
3. Neonatal resuscitation.
4. Apgar score less than seven at one minute.
5. Apgar score less than seven at five minutes.
6. Apgar score less than seven at ten minutes.
7. Admission to special care baby unit/neonatal intensive care
unit (as defined by trialists).
8. Newborn neuro-behavioural scores.
9. Neurodevelopment outcomes during infancy.
Other
1. Cost (as defined by trialists).
Search methods for identification of studies
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (30
April 2011).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of EMBASE;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
EMBASE, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Searching other resources
We searched the reference lists of background review articles and
the reference lists of papers retrieved by the search described above.
We did not apply any language restrictions.
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Data collection and analysis
Selection of studies
Four review authors (R Ullman, T Dowswell, L Smith, E Burns)
independently assessed for inclusion all the studies identified as a
result of the search strategy. Two authors assessed each report and
we resolved any disagreement through discussion or, if required,
we consulted a third author.
Data extraction and management
We designed a form to collect data. For each report, two review
authors independently collected the data using the agreed form
(all review authors were involved in data collection). We resolved
discrepancies through discussion or, if required, we consulted a
third author. We entered data into Review Manager software (
RevMan 2011) and checked them for accuracy.
When information in trial reports was unclear, we attempted to
contact authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
included study using the criteria described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) and
outlined below. We resolved any disagreement by discussion, or
by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We will assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered studies to be at
low risk of bias if they were blinded, or if judged that the lack of
blinding would be unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel;
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated” analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
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• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We describe for each included study any important concerns we
have about other possible sources of bias, for example was there a
potential source of bias related to the specific study design? Was
the trial stopped early due to some data-dependent process? Was
there extreme baseline imbalance? Has the study been claimed to
be fraudulent?
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it likely to impact on the findings. We aimed to explore
the impact of the level of bias through undertaking sensitivity
analyses - see Sensitivity analysis.
Measures of treatment effect
We carried out statistical analysis using Review Manager software
(RevMan 2011). We used fixed-effect meta-analysis for combin-
ing data where trials examined the same intervention, and where
we judged the trials’ populations and methods to be sufficiently
similar. Where we suspected clinical or statistical heterogeneity
between studies, sufficient to suggest that treatment effects might
differ between trials, we carried out random-effects meta-analysis.
Dichotomous data
For dichotomous data, we have presented results as summary risk
ratio with 95% confidence intervals.
Continuous data
For continuous data, we have used the mean difference if out-
comes were measured in the same way (e.g. using the same pain
scale) between trials. We used the standardised mean difference to
combine trials that measured the same outcome, but used differ-
ent scales.
Unit of analysis issues
Cluster-randomised trials
We intended to include cluster-randomised trials in the analyses
along with individually randomised trials using the methods de-
scribed in theHandbook (Higgins 2011). Their sample sizes would
be adjusted using an estimate of the intracluster correlation co-
efficient (ICC) derived from the trial (if possible), or from another
source. If we used ICCs from other sources, we would report this
and conduct sensitivity analyses to investigate the effect of vari-
ation in the ICC. If we had identified both cluster-randomised
trials and individually randomised trials, we planned to synthe-
sise the relevant information. We would consider it reasonable to
combine the results from both if there was little heterogeneity be-
tween the study designs and the interaction between the effect of
intervention and the choice of randomisation unit was considered
to be unlikely.
Crossover trials
We did not include crossover trials.
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data (more than 10% for outcomes where data were collected
in labour) in the overall assessment of treatment effect by using
sensitivity analyses.
Where data were not reported for some outcomes or groups, we
attempted to contact the study authors for further information.
We analysed data on all participants with available data in the
group to which they were allocated, regardless of whether or not
they received the allocated intervention. If in the original reports
participants were not analysed in the group to which they were
randomised, and there was sufficient information in the trial re-
port, we attempted to restore them to the correct group.
Assessment of heterogeneity
We examined heterogeneity between trials using the T² and I²
statistics. If we identified heterogeneity among the trials, we
planned to explore it by prespecified subgroup analysis provided
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data were available to do this, and by performing sensitivity anal-
ysis. Where we thought that an average treatment effect was clini-
cally meaningful, we used a random-effects model for meta-anal-
ysis in the presence of moderate or high levels of heterogeneity (I²
greater than 30%), and for these outcomes we have reported I²,
T², the P value for the Chi² test for heterogeneity.
Assessment of reporting biases
Where we suspected reporting bias (see ’Selective reporting bias’
above), we attempted to contact study authors asking them to
providemissing outcomedata.Wewere not able to explore possible
publication bias by using funnel plots, as too few studies were
included in each comparison.
Subgroup analysis and investigation of heterogeneity
We intended to conduct planned subgroup analysis using the
methods described by Deeks 2001 and set out in the Cochrane
Handbook for Systematic Reviews (Higgins 2011).
We had planned to carry out the following subgroup analyses.
1. By parity (nulliparous versus multiparous women).
2. By spontaneous versus induced or augmented labour.
3. Term versus preterm birth.
4. Continuous support in labour versus no continuous
support.
Where different doses of the same drug were examined (e.g. pethi-
dine 40 mg or pethidine 80 mg versus a placebo), we separated
analyses into subgroups to examine the impact of different doses.
For fixed-effect and random-effects meta-analyses we planned to
assess differences between subgroups by inspection of the sub-
groups’ confidence intervals: non-overlapping confidence intervals
indicating a statistically significant difference in treatment effect
between the subgroups.
Sensitivity analysis
We planned to carry out sensitivity analyses to explore the effect
of trial quality for important outcomes in the review. Where there
was risk of bias associated with a particular aspect of study quality
(e.g. inadequate allocation concealment), we have explored this by
sensitivity analyses.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Using the search strategy, in an earlier version of this review,
we identified 165 papers representing 138 studies. For this up-
dated version we identified a further five studies (Castro 2004;
El-Kerdawy 2010; Solek-Pastuszka 2009; Tawfik 1982; Thakur
2004) and an additional published report for a study which was
ongoing when the earlier review was completed (Douma 2010).
Following the updated search we excluded three of these studies
(Castro 2004; El-Kerdawy 2010; Solek-Pastuszka 2009) and in-
cluded three (Douma 2010; Tawfik 1982; Thakur 2004). In this
update we have included 57 studies and excluded 86.
Included studies
We included 57 studies involving more than 7000 women (see
Characteristics of included studies).
Most of the studies included in the review examined an opioid
drug administered intramuscularly (IM) and compared either an
opioid with placebo, or with another opioid. A smaller number of
studies examined opioid drugs administered intravenously (IV),
sometimes with a degree of patient control over the amount of
drug infused (PCA). None of the included studies examined sub-
cutaneous administration of opioids. Some of the studies com-
pared opioids with other non-pharmacological interventions such
as TENS (three studies). Trials with more than two arms may be
included in more than one comparison.
IM comparisons
1. IM pethidine versus IM placebo (three studies) (Kamyabi
2003; Sliom 1970; Tsui 2004).
2. IM meptazinol versus IM pethidine (eight studies) (De
Boer 1987; Jackson 1983; Morrison 1987; Nel 1981; Nicholas
1982; Osler 1987; Sheikh 1986; Wheble 1988). (In the studies
by De Boer 1987 and Jackson 1983, women in both study
groups also received add-on drugs.).
3. IM meptazinol versus IM pethidine PCA administration
(one study) (Li 1988).
4. IM diamorphine versus IM pethidine (both groups had
prochlorperazine) (Fairlie 1999).
5. IM tramadol versus IM pethidine (seven studies) (Bitsch
1980; Fieni 2000; Husslein 1987; Keskin 2003; Khooshideh
2009; Prasertsawat 1986; Viegas 1993).
6. In an additional study comparing tramadol with pethidine,
both groups also had triflupromazine (Kainz 1992).
7. IM dihydrocodeine versus IM pethidine (Sliom 1970).
8. IM pentazocine versus IM pethidine (six studies) (Borglin
1971; Duncan 1969; Levy 1971; Moore 1970; Mowat 1970;
Refstad 1980).
9. IM Pentazocine + promazine versus IM pethidine +
promazine (Refstad 1980).
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10. IM nalbuphine versus IM pethidine (four studies)
(Lardizabal 1999; Lisboa 1997; Mitterschiffthaler 1991; Wilson
1986).
11. IM phenazocine versus IM pethidine (Grant 1970).
12. IM morphine versus pethidine (one study) (Prasertsawat
1986).
13. IM butorphanol versus IM pethidine (Maduska 1978).
14. IM tramadol versus no treatment (one study) (Li 1994).
15. One study compared a spasmolytic drug (Avacan ®) with
IM pentazocine (Hamann 1972).
16. IM pentazocine versus IM Pethilorphan® (O’Dwyer 1971).
We were unable to include data from the following comparisons
because of a lack of information in the reports of the studies.
IM buprenorphine versus IM pethidine (Tharamas 1999).
A four-arm trial by Wahab 1988 compared nalbuphine, butor-
phanol, pentazocine and a placebo.
IV comparisons
17. IV fentanyl versus IV pethidine (one study) (Rayburn 1989).
18. IV nalbuphine versus IV pethidine (one study) (Giannina
1995).
19. IV phenazocine versus IV pethidine (one study) (Olson 1964).
20. IV butorphanol versus IV pethidine (three studies) (
Hodgkinson 1979; Nelson 2005; Quilligan 1980).
21. IV morphine versus IV pethidine (two studies) (Campbell
1961; Olofsson 1996).
22. IV alphaprodine (nisentil) versus IV pethidine (one study)
(Gillam 1958).
23. IV fentanyl versus butorphanol (one study) (Atkinson 1994).
IV pethidine versus no treatment (one study) (Neumark 1978).
(We were unable to use data from this study for this comparison
in the review. See Characteristics of included studies tables.)
IV/PCA comparisons
24. PCA pentazocine versus PCA pethidine (one study) (Erskine
1985).
25. PCA remifentanil versus PCA pethidine (three studies) (Blair
2005; Douma 2010; Volikas 2001).
26. PCA nalbuphine versus PCA pethidine (one study) (Frank
1987).
27. PCA fentanyl versus PCA alfentanil (one study) (Morley-
Forster 2000).
28. PCA fentanyl versus PCA pethidine (one study) (Douma
2010).
Opioids versus TENs
29. IV pethidine (50 mg) versus TENS to lower back (Neumark
1978), IMpethidine (50mg) versus TENS to back (Tawfik 1982),
IM tramadol (100 mg) versus TENS to back (Thakur 2004).
Excluded studies
We have excluded 86 studies (see Characteristics of excluded
studies).
Reasons for exclusions (some of the studies were excluded formore
than one reason).
• In 16 studies the focus was on epidural analgesia (Camann
1992; Evron 2007; Evron 2008; El-Kerdawy 2010; Gambling
1998; Ginosar 2003; Grandjean 1979; McGrath 1992; Morris
1994; Nafisi 2006; Polley 2000,Rabie 2006; Solek-Pastuszka
2009; Volmanen 2008; Wiener 1979; Wong 2005). The use of
epidural analgesia for pain management in labour is covered in
related Cochrane reviews (Anim-Somuah 2005; Simmons 2007).
• In 13 studies, women in both groups received the same
opioid and the focus of studies was on add-on drugs; so, for
example, both groups received pethidine with one group, in
addition, receiving a sedative. The focus of these trials was on the
effects of the add-on drug (Aiken 1971; Ballas 1976; De
Lamerens 1964; Hodgkinson 1978; Malkasian 1967; McQuitty
1967; Posner 1960; Powe 1962; Ron 1984; Roberts 1960;
Spellacy 1966; Wan 1965; Williams 1962).
• Eighteen studies were not randomised trials, or it was not
clear that there was any random allocation to groups (Balcioglu
2007; Bredow 1992; Brelje 1966; Callaghan 1966; Cincadze
1978; Cullhed 1961; Eliot 1975; MacVicar 1960; Moore 1974;
Pandole 2003; Rowley 1963; Savage 1955; Singh 2001;
Soontrapa 2002; Suvonnakote 1986; Tripti 2006; Vavrinkova
2005; Volmanen 2005).
• In three studies it was not clear that participants were in
labour (Chang 1976; Krins 1969; Tomlin 1965).
• In the study by Bare 1962 women did not receive an opioid.
• In the study by Kaltreider 1967 the focus was on a high-risk
group (women in preterm labour) and post-randomisation
exclusions meant that results were difficult to interpret.
• We excluded two studies as levels of attrition meant that
results were at high risk of bias. There were serious
methodological problems in the study by Robinson 1980 and
complete data were available for only approximately one-third of
those randomised. In the study by De Kornfeld 1964, data on
pain outcomes were available for less than half the sample at one
hour; results from this study were therefore very difficult to
interpret.
• Five trials were reported in trial registers or in brief abstracts
and we were unable to assess risk of bias or extract results. We
attempted to contact authors for more information without
success (Goodlin 1988,Kalaskar 2007; Morgan 2004; Overton
1992; Taskin 1993).
• The focus of four studies was not on pain relief, so women
may have received an opioid with the purpose of promoting
progress in labour (Sosa 2004; Tournaire 1980; Treisser 1981;
Von Vorherr 1963). In one of these studies women were
specifically excluded if they complained of pain (Sosa 2004), and
in another, women in the two groups also received oxytocin with
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each study group receiving a different dose (Von Vorherr 1963).
A further two studies did not focus on pain relief but rather on
newborn serum bilirubin (McDonald 1964) or platelet function
(Greer 1988).
• Seven studies focused on drugs no longer in use, or drugs
not used nowadays for obstetric analgesia (Cahal 1960;
Cavanagh 1966; Eames 1964; Ransom 1966; Roberts 1957;
Sentnor 1966; Walker 1992).
• In five studies the same opioid was given to women in both
arms of trials and the difference between groups was mode of
administration; different modes of administration of parenteral
opioids will be considered in a separate Cochrane review (Balki
2007; Isenor 1993; McInnes 2004; Rayburn 1989; Rayburn
1991).
• In two studies women in one arm of the trial, as well as
receiving an opioid, were also given another add-on drug that the
comparison group did not receive. In these studies results are
difficult to interpret, as any differences between groups may be
due to the add-on drug rather than the opioid (Busacca 1982;
Calderon 2006).
• In the studies by Calderon 2006, Evron 2005, Li 1995,
Nikkola 2000; Shahriari 2007 and Thurlow 2002, different
drugs were administered using different methods, and so it is
difficult to interpret results as any differences between groups
may be due to drug, method or both together.
• In one study the effect of the opioid analgesia was not
assessed during childbirth, but for second trimester labour
following termination of pregnancy (Castro 2004).
Risk of bias in included studies
See Figure 1; Figure 2.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
10Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
In eight studies, authors stated that a computer-generated random
sequence was used (Atkinson 1994; Douma 2010; Fieni 2000;
Giannina 1995;Khooshideh2009; Lardizabal 1999;Nelson2005;
Tsui 2004); in two that an external randomisation service was used
(Morley-Forster 2000; Rayburn 1989a); and in four studies that
random number tables were consulted (Erskine 1985; Hamann
1972; Kainz 1992; Tharamas 1999).The majority of included
studies did not give clear information about how the randomisa-
tion sequence was generated.
Allocation concealment
Allocation concealment was not generally described in sufficient
detail to allow assessment of risk of bias; it was not always clear
at what stage randomisation took place, and whether or not the
person carrying out randomisation was aware of group allocation.
Four studies described using numbered opaque sealed envelopes
to conceal allocation (Giannina 1995; Khooshideh 2009; Tsui
2004; Volikas 2001). Seventeen studies described using identical
coded drug boxes (although it may not have been clear who had
access to the code or when the code was broken) (Atkinson 1994;
Borglin 1971; Campbell 1961;Douma 2010; Fairlie 1999;Gillam
1958; Grant 1970; Lardizabal 1999; Levy 1971; Maduska 1978;
Moore 1970; Morley-Forster 2000; Morrison 1987; Olofsson
1996; Olson 1964; Sheikh 1986; Wilson 1986). In the remaining
studies it was not clear what steps were taken to conceal allocation
at the point of randomisation.
Blinding
Many of the studies were described as double blind; in themajority
of these trials women in the control arms were given preparations
of similar appearance to those given to women in the experimental
arms (either a placebo or an indistinguishable comparison drug).
It was not always clear that blinding was effective; for example,
some IMdrugsmay appear similar, but different consistencies may
be apparent to experienced staff. It was also not generally clear at
what point blinding ended, and whether outcome assessors were
blind to group allocation.
In six studies blinding was impractical as women were given dif-
ferent types of treatment (e.g. IM drug versus no treatment; IM
drug versus TENS) (Li 1994; Neumark 1978; Rayburn 1989a;
Refstad 1980; Tawfik 1982; Thakur 2004), and in a further nine
studies methods were not described or were not clear (Bitsch 1980;
Erskine 1985; Fieni 2000; Giannina 1995; Husslein 1987; Keskin
2003; Lisboa 1997; Mitterschiffthaler 1991; Wahab 1988).
Incomplete outcome data
Assessing levels of attrition was very difficult in these studies, as
denominators were frequently absent from results tables. In addi-
tion, even where all women appeared to be accounted for at fol-
low-up, there were frequently missing data for specific outcomes.
In some studies loss to follow-up or missing data were greater
than 10% (Bitsch 1980; Fairlie 1999; Hamann 1972; Levy 1971;
Moore 1970; Mowat 1970; Olson 1964; Wilson 1986), or greater
than 20% (De Boer 1987; Frank 1987; Giannina 1995; Gillam
1958; Nicholas 1982; O’Dwyer 1971; Refstad 1980).
In several studies there were missing data on pain outcomes. This
may have occurred because drugs were given at a late stage in
labour, so that women had already given birth before the first
scheduled pain assessment. For example, in Fairlie 1999 17%,
and in O’Dwyer 1971 and Refstad 1980 more than one-third of
women had given birth within an hour of drug administration.
In some studies women were explicitly excluded from the analysis
because of factors that may have related to study medication; in
Hamann 1972 13% were excluded after randomisation because
they had a long labour or a caesarean section, and in Moore 1970
women were excluded because they had had additional pain re-
lief. Wilson 1986 excluded 10% of the sample because women
reported that they had had inadequate pain relief. In the study by
Nelson 2005 any woman undergoing artificial rupture of mem-
branes, commencing oxytocin or requesting epidural was excluded
after randomisation and were replaced. Further, any women who
reached 10 cm cervical dilation within one hour of drug adminis-
tration were also excluded from the analysis; it was not clear how
many women were lost and replaced for these reasons.
Selective reporting
We did not formally assess outcome reporting bias, as we had ac-
cess only to published study reports and without study protocols
it is difficult to assess whether all outcomes have been accounted
for. We were not able to explore possible publication bias by using
funnel plots as too few studies were included in different compar-
isons.
Other potential sources of bias
Most of the studies reported that there was no apparent baseline
imbalance between groups although this was not always explicit,
and where tables describing characteristics of the two groups were
provided, they frequently included only a small number of ob-
stetric or demographic variables. In the study by Tsui 2004, there
was imbalance between groups in terms of the numbers of women
undergoing induction of labour in the two groups (20/25 in the
pethidine group and 12/25 in the placebo group), and this may
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have had an impact on outcomes. In the study by Rayburn 1989a
women were only recruited to the study at very limited times
(weekdays 8am to 3pm), and while this may not put findings at
high risk of bias, it may mean that those recruited were not repre-
sentative of the population served by the study hospital.
In the Characteristics of included studies and risk of bias tables we
have set out more information which will assist in the interpreta-
tion of results.
Effects of interventions
In this section where several studies have contributed data to a
comparison, we have reported primary and secondary outcomes
separately. For some comparisons single studies provided data on a
very limited number of outcomes; for these comparisons we have
reported outcomes under one heading. We had planned subgroup
analysis by parity, by whether or not the labour was induced or
augmented, by gestational age (preterm versus term birth) and by
whether or not women had continuous support during labour. In
this version of the review we were unable to carry out this analysis,
as data were not provided by subgroups. In addition, we did not
carry out planned sensitivity analysis by study quality as for most
outcomes only one or two studies contributed data, and excluding
lower-quality studies from the analyses was unlikely to shed any
further light on findings.
Intramuscular opioids for pain relief in labour
1. IM pethidine versus placebo
Three studies with 254 women were included in this comparison
(Kamyabi 2003; Sliom 1970; Tsui 2004), although for most out-
comes only a single study contributed data.
Primary outcomes
One study involving 50 women (Tsui 2004) showed no significant
difference inmaternal satisfaction 30minutes after administration
of study drug (risk ratio (RR) 7.00, 95% confidence interval (CI)
0.38 to 128); only three of 25women receivingpethidine andnone
of the women receiving placebo were ’satisfied’ or ’very satisfied’
with analgesia (Analysis 1.1).
One study involving 116 women (Sliom 1970) reported signifi-
cantly more women in the pethidine group with “fair” or “good”
pain relief (RR 1.75, 95% CI 1.24 to 2.47) (Analysis 1.2).
Secondary outcomes
Maternal
Maternal pain relief 30 minutes after study drug administration,
defined as a reduction in visual analogue scale (VAS) score of at
least 40 mm, was measured in one study with 50 women (Tsui
2004) andwas significantly greater for pethidine 100mgcompared
with placebo (RR 25, 95% CI 1.56 to 400) though the CI for this
estimate is very wide (Analysis 1.3). In this study, although the
majority of women in both groups required additional analgesia,
this applied to fewer women with pethidine 100 mg compared
with placebo (RR 0.71, 95% CI 0.54 to 0.94) (Analysis 1.4).
There was no evidence of differences between groups in the num-
ber of women requiring an epidural (RR 0.50, 95% CI 0.14 to
1.78) (Analysis 1.5), in the incidence of nausea and vomiting (RR
1.47, 95% CI 0.65 to 3.31) (Analysis 1.6), assisted vaginal birth
(RR 0.86, 95% CI 0.34 to 2.19) (Analysis 1.8), or caesarean sec-
tion (RR 0.83, 95% CI 0.29 to 2.38) (Analysis 1.9). Significantly
more women reported sleepiness with pethidine 100 mg, with half
of those receiving pethidine feeling sedated compared with 11%
of controls (RR 4.67, 95% CI 2.43 to 8.95) (Analysis 1.7).
In one study, 12/25 women in the placebo group had pethidine
at 30 minutes as rescue analgesia confounding interpretation of
reported outcomes after 30 minutes (Tsui 2004).
Neonatal
The number of babies with Apgar scores of seven or less at one
minute did not differ between the placebo and pethidine groups;
for this outcome we used a random-effects model because of high
heterogeneity (average RR 1.64, 95% CI 0.52 to 5.18), (hetero-
geneity: I² = 61%, Tau² = 0.46, Chi² test for heterogeneity P =
0.11) (Analysis 1.10). No babies had Apgar scores less than or
equal to seven at five minutes in the one study that reported this
outcome (Analysis 1.10). The incidence of newborn resuscitation
and admission to neonatal intensive care unit (NICU) was low;
no significant differences between groups was detected (Analysis
1.11; Analysis 1.12).
One study reported incidence of fetal respiratory depression, but
the study drugs were given late in labour to assess maximum fetal
effect. Participants were not included in the analysis if birth was
less than 30 minutes or more than four hours after administration
of study drugs (Sliom 1970).
We were unable to include any results from one study that met the
inclusion criteria, as it was unclear when outcomes were measured
how they were defined and how many participants were included
in the analysis (Kamyabi 2003). In this study,mean Apgar scores at
oneminute were reported to be higher (P = 0.008) in the pethidine
75 mg group compared with placebo group (data not shown).
2. IM meptazinol versus IM pethidine
IM meptazinol versus IM pethidine was evaluated in six studies
with 1898 women (Morrison 1987; Nel 1981; Nicholas 1982;
Osler 1987; Sheikh 1986; Wheble 1988), and in two additional
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studies where women in both study groups also received add-on
drugs (De Boer 1987; Jackson 1983).
Primary outcomes
One study (Morrison 1987) involving 801 women showed no
evidence of a difference between meptazinol 100 mg to 150 mg
compared with pethidine 100 mg to 150 mg for assessment of
analgesic effect measured at three to five days postpartum (RR
1.01, 95% CI 0.91 to 1.12) (Analysis 2.1). In this study, more
than half of the women receiving either of these opioids reported
that they received no or poor relief despite the fact that women in
both groups could also receive an additional dose of study drug,
epidural or nitrous oxide as required.
In two studies (Nel 1981; Sheikh 1986) involving 239 women,
there was no evidence of a difference between groups in pain in-
tensity one hour after administration of meptazinol 100 mg or
pethidine 100mg; more than two-thirds of women in both groups
were rating their pain as severe (four or five on a five-point scale) at
one hour (average RR 1.11, 95% CI 0.69 to 1.80 (random-effects;
heterogeneity: I² = 43%, Tau² = 0.08, Chi² test for heterogeneity
P = 0.18) (Analysis 2.2).
Secondary outcomes
Maternal
Two studies (Osler 1987; Wheble 1988) involving 233 women
found no evidence of a difference in requirement for additional
analgesia between those who received meptazinol compared with
pethidine (RR 1.03, 95% CI 0.88 to 1.20) (Analysis 2.3). This
outcome is difficult to interpret as women in the study by Osler
1987 were allowed up to three doses of study drug (meptazinol
100mg or pethidine 75mg).Overall, 56women required a second
dose and 15 a third dose, but the number per group was not
reported. Whereas in the study by Wheble 1988, women were
allowed a second dose of study drug (meptazinol 100 mg or 150
mg or pethidine 100 mg or 150 mg) or epidural or nitrous oxide
at the discretion of the caregiver. Additional analgesia relates to
a pudendal in the one study (Osler 1987), and a second dose of
study drug in the other (Wheble 1988).
The use of epidural analgesia was similar between meptazinol
and pethidine (RR 0.96, 95% CI 0.71 to 1.29) in four studies
(Nicholas 1982; Osler 1987; Sheikh 1986; Wheble 1988) involv-
ing 788 women (Analysis 2.4). Instrumental birth was reported
in three studies (Morrison 1987; Osler 1987; Wheble 1988) in-
volving 1266 women, and rates were similar between groups (RR
1.00, 95% CI 0.81 to 1.22) (Analysis 2.7). Overall, there was
no evidence of a difference in rates of caesarean section between
meptazinol and placebo. However, substantial heterogeneity was
detected; therefore, we used a random-effects model (average RR
0.56, 95% CI 0.16, 2.00) (heterogeneity: I² = 75%, T² = 0.84,
Chi² test for heterogeneity P = 0.02), (Analysis 2.8).
Three studies each reported nausea, vomiting and sleepiness
(Morrison 1987; Nicholas 1982; Sheikh 1986). There was no ev-
idence for a difference in nausea (RR 1.11, 95% CI 0.95 to 1.28);
however, significantly more women reported vomiting (RR 1.25,
95% CI 1.06 to 1.47) with meptazinol compared with pethidine.
Fewer women in the meptazinol group reported sleepiness (aver-
age RR 0.55, 95% CI 0.28 to 1.07), although there was moder-
ate heterogeneity for this outcome (heterogeneity: I² = 44%, T² =
0.18, Chi² test for heterogeneity P = 0.17) and the difference be-
tween groups did not reach statistical significance (Analysis 2.6).
Neonatal
Four studies involving 662 women reported number of babies
with Apgar scores less than or equal to seven at one minute (
Nel 1981; Nicholas 1982; Osler 1987; Wheble 1988), and three
studies reported this outcome at five minutes (Nel 1981; Nicholas
1982; Osler 1987). There was no evidence of a difference between
groups at one minute (RR 0.76, 95% CI 0.50 to 1.13) or five
minutes (RR 0.49, 95% CI 0.05 to 5.37) with three babies with
low scores at five minutes reported in one study (Osler 1987) and
none in the other two (Nel 1981; Nicholas 1982) (Analysis 2.10).
We found no evidence of a difference between meptazinol com-
pared with pethidine for naloxone administration (RR 0.89, 95%
CI 0.77 to 1.02), admission to NICU (RR 0.88, 95% CI 0.48
to 1.63) or newborn resuscitation (Analysis 2.11; Analysis 2.12;
Analysis 2.13). In one study (Morrison 1987), 40% of the babies
were given naloxone, reflecting local practice at the time rather
than low Apgar scores; with 41% of the babies having Apgar scores
greater than or equal to eight at the time of administration.
Breastfeeding problems were reported by a small number of
women in one study (Sheikh 1986); there was no evidence of a
difference between groups (RR 0.76, 95% CI 0.17 to 3.30).
Meptazinol versus pethidine with add-on drugs
One study compared IMmeptazinol 1.8mg/kgwith IMpethidine
1.8 mg/kg; all women also received promazine 25 mg IM (Jackson
1983). A second study compared IM meptazinol 1.5 mg/kg with
IM pethidine 1.5mg/kg; all women also receivedmetoclopramide
10 mg IM (De Boer 1987). Women could receive a second dose
of study drug after three hours in both studies. Both studies were
conducted to assess effects of the study drugs on the newborn only.
Primary and secondary outcomes
Maternal outcomes were not measured.
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Neonatal
Both studies reported the number of babies with Apgar scores less
than or equal to seven at one minute. There was no evidence of
a difference between meptazinol compared with pethidine (RR
0.89, 95%CI, 0.47 to 1.67). In the study byDe Boer 1987, Apgar
at five and 10minutes were reported as ’similar’ in both groups and
there was no evidence of difference in the number of babies with
fetal heart rate changes (decelerations). In the study by Jackson
1983, no babies in either group had Apgar scores less than or equal
to seven at 10 minutes. In one study (Jackson 1983), three babies
in the meptazinol group and two in the pethidine group required
resuscitation.
3. PCA (IM) meptazinol versus PCA (IM) pethidine
One study involving 10 women examined the feasibility of IM
meptazinol versus IM pethidine with PCA administration (Li
1988).
Primary and secondary outcomes
All women in both groups were satisfied with the mode of admin-
istration (Analysis 3.2).
Pain scores measured one day postpartum were lower with mep-
tazinol compared with pethidine; however, there was no evidence
of a significant difference (mean difference (MD) -17.60, 95%
CI -49.93 to 14.73) (Analysis 3.1). Epidural rates and nausea and
drowsiness scores evaluated one day postpartum were similar be-
tween groups (Analysis 3.3; Analysis 3.4; Analysis 3.5).
Neonatal
Naloxone was administered to one baby in each group (Analysis
3.6).
4. IM diamorphine + prochlorperazine versus IM pethidine +
prochlorperazine
One study involving 133 women compared IM diamorphine 5
mg to 7.5 mg versus IM pethidine 100 mg to 150 mg. All women
also received IM prochlorperazine 12.5 mg at the same time as the
study drug (Fairlie 1999).
Primary outcomes
Global assessment of pain relief was evaluated at 24 hours; there
was no evidence of a difference between groups in the number of
women reporting ’fair’ or ’poor’ as opposed to ’good’ pain relief,
with more than half of the women in both groups having inade-
quate relief (RR 0.88, 95% CI 0.67 to 1.16) (Analysis 4.1).
Secondary outcomes
Maternal
More women reported pain intensity as moderate or severe one
hour post administration of study drug with pethidine compared
with diamorphine, though there was no evidence of a significant
difference between groups, with the majority of women in both
groups reporting moderate or severe pain (RR 0.85, 95% CI 0.72
to 1.01) (Analysis 4.2). There was no evidence for a difference
between groups in the number of women requiring additional
analgesia (RR1.35, 95%CI0.53 to 3.4) (Analysis 4.3), an epidural
(RR 1.22, 95% CI 0.72 to 2.07) (Analysis 4.4), assisted vaginal
birth (RR 0.96, 95% CI 0.46 to 2.02) (Analysis 4.7), or caesarean
section (RR 0.52, 95% CI 0.10 to 2.76) (Analysis 4.8).
The number of women vomiting was significantly lower with di-
amorphine compared with pethidine (RR 0.39, 95% CI 0.17 to
0.86) (Analysis 4.5), but the number of womenmoderately drowsy
or asleep one hour after study drug administration was similar be-
tween groups (RR 0.93, 95% CI 0.52 to1.66) (Analysis 4.6).
Neonatal
Significantly fewer babies had Apgar scores less than seven at one
minute with diamorphine compared with pethidine (RR 0.41,
95% CI 0.18 to 0.91) (Analysis 4.9). However, there was no ev-
idence of a difference between groups at five minutes, with few
babies with an Apgar score less than seven in either group (RR
0.35, 95%CI 0.04 to 3.27) (Analysis 4.10). There were no signifi-
cant differences between groups for the number of babies needing
resuscitation (RR 1.21, 95% CI 0.73 to 2.02) (Analysis 4.11), or
admission to NICU (RR 0.58, 95% CI 0.21 to 1.64) (Analysis
4.12).
5. IM tramadol versus IM pethidine
Seven studies involving 569 women compared IM tramadol versus
IM pethidine (Bitsch 1980; Fieni 2000; Husslein 1987; Keskin
2003; Khooshideh 2009; Prasertsawat 1986; Viegas 1993). Tra-
madol and pethidine doses varied between studies and were 50,
75 or 100 mg.
Primary and secondary outcomes
Maternal
Women’s satisfaction with pain relief was not measured in any of
the studies.
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Pain intensitywas defined indisparateways in the studies; however,
significantlymore womenhad poor pain relief with tramadol com-
pared with pethidine (RR 1.56, 95% CI 1.10 to 2.21) (Analysis
5.1).
In three studies which reported requirement for additional anal-
gesia, no evidence of a difference was detected (average RR 1.07,
95% CI 0.60 to 1.91) (Analysis 5.2).
There was no evidence for a difference in incidence of nausea and/
or vomiting with tramadol compared with placebo (average RR
0.97, 95%CI 0.34 to 2.76) (Analysis 5.3). There was a substantial
level of heterogeneity detected for this outcome (I² = 72%, T² =
1.09, Chi² test for heterogeneity P = 0.003) therefore we used a
random-effects model for the analysis. More women in the pethi-
dine group reported sleepiness and the difference between groups
reached statistical significance although, again, heterogeneity was
high and we used a random-effects model (average RR 0.57, 95%
CI 0.33 to 0.97), (heterogeneity I² = 72%, T² = 0.24, Chi² test
for heterogeneity P = 0.007) (Analysis 5.4).
Neonatal
Only two studies reported Apgar scores (Khooshideh 2009;
Prasertsawat 1986), and reported no babies in either group with
Apgar scores less than or equal to seven at one or five minutes, and
no babies requiring resuscitation (Analysis 5.7; Analysis 5.8).
One study (Keskin 2003) reported the incidence of respiratory
distress and admission to NICU which occurred more frequently
with tramadol 100 mg compared with pethidine 100 mg, though
results were not statistically significant for either outcome (RR
2.26, 95% CI 0.64 to 7.89) (Analysis 5.9; Analysis 5.10).
6. IM tramadol + triflupromazine versus IM pethidine +
triflupromazine
One study involving 66 women compared tramadol 500 mg with
pethidine 50 mg, and both groups also received triflupromazine
10 mg (Kainz 1992). A third study arm received tramadol 100
mg.
Primary and secondary outcomes
Maternal satisfaction with analgesic effect was not measured.
The authors reported that the analgesic effect was equally good
in each study arm. Data for effects on pain were not reported (P
values for the change within groupswere reported; not the between
group differences; data not shown).
The incidence of nausea or vomiting was reported and was infre-
quent, with no evidence of differences between groups (RR 0.82,
95% CI 0.13 to 5.25 and RR 0.40, 95% CI 0.02 to 9.35, respec-
tively) (Analysis 6.1). Sleepiness was more frequently reported by
women who received tramadol, though no statistically significant
difference between groups was detected (RR 2.86, 95% CI 0.68
to 12.12) (Analysis 6.2).
The authors report that there were no negative effects on the new-
born; though no data were presented.
7. IM dihydrocodeine versus IM pethidine
One study involving 106 women compared a single dose of IM
dihydrocodeine 50 mg with IM pethidine 100 mg (Sliom 1970).
An additional study arm received placebo.
Primary and secondary outcomes
There was no evidence of a difference in pain relief between groups
with a substantial proportion of women in each group reporting
poor pain relief one hour after administration of study drug (RR
1.09, 95% CI 0.64 to 1.86) (Analysis 7.1).
There was no evidence of a difference between dihydrocodeine
and pethidine for nausea and vomiting (RR 0.87, 95% CI 0.40
to 1.88) (Analysis 7.2), or sleepiness (RR 0.67, 95% CI 0.43 to
1.04) (Analysis 7.3).
Significantly fewer babies had Apgar scores less than or equal to
seven at one minute with dihydrocodeine compared with pethi-
dine (RR 0.57, 95% CI 0.39 to 0.84) (Analysis 7.4). Apgar score
at five minutes was reported as mean scores rather than number of
babies in each group: there was no significant difference between
groups reported (data not shown).
8. IM pentazocine versus pethidine
Six studies with 877 women are included in this comparison (
Borglin 1971; Duncan 1969; Levy 1971; Moore 1970; Mowat
1970; Refstad 1980).
Primary outcomes
Two studies reported on the numbers of women rating pain relief
as good or very good at birth (Borglin 1971; Mowat 1970), and
there was no statistically significant difference between groups in
either study, or when results were pooled (Analysis 8.1).
Four studies reported poor pain relief (Duncan 1969; Levy 1971;
Moore 1970; Refstad 1980); more than half of the women in both
groups had only partial or poor relief and there was no statistically
significant difference between groups (Analysis 8.2).
Secondary outcomes
The use of additional analgesic drugs was reported by two studies
(Mowat 1970; Refstad 1980). There was no statistically significant
difference between groups in either study (Analysis 8.3).
One or more studies reported nausea, vomiting, sleepiness or as-
sisted vaginal birth; there was no significant evidence of a dif-
ference between groups for any of these outcomes (Analysis 8.4;
Analysis 8.5; Analysis 8.6).
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Two studies reported the incidence of low Apgar scores at one
and five minutes (Borglin 1971; Levy 1971) with no statistically
significant difference between groups (Analysis 8.7).
9. IM pentazocine + promazine versus pethidine + promazine
One study with 85 women contributed data to this comparison
(Refstad 1980).
Primary and secondary outcomes
This study reported on only two of the review’s outcomes: low
Apgar score at one and five minutes and naloxone administration.
There was no statistically significant difference between groups for
either outcome (Analysis 9.1; Analysis 9.2).
10. IM nalbuphine versus pethidine
Four studies with 486 women are included in this comparison
(Lardizabal 1999; Lisboa 1997; Mitterschiffthaler 1991; Wilson
1986).
Primary outcomes
One study reported maternal satisfaction with analgesia at 24
hours (Wilson 1986). The majority of women receiving both nal-
buphine and pethidine thought that analgesia had been “mini-
mally effective” (63% and 85% respectively), although the differ-
ence between groups was statistically significant (RR 0.73, 95%
CI 0.55 to 0.96) (Analysis 10.1). One study reported the number
of women that were free of pain (Mitterschiffthaler 1991); the dif-
ference between groups was not statistically significant, with few
women in either group having no pain (Analysis 10.2). Two stud-
ies reported pain intensity: one at 30 minutes (Lardizabal 1999)
and the other at 60 minutes (Wilson 1986). There was no statisti-
cally significant difference between groups in either study (Analysis
10.3; Analysis 10.4).
Secondary outcomes
Maternal
Two studies reported the use of additional analgesia (Lardizabal
1999; Wilson 1986) and there was no statistically significant dif-
ference between groups in either study (Analysis 10.5; Analysis
10.6). One study reported nausea and vomiting as separate out-
comes (Lardizabal 1999), and another reported nausea and vom-
iting as a single outcome (Wilson 1986). Statistically significantly
fewer women who received nalbuphine reported nausea alone (RR
0.62, 95% CI 0.42 to 0.91, P = 0.02), or vomiting (RR 0.41, 95%
CI 0.22 to 0.76) compared with women who received pethidine.
Likewise, fewer women who received nalbuphine reported nausea
and vomiting combined (RR 0.41, 95% CI 0.18 to 0.94). There
was no evidence of significant differences between groups for ma-
ternal sleepiness, assisted or caesarean births in studies reporting
these outcomes (Analysis 10.8; Analysis 10.9; Analysis 10.10).
Neonatal
Two studies reported neonatal outcomes (Lardizabal 1999;Wilson
1986). There was no statistically significant difference between
groups for low Apgar scores at one, five and 10 minutes, naloxone
administration or admission to NICU (Analysis 10.11; Analysis
10.12; Analysis 10.13). One study reported a neonatal neuro-
behavioural score two to four hours followingbirth (Wilson 1986);
babies of women who received nalbuphine had lower scores than
babies born to women in the control group (MD -3.70, 95% CI
-6.14 to -1.26).
11. IM phenazocine versus pethidine
One study with 212 women (Grant 1970) compared IM
phenazocine versus IM pethidine.
Primary and secondary outcomes
This study reported only two outcomes: epidural uptake and
vomiting. There was no statistically significant difference between
groups for epidural (Analysis 11.1), but fewerwomenwho received
phenazocine vomited (RR 0.39, 95% CI 0.20 to 0.78) compared
with those who received pethidine.
12. IM morphine versus pethidine
We included one study with 135 women in this comparison (
Prasertsawat 1986).
Primary and secondary outcomes
There was no statistically significant difference between groups in
the number ofwomendescribing their pain relief as poor (RR1.22,
95%CI 0.56 to 2.66), additional analgesia (Analysis 12.2), nausea
and vomiting (Analysis 12.3), or maternal sleepiness (Analysis
12.4). There was also no statistically significant difference between
groups for number of babies born with an Apgar score less than or
equal to seven at birth (Analysis 13.1), or requiring resuscitation
(Analysis 12.6).
13. IM butorphanol versus pethidine
One study with 80 women compared IM butorphanol with IM
pethidine (Maduska 1978).
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Primary and secondary outcomes
This study did not report on the review’s primary outcomes. There
was no significant evidence of differences between groups for ad-
ditional analgesia (Analysis 13.1), nausea (Analysis 13.2), or vom-
iting (Analysis 13.3). Likewise, there was no significant difference
between groups for neonatal resuscitation (Analysis 13.4) or nalox-
one administration (Analysis 13.5).
14. IM tramadol versus no treatment
One study with 60 women compared IM tramadol with no treat-
ment (Li 1994).
Primary and secondary outcomes
This study reported only two outcomes: satisfaction with analgesia
and mean blood loss at birth. Only five out of 30 of the women
receiving tramadol described it as satisfactory, but the difference
between groups was not significant (Analysis 14.1). There was no
difference between groups for mean blood loss at birth (Analysis
14.2).
15. IM Avacan® versus IM pentazocine
We included one study with 185 women in this comparison (
Hamann 1972).
Primary and secondary outcomes
This study did not report on either of our primary outcomes.
There were no statistically significant differences between groups
for the uptake of nitrous oxide (Analysis 15.1). More women in
the Avacan® group received a pudendal-paracervical block (RR
2.02, 95% CI 1.16 to 3.53). There was no evidence of a difference
between groups for the number of women having a caesarean
section, or babies born with an Apgar score less than or equal to
seven at birth (Analysis 15.3; Analysis 15.4). This study did not
report on any other secondary outcomes.
16. IM pentazocine versus IM Pethilorfan®
One trial involving 98 women compared pentazocine with
Pethilorfan® (O’Dwyer 1971).
Primary and secondary outcomes
There was no statistically significant difference between study
groups in the number of women saying that they did not obtain
any relief from medication at one hour (RR 1.22, 95% CI 0.77
to 1.95) (Analysis 16.1).
No statistically or clinically significant differences were reported
for any of the secondary outcomes recorded (additional analgesia
required, assisted vaginal birth, Apgar score less than eight at one
minute, Apgar score less than eight at five minutes) (Analysis 16.2;
Analysis 16.3; Analysis 16.4; Analysis 16.5).
Intravenous opioids for pain relief in labour
17. IV fentanyl versus IV pethidine
We included one study with 105 women in this comparison (
Rayburn 1989a).
Primary and secondary outcomes
The mean maternal pain score was significantly lower one hour
after drug administration for women allocated to the IV fentanyl
compared with those in the IV pethidine group; however, women
in both groups reported mean pain scores of approximately six on
a 10 mm scale (MD -0.20, 95% CI -0.34 to -0.06).
Maternal sedation was significantly lower in women allocated to
the IV fentanyl group compared with those in the IV pethidine
group (RR 0.05, 95% CI 0.00 to 0.82). There were no statistically
significant differences for all other reported outcomes including
side effects, interventions in labour and outcomes for babies (
Analysis 17.3; Analysis 17.4; Analysis 17.6; Analysis 17.7; Analysis
17.9; Analysis 17.11). The study, however, recruited women only
during a limited time periodMonday to Friday and allocation was
not blinded due to the different half-lives of the treatment options.
18. IV nalbuphine versus IV pethidine
We included one study involving 28 women compared IV nal-
buphine with IV pethidine (Giannina 1995).
Primary and secondary outcomes
No outcomes relating to maternal pain during labour were re-
ported.
This study reported estimable data for only two relevant secondary
outcomes (caesarean section and low Apgar score at one minute),
neither of which showed any significant difference between the
two groups (Analysis 18.1; Analysis 18.2).
19. IV phenazocine versus IV pethidine
We included one study including 194 women compared IV
phenazocine with IV pethidine (Olson 1964).
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Primary and secondary outcomes
There was no statistically significant difference between groups for
women’s satisfaction with pain relief (comparing the number of
women with “fair” or “poor” pain relief ) (RR 0.72, 95% CI 0.48
to 1.10). No other primary outcomes were reported.
Only one identified secondary outcome reported estimable data:
nausea with vomiting. There was no statistically significant differ-
ence between the two groups for this outcome (Analysis 19.2).
20. IV butorphanol versus IV pethidine
Three studies involving a total of 330 women compared IV bu-
torphanol with IV pethidine (Hodgkinson 1979; Nelson 2005;
Quilligan 1980).
Primary outcomes
One study (Quilligan 1980) involving 100 women (findings for
these primary outcomes reported for 80 women) included two
measures of women’s pain during labour; women’s reported pain
relief and pain score. Women’s mean pain relief score was signifi-
cantly higher for those in the group receiving butorphanol (MD
0.67, 95% CI 0.25 to 1.09). This finding was supported by data
regarding reported pain scores one hour after drug administration
which were lower for women in the butorphanol group (MD -
0.60, 95% CI -1.02 to -0.18). The clinical significance of a dif-
ference of this magnitude (i.e. 0.6 on a 10-point scale) is more
difficult to determine.
The other two studies comparing IV butorphanol with IV pethi-
dine did not report any outcomes relating to women’s pain during
labour.
Secondary outcomes
One study (Hodgkinson 1979) involving 200 women reported
a lower incidence of nausea and vomiting associated with butor-
phanol compared with pethidine (0/100 in the butorphanol group
versus 12/100 in the pethidine group; RR 0.04, 95% CI 0.00
to 0.67). Other secondary outcomes reported by one or more of
the three studies within this comparison (second dose of analge-
sia required, epidural analgesia, assisted vaginal birth, caesarean
section, Apgar score less than or equal to seven at one and five
minutes) showed no statistically significant differences between
groups (Analysis 20.3; Analysis 20.4; Analysis 20.6; Analysis 20.7;
Analysis 20.8).
21. IV morphine versus IV pethidine
Two trials involving a total of 163 women compared IV morphine
with IV pethidine (Campbell 1961; Olofsson 1996).
Primary and secondary outcomes
One study involving 143 women reported women’s satisfaction
with pain relief assessed three days postpartum (Campbell 1961).
Fewer women allocated to receive IVmorphine during labour were
satisfied with pain relief than those allocated to receive pethidine
(RR 0.87, 95% CI 0.78 to 0.98), although the proportion of
women who reported that they were satisfied was high in both
groups (60/72 and 66/69).
Campbell 1961 also reported that women allocated to receive IV
morphine were significantlymore likely to request a second dose of
analgesia compared with women allocated to receive IV pethidine
(RR 3.41, 95% CI 1.90 to 6.12). This difference may simply
reflect a lack of equivalence in the study doses of analgesia given
(pethidine initial dose = 100 mg; morphine initial dose = 8 mg)
rather than true differences between analgesic effects.
A second study which investigated this comparison (Olofsson
1996) included only 10 women in each trial arm. No statistically
significant differences were found for each of the three secondary
outcomes reported (nausea, vomiting and caesarean section), al-
though the incidence of nausea was lower in the morphine group
(6/10 pethidine versus 1/10 morphine; RR 0.17, 95% CI 0.02 to
1.14) (Analysis 21.3; Analysis 21.4).
22. IV nisentil versus IV pethidine
One study including 395 women compared IV nisentil with IV
pethidine (Gillam 1958).
Primary and secondary outcomes
The study did not report any outcomes relating to women’s pain
relief.
Women allocated to the nisentil group were less likely to suffer
vomiting than those receiving pethidine (RR 0.38, 95% CI 0.22
to 0.66). There was also less risk of nausea in the nisentil group,
although this difference was not statistically significant (RR 0.71,
95% CI 0.33 to 1.52).
The incidence of babies requiring resuscitation and/or ventilatory
support was two times higher in babies born to women in the
nisentil group (14/185) compared to those in the pethidine group
(8/210) (RR 1.99, 95%CI 0.85 to 4.63). Although this difference
is not statistically significant, and this finding may have occurred
by chance, if this is a true reflection of differences between groups
then this degree of harmful effect on newborn babies is not clini-
cally acceptable.
23. IV fentanyl versus IV butorphanol
One trial involving 100 women compared IV fentanyl with IV
butorphanol (Atkinson 1994).
19Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Primary and secondary outcomes
The study did not report any outcomes relating to women’s pain
relief.
Women allocated to receive IV fentanyl were statistically signifi-
cantly more likely to request additional doses of the study anal-
gesia compared with women allocated to receive IV butorphanol
(RR 1.39, 95% CI 1.05 to 1.85). The study author claims the
study doses of drug were equivalent (IV fentanyl 50 to 100 mcg
every one to two hours; IV butorphanol 1 to 2 mg every one to
two hours). Additionally, women in the fentanyl group were twice
as likely as those in the butorphanol group to go on to request an
epidural (RR 2.00, 95% CI 1.00 to 4.02). Other women’s out-
comes reported (drowsiness, caesarean section) showed no statis-
tically significant difference between study groups (Analysis 23.3;
Analysis 23.4).
Whilst there were no statistically significant differences observed
between groups for any of the neonatal outcomes reported (Apgar
score less than seven at five minutes, naloxone administration,
need for ventilatory support, neuro-behavioural score at two to
four hours and neuro-behavioural score at 24 to 36 hours) babies
born to women allocated to the fentanyl group were more likely
to need ventilatory support (5/50 versus 0/50; RR 11.00, 95%
CI 0.62 to 193.80) and naloxone administration (14/50 versus 8/
50; RR 1.75, 95% CI 0.81 to 3.80) (Analysis 23.5; Analysis 23.6;
Analysis 23.6; Analysis 23.7; Analysis 23.8; Analysis 23.9).
Intravenous patient controlled opioids for pain relief
in labour
24. PCA pentazocine versus PCA pethidine
One trial involving 29 women compared PCA pentazocine with
PCA pethidine (Erskine 1985).
Primary and secondary outcomes
Women’s self-reported pain score during labour was found to be
lower for those allocated to the pentazocine group compared with
women in the pethidine group, although this difference failed
to reach statistical significance (SMD -0.76, 95% CI -1.62 to
0.09), a difference of 1.6 cm on a 10 cm pain scale might be
considered clinically significant. Similar numbers of women in the
two treatment groups rated their pain relief as good one day after
the birth (Analysis 24.2).
None of the secondary outcomes studied showed a significant dif-
ference between the two study groups (epidural use, sedation, cae-
sarean section, Apgar score less than seven at five minutes, breast-
feeding at discharge) (Analysis 24.3; Analysis 24.5; Analysis 24.6;
Analysis 24.7; Analysis 24.8), with lownumbers of events recorded
for a number of these outcomes. Nausea and vomiting was re-
portedmore frequently bywomen allocated to the pethidine group
compared with the pentazocine group (5/15 versus 0/14; RR 0.10,
95% CI 0.01 to 1.61) but the difference between groups was not
significant.
25. PCA remifentanil versus PCA pethidine
Three trials involving a total of 161 women compared PCA
remifentanil with PCA pethidine (Blair 2005; Douma 2010;
Volikas 2001).
Primary
No primary outcomes were reported upon in these studies.
Secondary outcomes
Two studies (Volikas 2001; Douma 2010) involving 122 women
reported women’s pain score during labour. In both studies pain
was assessed using a VAS ranging from 0 (“no pain”) to 10 cm
(“worst imaginable pain”). In both studies women were asked to
mark the level of pain experienced every hour, starting before anal-
gesia was administered. Results for the Volikas 2001 study were
recorded in a graph and so values have been estimated from the
graph. There was no evidence of a significant difference in mean
pain scores at one hour between the remifentanil and pethidine
groups (average MD -8.59, 95% CI -27.61 to 10.44), Analysis
25.1. There was substantial heterogeneity for this outcome and so
a random-effects model has been used (heterogeneity I² = 62%,
T² = 136.73, Chi² test for heterogeneity P = 0.10) (Analysis 25.1).
Two included studies (Blair 2005; Volikas 2001) reported num-
ber of women requiring additional analgesia (Entonox®) as an
outcome, with most women in both study groups requiring ad-
ditional analgesia (22/29 versus 24/27; RR 0.86, 95% CI 0.69 to
1.08), Analysis 25.2.
Two studies reported number of women crossing over to epidural
as an outcome (Douma 2010; Volikas 2001), with fewer women
in the remifentanil group requiring an epidural (RR 0.42, 95%
CI 0.20 to 0.89) (Analysis 25.3).
Maternal sleepinesswas reported in one study (Douma 2010). This
outcome was assessed using an observer sedation score recorded
hourly (1, awake; 2, sleepy; 3 eyes closed, but rousable by vocal
stimuli; 4, eyes closed, but rousable by physical stimulus; and 5,
unrousable). Mean hourly scores at inclusion and then at one,
two and three hours after analgesia were reported. There was no
evidence of a significant difference in mean sedation scores at one
hour between the remifentanil and pethidine groups (MD 0.40,
95% CI 0.14 to 0.66, (Analysis 25.4).
There was no significant difference found between groups for any
of the other secondary outcomes reported (nausea and vomiting,
assisted vaginal birth, caesarean section, Apgar score less than seven
at five minutes, naloxone administration, admission to NICU) (
Analysis 25.5; Analysis 25.6; Analysis 25.7; Analysis 25.8; Analysis
25.9; Analysis 25.10). Douma 2010 provided mean and standard
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deviation (SD) values for Apgar scores at five minutes and so these
data could not be included in an analysis.
Satisfaction with childbirth experience was reported in one study
(Douma 2010). Two hours after delivery women were asked to
score their overall satisfaction on a 10-point scale (tool not speci-
fied). Women in the remifentanil groups had slightly higher mean
satisfaction scores (MD 1.10, 95% CI 0.46 to 1.74) (Analysis
25.11).
Newborn neuro-behavioural scores were reported in one study
(Douma 2010). The Neurologic and Adaptive Capacity Score
(NACS) was recorded at 15 minutes and two hours after deliv-
ery. There was no significant difference found between groups for
mean scores at 15 minutes or two hours after delivery (Analysis
25.12; Analysis 25.13).
26. PCA nalbuphine versus PCA pethidine
One trial involving 60 women compared PCA nalbuphine with
PCA pethidine (Frank 1987).
Primary and secondary outcomes
Pain score recorded in labour was lower in women allocated to
the PCA nalbuphine group compared with women in the PCA
pethidine group (SMD -0.51, 95% CI -1.02 to 0.00) (Analysis
26.3). Satisfaction with pain relief recorded one day postnatally
was greater for women allocated to receive nalbuphine compared
to those allocated to receive pethidine, although this difference
was not statistically significant (RR 1.29, 95% CI 0.88 to 1.89)
(Analysis 26.1). Similar numbers in the two groups said that they
would use the same pain relief method again in a future labour
(Analysis 26.2).
No statistically significant differences were found between groups
for the three secondary outcomes reported (additional analgesia,
nausea and vomiting, Apgar score less than seven at five minutes)
(Analysis 26.4; Analysis 26.5; Analysis 26.6).
27. PCA fentanyl versus PCA alfentanil
One study involving 23women comparedPCA fentanyl with PCA
alfentanil (Morley-Forster 2000).
Primary and secondary outcomes
Women in the PCA fentanyl group reported lower pain scores on
average than those in the alfentanil group, although the observed
mean difference of 1.3 cm was not statistically significant (MD -
12.80, 95% CI -32.12 to 6.52). In contrast, women allocated to
receive fentanyl were less likely to describe their satisfaction with
their pain relief as “adequate” or “good” within six hours of giving
birth compared with women allocated to receive alfentanil (10/11
versus 7/12; RR 1.56, 95% CI 0.93 to 2.60).
No statistically significant differences were found for any of the
other secondary outcomes reported (nausea, caesarean section,
naloxone administration) (Analysis 27.3; Analysis 27.4; Analysis
27.5).
28. PCA fentanyl versus PCA pethidine
One trial involving 107 women compared PCA fentanyl with
PCA pethidine (Douma 2010).
Primary outcomes
No primary outcomes were reported upon in this study (Douma
2010).
Secondary outcomes
One study (Douma 2010) involving 107women reportedwomen’s
pain score during labour. Pain scores were assessed using a VAS
ranging from 0 (“no pain”) to 10 cm (“worst imaginable pain”).
Mean pain scores were presented at baseline and at one, two and
three hours after analgesia. There was no evidence of a signifi-
cant difference in mean pain scores at one hour between the fen-
tanyl and pethidine groups (MD -0.65, 95% CI -1.56 to 0.26,
Analysis 28.1); however, fewer women in the fentanyl group re-
quired epidural (RR 0.44, 95% CI 0.21 to 0.92) (Analysis 28.2).
Maternal sleepiness was reported in one study (Douma 2010).
This outcome was assessed using an observer sedation score ( from
1, awake to 5, unrousable) recorded hourly. There was no evidence
of a significant difference in mean sedation scores at one hour
between the fentanyl and pethidine groups (MD -0.06, 95% CI -
0.25 to 0.13) (Analysis 28.3).
There was no significant difference found between groups for any
of the other secondary outcomes reported (nausea and vomiting,
assisted vaginal birth, caesarean section) (Analysis 28.4; Analysis
28.5; Analysis 28.6).
Douma 2010 only provided mean and SD values for Apgar scores
at five minutes and so these data could not be included in an
analysis. NACS were recorded at 15 minutes and two hours after
delivery. There was no significant difference found between groups
for mean scores at either time point (Analysis 28.7; Analysis 28.8).
Opioids versus TENS for pain relief in labour
29. Opioids versus TENS
Three trials involving 305women are included in this comparison.
One trial compared IV pethidine (50 mg) versus TENS to the
lower back (Neumark 1978), another IMpethidine (50mg) versus
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TENS to the back (Tawfik 1982) and the third IM tramadol (100
mg) versus TENS to the back (Thakur 2004).
Primary and secondary outcomes
Two studies (Neumark 1978; Tawfik 1982) involving 105 women
reported on maternal satisfaction with analgesia measured post
delivery. In the study by Neumark 1978 women were asked to rate
their satisfaction with analgesia the day after the birth as having
“good”, “inadequate” or “no” analgesic effect. In the study by
Tawfik 1982 women were asked about the degree of relief they had
obtained during the whole period of delivery. This was scored as
being “excellent”, “good” or “satisfactory”. We found no evidence
of a significant difference in maternal satisfaction with analgesia
rated as “good/excellent” between the TENS and opioid groups
(RR 1.23, 95% CI 0.79 to 1.92, two studies) (Analysis 29.1).
Three studies (Neumark 1978; Tawfik 1982; Thakur 2004) in-
volving 305women reported onmaternal painmeasured in labour.
In the study by Neumark 1978 pain was assessed on a six-point
pain scale for a 70-minute period (from 1, “no pain” through 6,
“unbearable pain”). However, data were reported in graphical form
which we were not able to include in the analysis. Tawfik 1982
assessed pain relief 30 minutes after analgesia as being complete,
excellent or good versus slight relief, while Thakur 2004 assessed
pain on a verbal response scale during labour as complete or mod-
erate relief; versus mild or no relief (the time of measurement was
not stated). There was no evidence of a significant difference in
maternal pain scores between the opioid and TENS groups (aver-
age RR 1.15, 95% CI 0.81 to 1.61, two studies). There was sub-
stantial heterogeneity for this outcome and so a random-effects
model has been used (heterogeneity I² = 64%, T² = 0.04, Chi²
test for heterogeneity P = 0.10) (Analysis 29.2).
Two studies (Tawfik 1982; Thakur 2004) involving 290 women
reported on maternal side effects of drowsiness and nausea/vomit-
ing.Women in the opioid groupweremore likely to report drowsi-
ness (RR 8.96, 95% CI 1.13 to 71.07) (Analysis 29.3) and nau-
sea/vomiting (RR 14.06, 95% CI 1.96 to 100.61) (Analysis 29.4)
compared with those in the TENS group, although the 95% CIs
were very wide for both of these outcomes.
One study reported on caesarean section and assisted vaginal birth
rates (Thakur 2004). There were no caesarean sections reported
in either the opioid or TENS groups. There was no evidence of
a significant difference in the number of assisted vaginal births
between groups (RR 5.00, 95% CI 0.24 to 102.85) (Analysis
29.6).
One study reported on fetal distress (Thakur 2004) and found
no evidence of a significant difference between groups (RR 5.00,
95% CI 0.24 to 102.85) (Analysis 29.7).
Two studies reported on Apgar scores (Tawfik 1982; Thakur
2004). However, both studies reported mean scores and these data
are very difficult to interpret. None of the studies reported infor-
mation on the number of babies with Apgar scores less than seven
at five minutes (prespecified outcome).
Subgroup analysis
We did not carry out planned subgroup analysis because most
meta-analyses included data from only one or two studies and
separate breakdown on subgroup categories were rarely provided.
We therefore did not think that examining outcomes for subgroups
would effect the conclusions of the reviewor offer any other helpful
insights.
D I S C U S S I O N
Summary of main results
We set out to answer the question of whether parenteral opioids
provide effective pain relief in labour without causing unpleasant
adverse effects or harm to women and babies. We don’t have a sim-
ple answer to this question. The review includes 29 different com-
parisons, where an opioid was compared with placebo, with an-
other opioid, where different modes of administration were used,
or with transcutaneous electrical nerve stimulation (TENS). Fur-
thermore, for many comparisons there was a lack of consistency
in what outcomes were measured, how they were measured, and
when they were recorded. For most comparisons, and many out-
comes, only one or two studies contributed data, and there were
few opportunities to pool data in meta-analysis. For many com-
parisons data were not reported for many of our prespecified out-
comes.
All of the studies were conducted in hospital settings, on healthy
women with uncomplicated pregnancies at 37 to 42 weeks’ gesta-
tion. We excluded studies focusing on women with preeclampsia
or pre-existing conditions or with a compromised fetus.
Summary of results
• Parenteral opioids provided some pain relief during labour.
• Up to two-thirds of women who received opioids reported
moderate or severe pain following administration of analgesia
and/or poor or moderate pain relief.
• Opioid drugs were associated with nausea, vomiting and
drowsiness, although different types of opioids were associated
with different adverse effects.
• For most outcomes there was no significant evidence of
differences between treatment groups.
• There was insufficient evidence to assess the safety of
opioids in labour.
Intramuscular administration
• For pethidine versus placebo, there was better pain relief
with pethidine, with sleepiness as the main adverse effect. There
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was no evidence of significant differences in adverse effects on
the woman or on the neonate.
• For meptazinol versus pethidine, there was no evidence of a
difference in analgesic effect whether assessed either early or late
during labour, although significantly more women had vomiting
with meptazinol. There was no evidence of a difference in
outcomes for the neonate.
• For diamorphine versus pethidine, an antiemetic was given
as co-therapy to both groups. There was no evidence of
difference in analgesic or adverse effects, with the exception of
vomiting which occurred more frequently in women given
pethidine. Whilst significantly more babies had Apgar less than
seven at one minute with pethidine, by five minutes there was no
difference between groups, and no evidence of differences in
other neonatal outcomes.
• For tramadol versus pethidine, the analgesic effect was
better with pethidine than tramadol, and there was no evidence
of a difference in adverse effects on mother or baby.
• For dihydrocodeine versus pethidine, only one study
contributed data and there was no evidence of a difference in
analgesic effect or adverse effects. Significantly more babies had
Apgar scores less than seven at one minute with pethidine
compared with dihydrocodeine, but the difference was not
apparent by five minutes, and there was no evidence of other
differences in neonatal adverse effects.
• Other intramuscular comparisons, most of which were
tested in only one study, provided few statistically significant
findings. For pentazocine versus pethidine (six studies, one with
antiemetic addition to opioid), phenazocine versus pethidine,
morphine versus pethidine, butorphanol versus pethidine, and
tramadol versus no treatment there was no evidence of a
difference in maternal or neonatal outcomes between groups.
• For nalbuphine versus pentazocine, one study found a
statistically significant difference in maternal satisfaction with
analgesia, in favour of nalbuphine. Fewer women who received
nalbuphine experienced nausea or vomiting.
Intravenous administration
• For most comparisons very few studies contributed data,
and for most outcomes there was no evidence of significant
differences between groups. Several intravenous opioids
(including fentanyl, butorphanol and morphine) appeared to
perform better than pethidine in terms of analgesic effect (either
satisfaction with analgesia or pain scores). Pethidine was
associated with worse side effects: compared with pethidine,
sedation was lower with fentanyl (one study), and nausea was less
with butorphanol and morphine (one study for each
comparison). When fentanyl and butorphanol were compared,
butorphanol was associated with fewer requests for further
analgesia, a reduced need for neonatal ventilatory support, and
fewer babies required naloxone (one study).
Opioids versus transcutaneous electrical nerve
stimulation (TENS)
• For most outcomes there was no evidence of significant
differences between groups (maternal satisfaction with analgesia;
maternal pain scores; caesarean section; assisted vaginal birth
rates; fetal distress). The only significant finding was that women
in the opioid group were more likely to experience drowsiness
and nausea and vomiting than women in the TENS group.
Overall completeness and applicability of
evidence
This review is one of a series of Cochrane reviews examining pain
management in labour; other reviews have examined pharmaco-
logical and non-pharmacological methods of pain management
in labour including biofeedback (Barragán 2011), aromather-
apy (Smith 2011b), relaxation techniques (Smith in progress),
acupuncture (Smith 2011a), TENS (Dowswell 2009), epidural
analgesia (Anim-Somuah 2005) and a range of other methods of
pain management.
Studies included in the review were carried out over a long time pe-
riod (1958 to 2009) during which there have been major changes
in women’s and clinicians’ expectations and views of childbirth
and analgesia during labour. Some drugs commonly used in the
1950s and 1960s may no longer be available. The increasing use
of epidural analgesia in resource-rich countries means that opi-
oids are now less likely to be the drugs of choice in these settings.
Having said this, in many parts of the world epidural analgesia is
not available to all women, and throughout the world parenteral
opioids are still widely used. It is important for all women to make
an informed choice about pain relief options available to them;
however, providing clear information on the effectiveness and sa-
fety of parenteral opioids is not simple in the light of the findings
from this review.
With somany different comparisons and outcomes we are not able
to provide clear information on the acceptability, effectiveness and
adverse outcomes associated with different opioids. In this review
we have not compared the effectiveness of parenteral opioids with
other types of analgesia or as a co-therapy. At the same time, in
many of the studies we have looked at, women were in fact able to
have other analgesia, and this may or may not have been reported.
The use of other analgesia and co-interventions may have differed
by randomisation group, and may have had an independent or
synergistic effect on outcomes for women and babies which we
were not able to detect. For example, women’s use of nitrous oxide
was not consistently reported; the fact that it was not mentioned
in a study does not necessarily mean that it was not used by the
women involved. It was also difficult to determine equivalence in
terms of dosages of different drugs used, their duration of effect
and speed ofmetabolism. Studies also varied in terms of number of
doses available to women, and the stage of labour at which further
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doses were not allowed in order to avoid detrimental effects on the
baby.
There was considerable heterogeneity between studies in the out-
comes measured and how they were reported and perceived. In
some of the older studies (pre-1970), maternal sedation may have
been regarded as a desired effect of opioid drugs, and pain relief
was sometimes reported by carers rather than by women them-
selves. There were varied definitions of similar outcomes such as
nausea, vomiting (or both), sleepiness, drowsiness, etc. and even
greater variation in the way pain and pain relief were measured,
and the time points at which measurements were made.
Despite including 57 studies, there were relatively few statistically
significant results. Many of the studies had small samples and
most did not have the statistical power (singly or pooled) to de-
tect differences between groups for intended or unintended effects
that occur infrequently or rarely. In view of the large number of
comparisons and outcomes, it is likely that some of the signifi-
cant findings we have reported occurred by chance. On the other
hand, for some less frequent outcomes (e.g. low Apgar scores or
the need for neonatal resuscitation), some findings suggested that
there may have been a difference between groups but the studies
often had small sample sizes, and differences between groups did
not achieve statistical significance. In addition, we are aware that
statistical and clinical significance may not be the same thing. For
example, it is difficult to know what a 0.6 cm difference in scores
on a 10 cm visual analogue scale means in this context.
We were surprised by the number of studies where women’s views
of pain relief, or their assessments of pain in labour, were not mea-
sured at all.We were also surprised at the paucity of data on breast-
feeding outcomes. Even more recent studies did not generally col-
lect data on this important outcome, even though observational
studies have suggested that opioids are associated with sedation
in babies and suppression of sucking in the minutes and hours
after birth. We had also hoped to collect information on the costs
associated with using opioid drugs; none of the included studies
provided data on the costs incurred by health service providers.
It is known that opioids cross the placental barrier, and short-term
effects such as the impact of opioids on fetal heart rate patterns
and very early neurological scores have been well documented in
observational and randomised studies. It is not clear that these ef-
fects have any clinical significance or lasting impact on infant well-
being. It has also been suggested that exposure to opioids during
labour may predispose children to serious long-term effects; how-
ever,muchmore research is needed to confirm or refute these find-
ings from observational studies (Jacobson 1990; Nyberg 2000).
None of the studies included in the review followed up women
and babies for more than a few hours or days so we are not able to
contribute to these debates.
All of the included studies examined intravenous or intramuscular
administration; two excluded studies examined the subcutaneous
administration of opioids (Cahal 1960; De Kornfeld 1964); three
studies compared opioids with TENS (Neumark 1978; Tawfik
1982; Thakur 2004).
Quality of the evidence
Overall we found the evidence to be of poor quality regarding
the analgesic effect of opioids, satisfaction with analgesia, adverse
effects and harm to women and babies.
In some studies women were not included in the analysis if they
received the study drug within 30 to 60 minutes of giving birth
or more than four hours before giving birth. Such exclusions are
likely to introduce serious bias; we do not know whether these
women had different outcomes from the rest of the sample, and
it is possible that outcomes may have differed by randomisation
group.
The review’s primary outcomes, maternal satisfaction with anal-
gesia reported during labour and postnatally, were reported in dif-
ferent ways (for example, reports of satisfaction, global assessment
of pain relief ) and were often poorly reported. It was not always
clearly stated to whomwomen reported their pain levels; indeed in
some cases clinicians may have made assessments. These method-
ological problems may mean there was serious response bias in
some studies.
Potential biases in the review process
We are aware that the possibility of introducing bias was present
at every stage of the reviewing process. We attempted to minimise
bias in a number of ways; two review authors carried out data
extraction and assessed risk of bias. Each worked independently.
Nevertheless, the process of assessing risk of bias, for example, is
not an exact science and includes many personal judgements.
While we attempted to be as inclusive as possible in the search
strategy, the literature identified was predominantly written in En-
glish and published in North American and European journals.
We are also aware that publication bias is a possibility, as the review
includes several small studies which reported a number of statis-
tically significant results. Although we did attempt to assess re-
porting bias, constraints of time meant that this assessment relied
on information available in the published trial report and thus,
reporting bias was not usually apparent.
We may have introduced some bias by converting three-, four-
and five-point categorical scales for the measurement of pain or
pain relief into binary outcomes. We attempted to be consistent
across studies, but this was not always possible as the wording of
categories varied in different studies. We have tried to indicate in
the results section, and in forest plots, what event rates in treatment
groups signify.
Agreements and disagreements with other
studies or reviews
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The findings and recommendations of this review are similar to
other reviews on this topic (Bricker 2002; NICE 2007) and to an
earlier Cochrane review looking at IM opioids (Elbourne 2006).
Clinical practice guidelines in the UK recommend that women
should be informed of the risks of intravenous and intramuscular
opioids and of their limitations; NICE 2007 guidelines suggest
that intramuscular and intravenous opioids should be available for
women to choose, women should be informed of the alternatives,
and should be made aware that parenteral opioids may have side
effects (such as nausea and drowsiness) and may interfere with
breastfeeding.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is little high-quality evidence to inform practice; however,
for healthy women with an uncomplicated pregnancy who are
giving birth at 37 to 42 weeks we have reached the following
conclusions.
Parenteral opioids providemoderate pain relief in labour, but cause
sedation, nausea and vomiting in the woman and effects on the
newborn are unclear.
There is insufficient evidence from the review to support the choice
of one opioid over another.
Implications for research
The question many women would like answered is how opioids
compare with other forms of pain relief available for use during
labour, in terms of analgesic effectiveness and the risk of adverse
effects for both women and babies. Given the paucity of useful
information from the current review, it is likely that the evidence
underlying this further question is also limited. It is important that
this evidence is reviewed, however, so that women can be provided
with information that is as complete and accurate as possible,
and so that remaining gaps in knowledge can be identified and
addressed through further research.
We recommend that a large pragmatic randomised controlled trial
(RCT) be undertaken to compare pain relief that includes an opi-
oid with a pain relief regimen not including an opioid, that collects
data prospectively on all important prognostic factors such as co-
interventions. These include additional analgesia and anti-emet-
ics, labour augmentation by means of artificial rupture of mem-
branes or intravenous infusion of oxytocin, use of electronic fetal
monitoring and mode of birth. Outcomes for women and their
babies in the short and longer term are also required.
Maternal outcomes that would be important to guide practice are
actual pain relief and maternal satisfaction with analgesia, impor-
tant unintended effects such as nausea, vomiting and sedation.
For the neonate, Apgar scores at five and 10 minutes, resuscitation
including use of naloxone, neonatal intensive care unit admission,
initial effective suckling and establishment of breastfeeding, seda-
tion and irritability.
With respect to measuring the effectiveness of an opioid for labour
pain, there are a number of issues. Assessment of pain should be
measured in the pause between contractions. In order to minimise
response bias, it is important that maternal pain assessment be
recorded by the woman herself and not by the woman’s caregiver.
Lastly, it is important to assess maternal satisfaction to encompass
more than just the effects on pain but include other CNS effects.
It would be important to measure satisfaction in the short term
(within 24 hours of delivery) and again several days postpartum.
In addition, it is known that maintaining control in labour is
important to women and this relates to pain and pain control;
formal assessment of sense of control in labour would therefore be
useful.
Stratification at baseline of two important predictors of outcome
should includematernal parity and spontaneous or induced labour
onset.
All studies were conducted on women labouring in hospital set-
tings exclusively. Many women labour and give birth in commu-
nity settings, the proportion of which is likely to increase due to
the international initiative to normalise birth, and reduce inter-
ventions associated with complications. Therefore, more research
in midwifery-led units and at home would inform practitioners
using opioids in these settings.
If recruitment of women to RCTs is hampered due to strong ma-
ternal preferences for pain relief, then a prospective observational
study, across different care settings, which collects data on impor-
tant predictors and outcomes as described for the RCT would also
be informative.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Atkinson 1994
Methods RCT 2-arm parallel group design.
Participants Setting: (not clear) hospital in Oklahoma, USA.
100 women in early active labour (with regular contractions and cervical dilatation 3-
4 cm); at term (at or > 37 weeks’ gestation); no medical or obstetric complications or
evidence of fetal distress; requesting a “pain shot” rather than an epidural (all women
were offered epidural)
Interventions Both groups had continuous electronic fetal monitoring and intrauterine pressure
catheters
Experimental: IV fentanyl 50-100 mcg every 1-2 hrs to a max of 5 doses
Control: IV butorphanol 1-2 mg every 1-2 hrs to a max 5 doses
(Doses of drugs were approximately equivalent in both arms of the trial.)
Outcomes Maternal uterine activity; adverse effects and side effects (including vomiting and seda-
tion); pain scored using 10-point VAS (0 = no pain, 10 = excruciating pain) scores were
recorded by nurses; Apgar scores at 1 and 5 min; infant neurological exam 2-4 and 24-
36 hrs after birth
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation schedule.
Allocation concealment (selection bias) Low risk Pharmacy prepared identical unlabelled, coded sy-
ringes.
Blinding (performance bias and detection
bias)
Women
Low risk Identical syringes.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Described as double blind.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Outcome assessors reported as blinded.
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Atkinson 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It was not clear at what point women were ran-
domised.155 women enrolled; 24 decided to have
an epidural and were excluded (it was not clear
whether or not this was after randomisation); 19
women delivered within one hour of first dose and
12 did not request analgesia and were not included
in the analysis. Data available for 100 women; if
loss occurred after randomisation this represents a
very high level of attrition
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Low risk None apparent.
Bitsch 1980
Methods RCT, 2-arm parallel groups.
Participants Germany: hospital setting.
45 women, in labour, cephalic presentation.
Interventions Experimental: IM tramadol 50 mg (N = 23).
Control: IM pethidine 50 mg (N = 22).
Outcomes Primary outcome: maternal analgesia. Pain assessed as good, not good relief 5-10 min
after injection
Secondary outcomes: maternal side effects and fetal heart changes
Notes German language paper, translation obtained. Tramadol 100 mg plus antiemetic arm
not extracted
If additional analgesia required, repeat doses could be administered within < 1 hr
Tramadol: could have up to 3 repeat doses, 50 mg.
Pethidine: could have up to 3 repeat doses, 25 mg.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk Not reported.
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Bitsch 1980 (Continued)
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Assessor was described as unaware of treatment assign-
ment.
Incomplete outcome data (attrition bias)
All outcomes
High risk Women not having a normal birth were excluded from
analyses. No information on pain relief was available for
7/45 women
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unclear.
Blair 2005
Methods RCT, 2-arm parallel groups.
Participants Setting: Belfast hospital, UK.
40 women (healthy and well) in labour, ASA I or II.
Exclusion criteria: women planning to have epidural analgesia, with pre-eclampsia, mul-
tiple pregnancy, premature labour, allergy to study medications
Interventions Experimental: PCA remifentanil 40 mcg with lock-out of 2 minutes
Control: PCA pethidine 15 mg with lock-out of 10 minutes.
Nitrous oxide was available to all women and women were free to choose an epidural at
any stage
Outcomes Maternal sedation score (1-5 fully awake to unrousable); VAS 0-10 for pain and satisfac-
tion with pain relief; nausea; anxiety; Apgar scores at 1 and 5 min; infant neurological
adaptive capacity score (2 hrs and 24 hrs after birth)
Notes VAS scores were reported as median with inter-quartile range. We were not able to enter
data into Revman tables but have described findings briefly in the text
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “women were randomly allocated.”
Allocation concealment (selection bias) Unclear risk Not clear when randomisation occurred or how it was
carried out
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Blair 2005 (Continued)
Blinding (performance bias and detection
bias)
Women
Low risk Described as double-blind study.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Double-blind.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk It was reported that for some outcomes assessment was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 40 women were randomised, 1 women was not included
in the analysis because of a “protocol violation”. 1 woman
that withdrew from the study was included in the analysis
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Low risk No baseline imbalance apparent.
Borglin 1971
Methods RCT, 2-arm parallel groups.
Participants Hospital setting.
199 women: in labour, at term gestation, following normal pregnancy
No inclusion or exclusion criteria reported.
Interventions Experimental: IM pentazocine 20-40 mg (N = 91).
Control: IM pethidine 50-100 mg (N = 89).
Outcomes Primary: analgesic and sedative effects. Pain assessed at time of birth or when second
injection administered, as very good, good, moderate or none
Secondary: maternal and neonatal side effects.
Notes If additional analgesia required opioid repeated once after 3 or > hrs of first injection.
Actual dose received by women not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Ampoules numbered and in random order.
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Borglin 1971 (Continued)
Blinding (performance bias and detection
bias)
Women
Unclear risk Reported as double blind, but no description of how
achieved. Identical volume but appearance not described
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Reported as double blind, but no description of how
achieved. Identical volume but appearance not described
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed, but missing data for some out-
comes
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Low risk Balanced at baseline for age, parity, blood pressure, pulse,
frequency contractions, FHR, augmented labour, inten-
sity of labour, membranes intact or ruptured
Campbell 1961
Methods RCT, 3-arm parallel group design.
Participants Setting: hospital in Baltimore, USA.
212 women randomised (141 included in the analyses in this review)
Inclusion criteria: women admitted to hospital for planned vaginal birth, at term, re-
questing analgesia (birth under regional anaesthesia)
Exlusions: imminent birth, allergy to any study medication or requiring birth under
general anaesthesia
Interventions Interventions at 3-4 cm dilatation for primiparous, and 4-5 cm for multiparous women
Group 1: pentobarbital IV (initial dose 200 mg) dosage varied
Group 2: pethidine IV (initial dose 100 mg), (69 women).
Group 3: morphine IV (initial dose 8 mg), (72 women).
All 3 groups also received 0.4mg of scopolamine. If further analgesia was requiredwomen
were given a half of the initial dose and 0.2 mg of scopolamine. If more than 2 additional
doses were required analgesia was at the discretion of the attending doctor
In this review we have included groups 2 and 3 only in the analyses; pentobarbital (a
barbiturate) is no longer used for pain relief in labour
Outcomes Length of labour, amount of analgesia required, obstetric complications and neonatal
condition (Apgar score at 1 minute). Maternal perceptions were recorded 3 days af-
ter birth (satisfaction and amnesia). A focus of this paper was the perception of staff
on whether women were ”manageable“. Unmanageable women were those who were
”possibly dangerous to others or themselves, perhaps by leaving her bed“. Staff had the
option of removing ”unmanageable women from the study and prescribing whatever
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Campbell 1961 (Continued)
medication was deemed suitable
Notes All women included delivered under regional anaesthesia.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “in a random manner.”
Allocation concealment (selection bias) Low risk Coded vials containing study drugs were provided
by pharmacy
Blinding (performance bias and detection
bias)
Women
Low risk Described as blinded.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk “None of the personnel concerned with the ad-
ministration of the drugs or the evaluation of the
patients’ reaction had access to the master list at
any time.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk “None of the personnel concerned with the ad-
ministration of the drugs or the evaluation of the
patients’ reaction had access to the master list at
any time.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All women appear to be accounted for in the anal-
ysis and there were few missing data.The data re-
garding babies was less clear, denominators were
not provided
Selective reporting (reporting bias) High risk Results were not provided for babies. There was a
statement in the text “there were few infant com-
plications in the neonatal period; none of these ap-
peared related to the drugs”
Other bias Unclear risk Baseline characteristics described as similar.
De Boer 1987
Methods RCT, 2-arm parallel groups.
Participants Setting: UK hospital.
46 women (20 primiparous and 14 multiparous women included in the analyses). Un-
complicated pregnancy
Exclusions: first stage of labour > 12 hr, second stage > 1 hr, body weight < 45 kg, multiple
41Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
De Boer 1987 (Continued)
pregnancy, non-vertex presentation, preterm or postmature labour, previous caesarean
section, birth weight outside the 5th and 95th centiles for gestational age, congenital
fetal abnormality
Interventions Experimental: IM meptazinol 1.5 mg/kg body weight plus 10 mg metoclopramide hy-
drochloride (N = 17)
Control: IM pethidine 1.5 mg/kg body weight plus 10 mg metoclopramide hydrochlo-
ride (N = 17)
Outcomes Neonatal acid-base balance. Maternal pH pre injection, repeated at head crowning,
neonatal pH at 10 and 60 min PN
Notes If additional analgesia required opioid repeated > 3 hrly. Actual dose received by women
not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind but not described.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind but not described.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk States double blind but not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk 12 women excluded from analysis, reasons for all exclu-
sions not explained
Selective reporting (reporting bias) High risk Reasons why some participant data excluded not ex-
plained. 3/12 excluded because problem with pH anal-
yser (meptazinol group)
Other bias Low risk No baseline imbalances.
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Douma 2010
Methods RCT, 3-arm parallel groups.
Participants Setting: The Netherlands, Department of Obstetrics and Gynaecology
180 enrolled, 159 completed the study.
Inclusion criteria: healthy ASA physical status I or II term parturients in an active stage
of labour, with singleton cephalic presentation, without prior administration of opioid
analgesics
Exclusion criteria: obesity (BMI ≥ 40 kg m−2), opioid allergy, substance abuse history,
and high-risk patients (pre-eclampsia, severe asthma, insulin-dependent diabetes melli-
tus, hepatic insufficiency, or renal failure)
Interventions 1. Remifentanil, patient controlled IV, 40 µg loading dose, remifentanil 40 µg per bolus
with a lockout of 2 min and max dose limit of 1200 µg h−1.
2. Meperidine, patient controlled IV, 49.5 mg loading dose and 5 mg bolus with lockout
of 10 min and max dose limit of 200 mg
3. Fentanyl, patient controlled IV, 50 µg loading dose and 20 µg bolus with lockout of
5 min and a max dose limit of 240 µg h−1.
Outcomes Outcomes: pain scores (VAS) every hour; sedation score (1 awake, 2 sleepy, 3 eyes closed,
4 eyes closed but rousable, 5 unrousable; overall satisfaction on 10-point scale 2 hours
after delivery; side effects - nausea,vomiting, itching; Apgar scores at 1, 5mins; cord blood
gas analysis; NACS scores at 15 min and 2 hr after delivery; oxytocin use; instrumental
delivery; CS; spontaneous delivery
Notes “All women received similar instructions on how to use the PCA device: all parturients
were instructed to press the bolus button whenever they needed pain relief.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Established using a computer generated random se-
quence in numbered envelopes.”
Allocation concealment (selection bias) Low risk “Study medication was prepared and blinded by hospital
pharmacy.”
Blinding (performance bias and detection
bias)
Women
Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk “Observants and medical personnel attending to the par-
turient were unaware of the drug assignment.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk “with exception of baseline data, all observations and
measurements were made by blinded observers.”
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Douma 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 180 enrolled, 159 completed the study:
52 R group;
53 M group;
54 F group;
21 excluded because delivered within 1 hour after ran-
domisation
Says “Data analysis was per-protocol”.
Selective reporting (reporting bias) Unclear risk All outcomes discussed in methods appear to have been
reported upon within results. However, the study proto-
col was not evaluated
Other bias Low risk Baseline characteristics similar.
Duncan 1969
Methods RCT, 2-arm parallel groups.
Participants Setting: UK hospital.
200 women. 66% primips, 34% multips, > 35 weeks’ gestation. Singleton, uncompli-
cated pregnancy
Exclusions: toxaemia, chronic medical disease, isoimmunization, obstetric complication
Interventions Experimental: IM pentazocine 48 mg (N = 100).
Control: IM pethidine 120 mg (N = 100).
Nalorphine hydrobromide + methylphenidate given if opioid administered within 2/24
of second stage diagnosis and, or fetal distress
Outcomes Primary outcome: analgesic effects: pain assessed at time of injection and every 30minutes
for 4 hrs. Severe or moderate pain. Pain relief complete, partial or none
Secondary outcomes: maternal: vomiting, blood pressure and pulse. Neonatal: Apgar at
1 minute in babies born within 4 hrs of opioid
Notes If additional analgesia required opioid repeated after 4 hrs. As inclusion criteria > 35
weeks’ gestation, may include preterm infants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States ’double blind’ but does not report how achieved.
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Duncan 1969 (Continued)
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States ’double blind’ but does not report how achieved.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 200 women randomised. Exclusion of women from anal-
yses if inadequacy of records, reached second stage before
analgesic assessment, operative birth or another interven-
tion. Exclusion of babies fromApgar analysis if additional
analgesia given, GA, antidote given to mother pre-birth
or clinical explanation for depressed baby. Denominators
for outcomes not clear
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Balanced at baseline for age, parity, height, weight, blood
pressure, attendance at antenatal classes and infantweight
Erskine 1985
Methods RCT 2-arm parallel group design.
Participants Setting: Cape Town, South Africa.
29 women in established labour, not clear howmany primips, mean age 24 years, women
were expected to have a vaginal birth and have no antenatal medical or obstetric problems
Interventions Experimental: pethidine, IV PCA 10 minute lock out, 0.3 mg per kg
Control: pentazocine, IV PCA 10 minute lock out, 0.15 mg per kg
Outcomes Pain relief in labour (assessed bymidwife); pain relief (measured immediately after labour
(10 cm VAS) and 24 hrs postpartum from mother); satisfaction with pain relief; ma-
ternal and neonatal serum samples; Apgar score at 1 and 5 min; infant weight; neuro-
behavioural examination on 1st and 5th day
Notes The study also included a non-randomised control group; we have not included this
group in the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
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Erskine 1985 (Continued)
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
Women
Unclear risk Not specified.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk It was reported that women were attended by the
same midwife throughout labour who was not in-
formed what medication women received. It is not
clear whether this blinding was achieved for all staff
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Outcome assessors of neonatal outcomes were re-
ported to be blind to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall attrition not clear, there was some missing
data for some outcomes. Denominators were not
provided in all of the results tables
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk No baseline imbalance apparent.
Fairlie 1999
Methods RCT 2-arm parallel group design.
Participants UK setting: hospital.
161 women randomised, data available for 133 women. 52% primips, 48% multips,
cx at least 3 cm dilated, 37 or > weeks’ gestation in spontaneous or induced labour
(induction by amniotomy and IV infusion oxytocin)
Interventions Experimental: IMdiamorphine 7.5mg (primips), 5mg (multips) plus 12.5mg prochlor-
perazine (N = 65)
Control: IM pethidine 150 mg (primips), 100 mg (multips) plus 12.5 mg prochlorper-
azine (N = 68)
Outcomes Primary outcome: maternal pain at 1 hr VAS (0-100), pain intensity (0 = no pain, 1 =
mild pain, 2 = moderate pain, 3 = severe pain), pain relief (0 = none, 1 = slight, 2 =
moderate, 3 = good, 4 = complete)
Secondary outcomes: maternal: vomiting, sedation, global analgesia assessment at 24 hr
(good or poor). Neonatal: Apgar at 1 and 5 min, resuscitation, naloxone administration,
SCBU admission, significant morbidity (seizures, respiratory distress, intraventricular
haemorrhage, necrotising enterocolitis)
Notes Second dose at maternal request: her choice of drug or epidural. Stratified by maternal
parity. Trial stopped early after recruitment of 150 women. Planned sample size was 200
women
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Fairlie 1999 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Block sizes of 6.
Allocation concealment (selection bias) Low risk Coded drug containers, randomisation code not
broken until analysis
Blinding (performance bias and detection
bias)
Women
Low risk States double blind, drug containers identical in
appearance
Blinding (performance bias and detection
bias)
Clinical staff
Low risk States double blind, drug containers identical in
appearance
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk It was stated that the randomisation code was not
broken until the analysis stage
Incomplete outcome data (attrition bias)
All outcomes
High risk 28 (17%) excluded as delivered within 1 hr of ad-
ministration of study drug
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Low risk Balanced at baseline.
Fieni 2000
Methods RCT 2-arm parallel group design.
Participants Italy: hospital care setting.
40 women. Full-term pregnancy, cx ≥ 4 cm, in spontaneous active labour and requiring
analgesia
Interventions Experimental: IM tramadol 100 mg (N = 20).
Control: IM pethidine 75 mg (N = 20).
Outcomes Primary outcome: maternal pain relief and acceptability. Pain assessed hrly up to 5 hrs,
VAS 1-3
Secondary outcomes: maternal: observations (pulse, BP, respiratory rate, arterial oxygen
saturation). Neonatal: Apgar at 1 and 5 min. Umbilcal cord pH
Notes Second dose of study drug allowed after 2 hrs as required. Italian language, translation
obtained. Data were presented in a way in which we were not able to incorporate them
into data tables in RevMan
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Fieni 2000 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many women analysed as only per-
centages reported
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias High risk No baseline characteristics table - unclear re mater-
nal parity
Likely response bias as no information on whom
women reported to about their pain post injection
Frank 1987
Methods RCT 2-arm parallel group design.
Participants Setting: London hospital, UK.
60 healthy women at term (38-42 weeks) requiring pain relief in labour
Women requesting epidural, that had already received opioid analgesia, were receiving
treatment for depression or where the fetus was at risk were excluded
Interventions Experimental: (30 women) nalbuphine, 3 mg with 3 mg increments to a max of 18 mg
per hour; lockout time 10 minutes (total max dose = 42 mg)
Control: (30 women) pethidine, 15 mg, 15 mg increments to a max of 90 mg per hr;
lockout time 10 minutes (total max dose = 210 mg)
Entonox ® was available to women in both groups but was withheld for 30 min for
analgesia assessment. Analgesia was stopped in the 2nd stage if there were side effects or
if the woman requested an alternative method
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Frank 1987 (Continued)
Outcomes Pain (measured on 5-point scale from 1- no pain to 5 - very severe); pain relief (assessed
1 day after birth; pain relief rated as good or excellent and women saying they would use
the same method again); sedation (1 awake, 3 asleep); neuro-behavioural assessment 6 -
10 hrs after birth; FHR
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated.”
Allocation concealment (selection bias) Unclear risk Described as double blind but allocation conceal-
ment was not described
Blinding (performance bias and detection
bias)
Women
Low risk Very little information. Described as double blind.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Very little information. Described as double blind.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Unclear.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was some outcome data for all but one of
the women randomised, but there were high levels
of missing data for some neonatal outcomes (e.g.
neurological infant assessments 40/60 babies avail-
able for analysis)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk There was some baseline imbalance; 6/30 in the
nalbuphine group were multiparous compared
with 12/30 in the pethidine group. The authors
report that they took this into account in the anal-
ysis. In this review data have not been adjusted for
baseline imbalance
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Giannina 1995
Methods RCT, 2-arm parallel groups.
Participants New Jersey USA, hospital setting, 1994.
28 women in labour (36 randomised) with uncomplicated pregnancies, singleton, vertex
presentation, at term (37 - 41 weeks), 4 cm or less cervical dilatation, at least 3 con-
tractions in 10 minutes, no known maternal or fetal conditions that would affect FHR
tracings, fetal reactive, no medications that would affect FHR in the previous 2 weeks
Exclusions criteria: meconium staining, pregnancy induced hypertension, fetal tachy- or
brady-cardia, arrhythmias or decelerations, chorioamnionitis, FGR, abnormal placenta,
maternal fever, fetal chromosomal disorder of structural abnormality
Interventions Experimental: IV nalbuphine10 mg.
Control: IV pethidine 50 mg.
Both groups had continuous fetal monitoring for 1 hour following medication
Outcomes FHR (accelerations, high and low variation); Apgar scores < 8 at 1 and 5 min; mode of
birth; cord pH < 7.15
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number table.
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed envelopes.
Blinding (performance bias and detection
bias)
Women
Unclear risk Not specified.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Not specified.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not specified
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 36womenwere enrolled. 8womendidnot have sufficient
FHR tracings and were not included in the analysis (22%
attrition)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Low risk No apparent baseline imbalance.
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Gillam 1958
Methods RCT, 2-arm parallel group design.
Participants Setting: hospital in USA.
500 women admitted to hospital in labour. Little information provided
Interventions Experimental: (185 women) alphaprodine (Nisentil), initial dose 40mg IV, subsequent
doses IM
Control: (210 women) pethidine, initial dose 100 mg IV, subsequent doses IM
Both groups received scopolamine. Analgesia was for the first stage of labour, birth
was carried out “with rare exception” under “saddle block or pudendal block terminal
anesthesia”
Outcomes Pain relief (rated just before leaving the room for childbirth); side effects and length of
labour
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information.
Allocation concealment (selection bias) Low risk Coded drug containers.
Blinding (performance bias and detection
bias)
Women
Low risk Drugs were prepared by pharmacy in coded con-
tainers and the codes were not revealed until after
birth
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Drugs were prepared by pharmacy in coded con-
tainers and the codes were not revealed until after
birth
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Drugs were prepared by pharmacy in coded con-
tainers and the codes were not revealed until after
birth
Incomplete outcome data (attrition bias)
All outcomes
High risk 500 women were randomised, 55 women received
no analgesia and were excluded, 22 women re-
ceived more than 1 dose of opioid (not necessarily
the same drug) and were excluded, 21 women who
were in preterm labour or had a CS were excluded
and 1 woman was excluded because she was sen-
sitive to study medication. Data available for 395
women (21% attrition)
Selective reporting (reporting bias) Unclear risk Unclear.
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Gillam 1958 (Continued)
Other bias Unclear risk Study medication was for pain relief in the first
stage of labour, most women received a pudendal
block for birth so outcomes relating to birth may
not be attributable to study medication alone
Grant 1970
Methods RCT 2-arm parallel group design.
Participants UK: hospital setting.
212 women in spontaneous or induced labour with cephalic presentation at > 36 weeks’
gestation. Recruited to the trial at 36 week antenatal clinic visit
Interventions Experimental: IM phenazocine 3 mg (N = 107).
Control: IM pethidine 150 mg (N = 105).
Outcomes Primary outcome: maternal analgesia assessed in labour as poor, fair, good, very good.
Pain relief also assessed in postnatal questionnaire within 36 hours of birth
Secondary outcomes: maternal: amnesia, restlessness, anxiety, vomiting. Neonatal: Apgar
at 1 and 5 min
Notes Epidural available if further analgesia required.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Code kept by hospital pharmacist and remained
unbroken until trial completed
Blinding (performance bias and detection
bias)
Women
Low risk States double blind, coded ampoules but no further
description given
Blinding (performance bias and detection
bias)
Clinical staff
Low risk States double blind, coded ampoules but no further
description given
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Code kept by hospital pharmacist and remained
unbroken until trial completed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 212 women randomised. Number of women anal-
ysed is not reported
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Grant 1970 (Continued)
Selective reporting (reporting bias) High risk MW assessed maternal side effects in labour.
Other bias Unclear risk Although baseline characteristics described as sim-
ilar - proportion of primips to multips not pro-
vided. Balanced for age, parity, height , weight, cx
dilatation
PN maternal recollection of pain within 36 hr and
unclear to whom women reported ratings
Hamann 1972
Methods RCT. 2-arm parallel group design.
Participants 185 randomised. Analysis for 160 women in labour.
Inclusion criteria: primiparous, no pregnancy complications.
Exclusions: women with hypertension or pre-eclampsia. It appeared that women who
had any complications during birth (e.g. CS) were excluded after randomisation
Interventions Intervention group: Avacan ® 25 mg IM (a spasmolytic).
Control group: Fortral ® 20 mg IM (pentazocine)
Outcomes Number of requests for analgesia, infant birthweight, Apgar score (at birth)
Notes Data extraction was done from translation notes.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers.
Allocation concealment (selection bias) Unclear risk Described as a double-blind trial butmethodswere
not described
Blinding (performance bias and detection
bias)
Women
Low risk Described as double-blind.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Described as double-blind.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Unclear.
53Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hamann 1972 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 185 women approached, 25 were excluded and re-
sults suggest that any women who had CS were
excluded from the analysis along with women who
had long labours (> 24 hrs) or where no injections
were given
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Assessment of risk of bias done using translation
notes.
Hodgkinson 1979
Methods RCT 4-arm parallel group design.
Participants Setting not clear, USA.
200 women admitted to hospital in the 1st stage of normal labour, mean age 24 years,
women received medication if they complained of moderate or severe pain
Interventions Experimental: (100 women) (i) IV butorphanol 1 mg (67 women) (ii) IV butorphanol
2 mg (33 women)
Control: (100 women) (i) IV pethidine 40 mg (68 women) (ii) IV pethidine 80 mg (32
women)
Outcomes Pain intensity (graphs with hourly readings); pain relief (4-point scale); neuro-be-
havioural assessment 1 day after birth (Scanlon scale)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information.
Allocation concealment (selection bias) Unclear risk No information. Described as “double blind”.
Blinding (performance bias and detection
bias)
Women
Low risk Described as double blind but little detail of meth-
ods of allocation concealment or blinding
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Described as double blind but little detail of meth-
ods of allocation concealment or blinding
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Hodgkinson 1979 (Continued)
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Described as double blind but little detail of meth-
ods of allocation concealment or blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up apparent.
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Very little information on study methods.
Husslein 1987
Methods RCT 2-arm parallel group design.
Participants Austria: hospital setting.
40 women with no pregnancy complications, in spontaneous and induced labour, cx 3
- 5 cm dilated. 72.5% primips, 27.5% multips
Interventions Experimental: IM tramadol 100 mg (N = 20).
Control: IM pethidine 100 mg (N = 20).
Outcomes Primary: pain relief, assessed 10, 30, 60, 120 min after injection using VAS 0-100, 0 =
pain free to 100 strongest pain experienced
Secondary: side effects, augmentation and type of birth.
Notes Not stated in one dose only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk Blinding not described.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Blinding not described.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Blinding not described.
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Husslein 1987 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women analysed.
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Baseline characteristics stated as similar.
Jackson 1983
Methods RCT 2-arm parallel group design.
Participants Setting: UK hospital.
100 women in labour at term gestation with uncomplicated pregnancy
Interventions Experimental: Meptazinol 1.8 mg/kg body weight (N = 50).
Control: pethidine 1.8 mg/kg body weight (N = 50).
All participants received promethazine 12.5 mg with first injection
Outcomes Primary: newborn effects: Apgar score at 1 and 3 min.
Notes If additional analgesia required, a repeat injection could be administered 3 hourly
6/50 women from each arm received a second dose at a 3-hourly interval
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind but method not described.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind but method not described.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk States double blind but method not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk 5 babies excluded from analysis due to heart defects
and fetal distress
Selective reporting (reporting bias) Unclear risk Unclear.
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Jackson 1983 (Continued)
Other bias Unclear risk Balanced for parity, weight and size of baby at base-
line.
Kainz 1992
Methods RCT 3-arm parallel group design.
Participants Setting: Germany, hospital.
66 women. 38-41 weeks’ gestation, free of complications, in active labour and requiring
analgesia, excluded if analgesia received within 4 hours of randomisation
Parity: not reported.
Interventions Experimental: IM tramadol 100 mg (N = 20); IM tramadol 100 mg + triflupromazine
10 mg (N = 25)
Control: IM pethidine 50 mg + triflupromazine 10 mg (N = 21)
Unclear if single or multiple doses administered, and if additional analgesia administered
Outcomes Maternal outcomes:maternal pain intensityVAS (0-10 cm) 30, 60, 120 and 180minutes,
vomiting, drowsiness, blood pressure, heart rate, cardiotocogram
Notes Tramadol 100 mg only group (A) not included in our analyses. German language,
translation obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “zulfallszahlentafel” coincidence number table.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk Stated as double blind but methods not described.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Stated as double blind but methods not described.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Stated as double blind but methods not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2/66 women excluded due to giving birth within 1
hour of study drug administration
Selective reporting (reporting bias) Unclear risk Unclear.
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Kainz 1992 (Continued)
Other bias Unclear risk Unclear.
Kamyabi 2003
Methods RCT 2-arm parallel group design.
Participants Setting: hospital in Iran.
88 primiparous women in spontaneous labour, gestation ≥ 37 weeks, and cervix 5 cm
dilated
Excluded if high-risk pregnancy, narcotic addiction.
Interventions Experimental: IM (placebo) normal saline 1.5 ml (N = 44).
Control: IM pethidine 75 mg (N = 44).
Outcomes Primary: analgesic effect. Pain assessed pre and post injection using Likert Scale VAS: 10
cm line, 0% = minimum effect, 100% = maximum effect
Secondary: side effects on uterine contractions (contraction duration and interval
recorded 3 times 15 - 60 min post injection) and neonatal Apgar score at 1 and 5 min
Notes Timing of maternal pain assessment not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’divided randomly’.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Low risk Study agents were of identical volume and appear-
ance.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Study agents were of identical volume and appear-
ance.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Study agents were of identical volume and appear-
ance.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants analysed and planned anal-
ysis not reported
Selective reporting (reporting bias) Unclear risk Unclear.
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Kamyabi 2003 (Continued)
Other bias Unclear risk The number of women allocated to each group
is not reported and unclear if there are baseline
imbalances in prognostic factors
Keskin 2003
Methods RCT 2-arm parallel group design.
Participants Turkey: hospital setting.
59 primiparous women with uncomplicated pregnancy at term gestation, in labour with
cervix 3-5 cm dilated and reporting a pain score 4 - 5 according to Wong-Baker Faces
Pain Rating Scales with 0 = no pain, 5 = most intense pain
Exclusions: maternal medical disorders, history of drug or alcohol abuse
Interventions Experimental: IM tramadol 100 mg, single dose (N = 30).
Control: IM pethidine 100 mg, single dose (N = 29).
Outcomes Primary: analgesic effect assessed 30, 60 and 120 minutes following injection using
Wong-Baker Faces Pain Rating Scales with 0 = no pain, 5 = most intense pain
Secondary: side effects: nausea, vomiting, drowsiness, fatigue and neonatal effects (Apgar
score at 1 and 5 min)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported. “randomly divided into two groups”.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Outcome assessor unaware of treatment group.
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-upnot explained andno intention-
to-treat analysis
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Keskin 2003 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unclear.
Khooshideh 2009
Methods RCT 2-arm parallel group design.
Participants Setting: Iran, hospital.
160 women. Free of complications, spontaneous and induced onset, cx 4 cm dilated, in
active labour and requiring analgesia. Women excluded if cx dilated > 5 cm
Parity: not reported.
Interventions Experimental: IM tramadol 100 mg (N = 80).
Control: IM pethidine 50 mg (N = 80).
2nd dose on maternal request after 4 hours but pethidine withheld if cx dilated > 8 cm
and tramadol given instead
Outcomes Maternal outcomes: maternal pain intensity VAS (0-10 cm) 10, 30 and 1 hourly intervals
until birth,maternal satisfaction 24 hours postpartum5-point scale (excellent, very good,
good, fair, poor), drowsiness, nausea, vomiting. Neonatal outcomes: Apgar score at 1
and 5 minutes, naloxone administration, respiratory depression
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated codes.
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed opaque envelopes.
Blinding (performance bias and detection
bias)
Women
Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Drugs administered by clinician blind to group al-
location, but does not state how this was achieved
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Women fed back theirmaternal pain score to anaes-
thetist.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow chart addresses all data.
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Khooshideh 2009 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Baseline characteristics similar.
Lardizabal 1999
Methods RCT 2-arm parallel group design.
Participants Argentina: 2 hospitals.
310 women of mixed parity, in labour 37-42 weeks’ gestation with cervix 4-6 cm dilated,
cephalic presentation and requiring analgesia
Exclusions: maternal medical condition, evidence of fetal distress, previous caesarean
section
Interventions Experimental: IM nalbuphine 20 mg, single dose (N = 152).
Control: IM pethidine 100 mg, single dose (N = 158).
Outcomes Primary: neonatal Apgar score < 7 at 1 min.
Secondary: maternal pain assessed using VAS pre-injection, and 30 and 120 min after-
wards (severe pain 75 or >), nausea, vomiting and type of birth. Neonatal side effects:
condition over first 24 hrs, admission to neonatal intensive care nursery
Notes Stratified by hospital.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated code.
Allocation concealment (selection bias) Low risk Coded ampoules, sealed and prepared by indepen-
dent pharmacist and identical in appearance
Blinding (performance bias and detection
bias)
Women
Low risk Identical ampoules.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Identical ampoules.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Few losses to follow-up.
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Lardizabal 1999 (Continued)
Selective reporting (reporting bias) Unclear risk Not mentioned if women reported pain to their
caregiver.
Other bias Unclear risk Data analyst unaware of coding. Balanced at base-
line.
Levy 1971
Methods RCT 2-arm parallel group design.
Participants USA: hospital setting.
93 primiparous women in labour, uncomplicated pregnancy at 37 or more weeks’ ges-
tation and in pain described as moderate or severe
Interventions Experimental: IM pentazocine 60 mg (N = 38).
Control: IM pethidine 100 mg (N = 45).
Outcomes Primary: pain relief assessed at 1 hr, as good or poor.
Secondary: maternal side effects, nausea or vomiting, labour progress.Neonatal Apgar
score at 1 and 5 min
Notes If additional analgesia was required, a second injection could be administered at the
discretion of medic. Not stated if IOL onset included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Identical vials with code number but no further
information given
Blinding (performance bias and detection
bias)
Women
Low risk Identical vials with code number.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Identical vials with code number.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk No-one involved with the immediate care of the
woman knew the drug identity
Incomplete outcome data (attrition bias)
All outcomes
High risk 83/93 women analysed and reasons for missing
data not reported
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Levy 1971 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unclear how many women randomised to each
group and balance at baseline unclear
Li 1988
Methods (Feasibility study) RCT, 2-arm parallel group design.
Participants 10 primiparous women in labour requesting pain relief, and who had no made any
request for alternative analgesia
Interventions Intervention group: meptazinol (PCA IM) up to 600 mg (75 mg per ml)
Comparison group: pethidine (PCA IM) up to 400 mg (50 mg per ml)
Doses described as equivalent. Nitrous oxide available to women in both groups
Outcomes Pain, drowsiness and nausea on a 100 mm VAS (0 = no pain) during labour and also
rated on the day after birth; Apgar score and neonatal weight gain over 3 days
Notes Feasibility study focusing on PCA IM administration of opioids
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described, “randomly allocated”.
Allocation concealment (selection bias) Unclear risk Described as a double-blind comparison
but methods not described
Blinding (performance bias and detection
bias)
Women
Unclear risk Described as a double-blind comparison
but methods not described
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Described as a double-blind comparison
but methods not described
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Described as a double-blind comparison
but methods not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10 women randomised and all accounted
for in the analysis.
Selective reporting (reporting bias) Unclear risk Unclear.
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Li 1988 (Continued)
Other bias Unclear risk No baseline imbalance apparent.
Li 1994
Methods RCT. 2-arm parallel groups.
Participants Setting: Beijing hospital, China.
60 women in early labour (cervical dilatation 2-3 cm) at term, with singleton pregnancy,
vertex presentation, with no pregnancy complications
Interventions Intervention group: 100 mg IM tramadol.
Comparison group: no analgesia.
Outcomes Analgesic effect (not clear when measured); satisfactory, some effect or no effect
Notes Data extraction from translation notes.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Women were divided “at random” into groups.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
Women
High risk Women in the control arm received no treatment.
Blinding (performance bias and detection
bias)
Clinical staff
High risk Women in the control arm received no treatment.
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Women in the control arm received no treatment.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Denominators not clear. No apparent loss to follow-up.
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk It was not clear whether or not women in the comparison
group were given any analgesia or whether they requested
any
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Lisboa 1997
Methods RCT 2-arm parallel group design.
Participants Brazil: hospital.
56 women.
No information in abstract about participant inclusion criteria or characteristics
Interventions Experimental: IM nalbuphine 10 mg.
Control: IM pethidine 100 mg.
Outcomes Analgesia and side effects.
Neonatal: Apgar score.
Notes Abstract only: insufficient information about participants.
Not reported if > 1 dose given or anti-emetic.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Described as “randomly selected” but not explained
how.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding (performance bias and detection
bias)
Women
Unclear risk Not mentioned.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Not mentioned.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not mentioned.
Selective reporting (reporting bias) Unclear risk Impossible to decipher.
Other bias Unclear risk Impossible to decipher.
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Maduska 1978
Methods RCT 2-arm parallel group design.
Participants Setting: US hospital.
80 women at term gestation, in spontaneous and induced labour with moderate to severe
pain
Exclusions: drug abuse history, systemic disease and women who planned to breastfeed
their babies
Interventions Experimental: IM butorphanol 1 or 2 mg (N = 40).
Control: IM pethidine 40 or 80 mg (N = 40).
Outcomes Primary: pain intensity assessed 30 and 60 min post injection. Described as 1 = slight
relief, 2 = moderate relief, 3 = good relief, 4 = complete relief. Maternal satisfaction of
overall drug effect assessed postnatally as 1 = poor, 2 = fair, 3 = very good, 4 = excellent
Secondary: neonatal Apgar score at 1 and 5 min, resuscitation. Maternal nausea and
vomiting
Notes If additional analgesia was required, a second dose of original drug could be administered
Maternal parity not reported but different drug dosage depending on parity
Almost all (77/80) participants were non-Caucasion and all were delivered with local or
regional anaesthesia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Drugs in consecutively numbered, identical vials
prepared by independent laboratory
Blinding (performance bias and detection
bias)
Women
Low risk States double blind, drugs in identical vials.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk States double blind, drugs in identical vials.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women analysed.
Selective reporting (reporting bias) Unclear risk Unclear.
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Maduska 1978 (Continued)
Other bias Unclear risk Balanced at baseline for type of labour, weight, age,
type of birth and anaesthetic agent
Mitterschiffthaler 1991
Methods RCT 2-arm parallel group design.
Participants Setting: Germany.
40 women. Term pregnancy, cx dilated 2-3 cm, spontaneous labour onset, in active
labour and requiring analgesia
Parity: not reported.
Interventions Experimental: IM nalbuphine 0.1 mg/kg (N = 20).
Control: IM pethidine 0.8 mg/kg (N = 20).
States dosing was ’on demand’. Unclear if single or multiple doses administered, and if
additional analgesia administered
Outcomes Maternal outcomes: maternal pain relief VAS (0-20 cm) 30, 60, 90 and 120 minutes,
opinion of pain relief 12 hours postpartum, sedation 4-point scale (awake, tired, sleeping
but will wake if spoken to, sleeping but will wake if shaken, asleep not possible to wake
up) 30, 60, 90 and 120 minutes, ’side effects’, blood pressure, heart rate, CTG. Neonatal
outcomes: Apgar score at 10 minutes, respiratory depression
Notes German language - translation obtained.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
High risk Not reported.
Blinding (performance bias and detection
bias)
Clinical staff
High risk Not reported.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 4/40 women excluded due to insufficient pain re-
lief.
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Mitterschiffthaler 1991 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unclear.
Moore 1970
Methods RCT 2-arm parallel group design.
Participants Setting: UK hospital.
206 mixed parity healthy women, in spontaneous or induced labour, at > 35 weeks’
gestation, cephalic presentation and in pain described as severe, moderate or slight
Interventions Experimental: IM pentazocine 40 mg (N = 73).
Control: IM pethidine 100mg or 50 mg (N = 133).
Outcomes Primary: pain intensity assessed at 30, 60 and 90 min post injection, described as severe,
moderate or slight. Asked at 12 - 24 hr postnatal if drug had helped
Secondary: neonatal Apgar score at 1 and 5 min, maternal side effects of nausea or
vomiting
Notes If additional analgesia required, a maximum of 3 further doses of study drug could be
administered at 2-3 hrly intervals. Women could also use nitrous oxide and some had a
paracervical block
> 35 weeks’ gestation therefore preterm babies may be included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Coded ampoules but no further information given.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind.Coded ampoules but not stated
if identical in appearance
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind.Coded ampoules but not stated
if identical in appearance
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk States double blind.Coded ampoules but not stated
if identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
High risk 29/206 excluded because delivered or had paracer-
vical block.
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Moore 1970 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unclear.
Morley-Forster 2000
Methods RCT, 2-arm parallel group design.
Participants Setting: labour ward of a university health centre in Canada
23 women randomised when they requested analgesia, 83% primips, gestational age >
32 weeks, weight < 100 kg or > 50 kg, able to speak English, no history of opioid abuse
and normal fetal heart tracing
(Women recruited to the study had medical contraindications to epidural although it
was no specified what these were.)
Interventions Experimental: fentanyl, PCA 10 micro g per ml, initial bolus dose 1 ml, basal infusion
rate of 2 ml per hr with PCA bolus 2 ml
Control: alfentanil, PCA 100 micro g per ml, initial bolus dose 1 ml, basal infusion rate
of 2 ml per hr with PCA bolus 2 ml
Doses described as equivalent. Drugs were discontinued in both groups when the at-
tending midwife estimated that birth was likely to take place within 15 min
Outcomes Pain (rated on a 100 mm VAS, recorded at baseline and every 30 minutes thereafter);
sedation (nurse rated hourly); side effects; satisfaction with pain relief (good, adequate,
inadequate); Apgar scores at 5 and 10 minutes;cord blood gases; naloxone dose; neonatal
neuro-behavioural score at 4 and 24 hrs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation schedule prepared by pharmacy.
Allocation concealment (selection bias) Low risk Plain, numbered vials prepared by pharmacy.
Blinding (performance bias and detection
bias)
Women
Low risk Plain vials prepared by pharmacy.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Plain vials prepared by pharmacy.
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Morley-Forster 2000 (Continued)
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Stated that assessmentwas carried out by staff blind
to group assignment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 25 women were randomised. 2 did not follow the
protocol andwere not followedup.Therewasmiss-
ing data for some variables
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Small sample size and the onset of analgesia varied.
Morrison 1987
Methods RCT 2-arm parallel group design.
Participants Setting: UK hospital.
1,100 women. 37-42 weeks’ gestation, in active labour and requiring analgesia
Parity: 44% primips, 56% multips.
Interventions Experimental: IM meptazinol 100 mg ≤ 70 kg, 150 mg > 70 kg (N = 513)
Control: IM pethidine 1100 mg ≤ 70 kg, 150 mg > 70 kg (N = 522)
Second dose, epidural or inhalation analgesia at maternal request
Outcomes Maternal outcomes: maternal pain at 30, 60, 90 and 120 minutes VAS (0-100 mm),
nausea, vomiting, sleepiness, use of supplementary analgesia, method of birth, opinion
of analgesic effect assessed 3-5 days postpartum (rated excellent, good, poor but just able
to cope, no effect and required additional analgesia). Neonatal outcomes: Apgar at 1 and
5 min, resuscitation, naloxone administration, fetal distress, type of feeding
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Coded drug containers prepared at a site remote
from the trial
Blinding (performance bias and detection
bias)
Women
Low risk States double blind and used coded drug contain-
ers.
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Morrison 1987 (Continued)
Blinding (performance bias and detection
bias)
Clinical staff
Low risk States double blind and used coded drug contain-
ers.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk States double blind and used coded drug contain-
ers.
Incomplete outcome data (attrition bias)
All outcomes
High risk 65 women excluded due to clerical errors or ad-
ministration of wrong drug
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Women were balanced at baseline for age, weight,
parity and gestation
Mowat 1970
Methods RCT 2-arm parallel group design.
Participants Setting: UK hospital.
94 women. > 35 weeks’ gestation, age ≥ 18 years, excluded if diabetic, history of renal
or hepatic impairment or taking monoamine oxidase inhibitors, in active labour and
requiring analgesia
Parity: ≤ 3.
Interventions Experimental: IM pentazocine 60 ≤ mg (N = 46).
Control: IM pethidine 15 ≤ 0 mg (N = 48).
Up to 3 injections > 3 hours apart at maternal request.
Outcomes Maternal outcomes: satisfied with analgesia, nausea, vomiting, sleepiness, use of addi-
tional analgesia (study drug), method of birth. Neonatal outcomes: Apgar at 1 and 5
min
Notes Data for some outcomes available after first dose.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind but how achieved not reported.
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Mowat 1970 (Continued)
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind but how achieved not reported.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk States double blind but how achieved not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Exclusions from most analyses.
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Low risk Balanced at baseline for age, parity, induced labour
onset.
Nel 1981
Methods RCT 2-arm parallel group design.
Participants Setting: South Africa - hospital.
75 women. Healthy with no clinically detectable abnormality, in active labour, sponta-
neous and induced, and requiring analgesia. Excluded if history of hypersensitivity to
any drug, previous caesarean, preterm labour, cardiac, pulmonary or renal disease and
significant hypertension
Parity: mixed.
Interventions Experimental: IM meptazinol 100 mg (N = 37).
Control: IM pethidine 100 mg (N = 38).
No concomitant analgesia given, metoclopramide 10 mg as required for nausea
Outcomes Maternal outcomes: pain at 1 hr 5-point VAS scale, drug-related side effects. Neonatal
outcomes: Apgar at 1 and 5 min, paediatrician assessment at 24 hours
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind but does not describe how
blinding achieved
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Nel 1981 (Continued)
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind but does not describe how
blinding achieved
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk States double blind but does not describe how
blinding achieved
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of women randomised not reported only
number analysed, not same numbers analysed for
all outcomes
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Women requiring caesarean or epidural were ex-
cluded from further study, unclear if this is pre- or
post-randomisation
Nelson 2005
Methods RCT, 3-arm parallel group design.
Participants Setting: hospital in North Carolina USA.
45 healthy women with singleton pregnancies requesting analgesia
Women with allergies to the study medication, those that had already had medication
and those taking opioids for chronic conditions were excluded, along with those with
any signs of fetal distress
Interventions Experimental: (15 women) IV butorphanol, 1 mg bolus.
Control: (15 women) IV pethidine, 50 mg bolus.
(A second control group received IV pethidine 25 mg plus 0.5 mg butorphanol; this
group has not been included in the analyses in this review.)
Outcomes Pain (measured on a 0 -10 numerical rating scale); sedation and nausea, Apgar scores at
1 and 5 minutes
Notes Results for pain outcomes were reported on bar charts and are difficult to interpret. We
have not included these results in the analyses in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer generated balanced block design”.
Block size not stated
Allocation concealment (selection bias) Unclear risk Study described as double-blind but not details on
allocation concealment provided
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Nelson 2005 (Continued)
Blinding (performance bias and detection
bias)
Women
Low risk Described as double blind.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk The “drug was prepared by an anaesthesiologist
not involved with the treatment of the patient or
obtaining study measures”
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk It was not clear how many women were ran-
domised. Any women undergoing ARM, com-
mencing oxytocin or requesting epidural were
excluded after randomisation and were replaced
“their randomization was re-entered for another
patient”. Women who reached 10 cm dilation
within 1 hr of drug administration were also ex-
cluded from the analysis
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unclear.
Neumark 1978
Methods Randomised trial (methods unclear).
Participants 30 women.
Inclusion criteria: ”co-operative patients“ with no drug dependency. Various ages and
social groups
Exclusion criteria: unclear.
Interventions 5 study groups:
1) TENS group - TENS to lower back (10 women).
2) 50 mg IV pethidine (5 women).
3) Placebo TENS (no current) (5 women).
4) ”Wrong“ TENS (electrodes applied to wrong positions) (5 women)
5) No analgesia or intervention (5 women).
Outcomes Pain intensity (grades 1 - 6 - no pain, light, bearable, heavy, very heavy, unbearable)
over 70-minute period. Satisfaction with analgesia 1 day after the birth ”Reaction of the
subjects the day after the birth to analgesia - rated as “good”, “inadequate analgesia” or
“none” - table 2. Progress in labour
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Neumark 1978 (Continued)
Notes Paper in German. Translation notes used for data extraction.
We were unable to use the data from this paper in the review. We had intended com-
paring outcomes for women receiving IV pethidine versus no treatment. The only out-
come reported in the paper was the amount of relief obtained from the analgesia and no
outcomes were reported for the control group (no treatment). 5 women received pethi-
dine and 5 women no treatment. It was reported that 2/5 women receiving pethidine
had “good relief ”, 3 had insufficient or no relief. All women in the control group were
reported as having an increase in pain
Results - categories for pain relief (good, insufficient, none) do not correspond with pain
scale - 6 perceptions reported in the translation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described - “randomly divided”.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
Women
Unclear risk 1 group received no treatment. TENS groups -
1 without current and 1 where it was applied
to wrong positions were blinded to the TENS
intervention. Pethidine group presumably were
not blinded
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Not clear.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not clear.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 woman was lost to follow-up.
Selective reporting (reporting bias) Unclear risk Small study and results were difficult to inter-
pret.
Other bias Unclear risk Translation, so difficult to evaluate other bias.
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Nicholas 1982
Methods RCT 2-arm parallel group design.
Participants Setting: UK hospital.
450 women. Healthy women with no obstetric complications, full-term pregnancy, in
active labour and requiring analgesia. Excluded if history of hypersensitivity to any drug,
previous caesarean, preterm labour, cardiac, pulmonary or renal disease and significant
hypertension
Parity: not reported.
Interventions Experimental: IM meptazinol (N = 186 analysed).
Control: IM pethidine (N = 172 analysed).
Both given according to body weight. 75 mg if 38-50 kg, 100 mg if 51-69 kg or 150
mg if 70-85 mg. Each patient received up to 2 injections of study drug, and if analgesia
still inadequate epidural given
Outcomes Maternal outcomes: maternal assessment of pain relief at 15, 30, 45, 60, 90 and 120 min
(rated none, poor, satisfactory, good, very good or complete), type of birth, epidural,
sleepiness, nausea and vomiting. Neonatal outcomes: Apgar at 1 and 5 min, apnoea,
resuscitation, and lethargy, muscle tone, irritability success of feeding within first 24-
hour period
Notes Does not report number randomised to each group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind but does not describe methods
used.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind but does not describe methods
used.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk States double blind but does not describe methods
used.
Incomplete outcome data (attrition bias)
All outcomes
High risk 79.5% follow-up but no intention-to-treat analy-
sis.
Selective reporting (reporting bias) Unclear risk Unclear.
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Nicholas 1982 (Continued)
Other bias Unclear risk Unclear.
O’Dwyer 1971
Methods RCT 2-arm parallel group design.
Participants Setting: UK hospital.
100 women. Age > 18 years, > 35 weeks’ gestation, uncomplicated singleton, vaginal
birth expected, in active labour and requiring analgesia
Parity: 9% primips, 76% multips, 15% grand multips.
Interventions Experimental: IM pentazocine 30 mg (N = 48 analysed).
Control: IM Pethilorfan ®100 mg (N = 50 analysed).
Second injection possible after 2 hr, each patient could receive up to 4 injections of study
drug, and nitrous oxide or trilene to supplement analgesia if required
Outcomes Maternal outcomes: maternal assessment of pain relief (numbers obtaining or not ob-
taining pain relief ), type of birth, additional analgesia required (study drug). Neonatal
outcomes: Apgar at 1 and 5 min, naloxone administration
Notes Does not state actual number randomised to each group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind but does not describe how this
was achieved
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind but does not describe how this
was achieved
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk States double blind but does not describe how this
was achieved
Incomplete outcome data (attrition bias)
All outcomes
High risk 31/98 excluded from primary outcome as delivered
within 1 hour of administration of study drug, and
16 babies excluded from Apgar assessment as study
drug administered more than 4 hours before birth
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O’Dwyer 1971 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Balanced at baseline for age, parity, contractions
and vital signs
Olofsson 1996
Methods RCT 2-arm parallel group design.
Participants Stockholm Sweden, hospital setting.
20 healthy nulliparous women in active labour after spontaneous rupture of the mem-
branes, cephalic presentation. No exclusion criteria specified
Interventions Experimental: 0.05 mg/kg IV morphine up to 3 doses (max 0.15 mg/kg body weight)
Control: 0.5 mg/kg IV pethidine up to 3 doses (max 1.5 mg/kg body weight)
Both groups had continuous FHR monitoring.
Outcomes Sedation rates; CS, nausea and vomiting.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “assigned at random.”
Allocation concealment (selection bias) Low risk Coded ampoules provided by pharmacy.
Blinding (performance bias and detection
bias)
Women
Low risk Described as double blind; pharmacy provided
identical coded ampoules
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Described as double blind; pharmacy provided
identical coded ampoules
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Unclear.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent loss to follow-up.
Selective reporting (reporting bias) Unclear risk Unclear.
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Olofsson 1996 (Continued)
Other bias Unclear risk Small sample and no clear information that groups
were comparable at baseline. Range of cervical di-
lations at recruitment between 4 and 9 cm
Olson 1964
Methods RCT, 2-arm parallel group design.
Participants Setting: Washington, USA.
194 women in established labour. Analgesia was given at approximately 4-5 cm cervical
dilatation
Interventions Experimental: IV phenazocine 1 mg.
Control: IV pethidine 50 mg.
Both groups received promethazine 50 mg, and for both groups “birth was accomplished
under pudendal nerve block anaesthesia with terminal self-administered trichloroethy-
lene”
Outcomes Pain relief (recorded by women on the first postpartum day); nausea and vomiting;
adverse effects; progress in labour; Apgar scores at 1 and 5 mins
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Low risk Drugs were prepared by pharmacy in identical
coded vials and the code was not broken by the
pharmacist until the study had been completed
Blinding (performance bias and detection
bias)
Women
Low risk Drugs in identical vials.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Pharmacy prepared identical coded drugs.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Unclear.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data for some outcomes (approximately
5% for maternal postpartum outcomes, and 10%
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Olson 1964 (Continued)
for nurse recorded evaluations in labour)
Selective reporting (reporting bias) Low risk None apparent.
Other bias Low risk None apparent.
Osler 1987
Methods RCT 2-arm parallel group design.
Participants Setting: Denmark - hospital.
199 women. Spontaneous or induced labour onset, in active labour and requiring anal-
gesia
Parity: 78% nullips, 22% multips.
Interventions Experimental: IM meptazinol 100 mg (N = 100). Control: IM pethidine 750 mg (N =
99). Each patient could receive up to 3 injections of study drug with an interval of not
less than 2 hours between doses
Outcomes Maternal outcomes: maternal assessment of pain relief 5, 15, 30, 60, 90, 120 min (rated
complete, good, satisfactory, unsatisfactory), type of birth, additional analgesia required,
epidural, adverse effects. Neonatal outcomes: Apgar at 1 and 5 min, neonatal distress,
admission to SCBU
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk Described as double blind but no methods de-
scribed.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Described as double blind but no methods de-
scribed.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Described as double blind but no methods de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women analysed.
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Osler 1987 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk No baseline imbalance in age, weight, height or
number of previous deliveries
Prasertsawat 1986
Methods RCT 3-arm parallel group design.
Participants Setting: Thailand - hospital.
135women. 37 to 42weeks’ gestation, cx≥ 3 cm, in active labour and requiring analgesia
Parity: not reported.
Interventions Experimental: IM tramadol 100 mg (N = 45); IMmorphine 100 mg (N = 45). Control:
IM pethidine 100 mg (N = 45). Second injection possible after 1 hr of half original study
dose, each participant could receive maximum of 2 doses
Outcomes Maternal outcomes: pain severity/relief 30min, 1, 2, 3, and4 hrs (rated good, satisfactory,
no response), drowsiness, nausea, vomiting. Neonatal outcomes: Apgar at 1 and 5 min,
neonatal resuscitation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States blind but does not describe the method.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States blind but does not describe the method.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Medical students unaware of group allocation as-
sessed outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed.
Selective reporting (reporting bias) Unclear risk Unclear.
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Prasertsawat 1986 (Continued)
Other bias Low risk Age and maternal weight balanced at baseline.
Quilligan 1980
Methods RCT, 2-arm parallel group design.
Participants Setting not clear (hospital in USA).
100 women in good health in active labour, with no addiction to or tolerance to drugs
and complaining of moderate to severe pain. Women who “planned to nurse” were
excluded
Interventions Experimental: (50 women) IV butorphanol 1-2 mg (44 women had an initial dose of 1
mg and 6 an initial dose of 2 mg, after one hr or more a 2nd dose was given if requested)
Control: (50 women) IV pethidine 40-80 mg (45 women had an initial dose of 40 mg
and 5 an initial dose of 80 mg, a 2nd dose was given after 1hr or more if requested)
Outcomes Pain (5-point scale 0 - no pain, 4 - very severe pain); pain relief (5-point scale 0 - none,
4 - complete relief ); FHR; Apgar scores at 1 and 5 minutes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
Women
Unclear risk Described as double blind study but no details pro-
vided.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Unclear.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Unclear.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Outcome data were available for all women ran-
domised.
Selective reporting (reporting bias) Unclear risk Unclear.
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Quilligan 1980 (Continued)
Other bias Unclear risk No baseline imbalance was apparent although 8
women in the butorphanol group were induced
compared with 1 woman in the pethidine group
Rayburn 1989a
Methods RCT. 2-arm parallel groups.
Participants Setting: Nebraska university hospital, USA.
105 women in early active labour (3-4 cm cervical dilation); at or beyond 37 weeks’
gestation with no medical or obstetric complications, with no signs of fetal distress
and requesting narcotic analgesia rather than an epidural. (Intervention group: 55%
nulliparous, 71% non-white race, mean age 23 years; control group: 48% nulliparous,
70% non-white race, mean age 23 years.)
Interventions Experimental: (49 women) IV fentanyl 50-100 mcg per hr.
Control: (56 women) IV pethidine 25-50 mg per hr.
Outcomes Pain (measured on 10-point VAS recorded by labour ward nurses); nausea and vomiting;
sedation; itching; fetal heart rate changes
Notes Women were recruited only between 8 am and 3 pm on weekdays.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pharmacy randomisation table.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
Women
High risk Decribed as not blinded.
Blinding (performance bias and detection
bias)
Clinical staff
High risk Staff not blind to group allocation.
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Staff not blind to group allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised seem to be included in the results.
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Rayburn 1989a (Continued)
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Women were recruited only on weekdays between 8am
and 3pm so may not represent the population attending
the study hospital
Refstad 1980
Methods RCT, 2-arm parallel group design.
Participants Setting: Norway - hospital.
85 women. Healthy women at term, expected to have a normal birth in active labour
and requiring analgesia
Parity: not reported.
Interventions Experimental: IM pentazocine 45 mg (N = 43).
Control: IM pethidine 100 mg (N = 42).
Half dose repeated after 1hr if required and further full dose after 3hr if labour prolonged.
All women received promazine 25 mg IM before 1st injection, nitrous oxide or pudendal
block or both allowed at end of 2nd stage
Outcomes Maternal outcomes: pain relief at 1 hr (0 = no pain, 1 = slight pain, 2 = moderate pain,
3 = severe pain), type of birth, additional analgesia required. Neonatal outcomes: Apgar
at 1 and 5 min, naloxone administration, fetal heart rate changes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
High risk No blinding.
Blinding (performance bias and detection
bias)
Clinical staff
High risk No blinding.
Blinding (performance bias and detection
bias)
Outcome assessor
High risk No blinding.
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Refstad 1980 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 25/85 women excluded from analysis as delivered
within 1 hour of 1st dose of study drug
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Nitrous oxide or pudendal block permitted during
second stage
Sheikh 1986
Methods RCT, 2-arm parallel group design.
Participants Setting: UK - hospital.
205 women. Healthy women 38-41 weeks’ gestation, uncomplicated pregnancy, spon-
taneous or induced labour onset, in active labour and requiring analgesia. Excluded if
epidural or forceps birth likely
Parity: mixed.
Interventions Experimental: IM meptazinol 100 mg (N = 98).
Control: IM pethidine 100 mg (N = 99).
Additional doses of test drug allowed at intervals no less than 2 hrs if required to a maxi-
mum of 3 doses. All women could receive nitrous oxide if required and prochlorperazine
12.5 mg IM for nausea and vomiting. Epidural at midwife discretion
Outcomes Maternal outcomes: pain intensity 30 min and then hourly intervals until birth (rated
none, mild, moderate, severe), pain relief (rated none, slight, moderate, strong or com-
plete), type of birth, additional analgesia required, nausea and vomiting. Neonatal out-
comes: Apgar at 1 and 5 min, resuscitation. Within 72 hrs postpartum feeding problems,
irritability and muscle tone
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Coded ampoules kept at a site remote from trial.
Blinding (performance bias and detection
bias)
Women
Low risk Described as double blind, used coded ampoules
and states that identity of drug unknown
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Described as double blind, used coded ampoules
and states that identity of drug unknown
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Sheikh 1986 (Continued)
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Blind outcome assessor for all bar 15% of women.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8 women excluded from analysis as delivered
within 30 minutes of administration
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Balanced at baseline for age and weight, but im-
balance in parity. 43/98 multip meptazinol group
versus 34/99 in pethidine group
Sliom 1970
Methods RCT, 3-arm parallel group design.
Participants Setting: SA - hospital.
196 women. Healthy women at term, uncomplicated labour, in active labour expected
to deliver in next 4 hours and requiring analgesia. Excluded if likely to deliver within 30
min and had received analgesia within previous 6 hours
Parity: mixed.
Interventions Experimental: IM dihydrocodeine 50 mg (N = 80).
Control: IM pethidine 100 mg (N = 58), placebo (saline) (N = 58)
Single dose of study drug.
Outcomes Maternal outcomes: pain relief at 1 hour (rated good, fair, poor), sedation (rated drowsy,
alert but calm, restless), nausea, vomiting. Neonatal outcomes: Modified Apgar at 1 and
5 min (minus colour)
Notes Women excluded after randomisation if delivered more than 4 hours after injection of
study drug
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind. Not reported how blinding
was achieved.
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Sliom 1970 (Continued)
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind. Not reported how blinding
was achieved.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk States double blind. Not reported how blinding
was achieved.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of women randomised not reported, au-
thors only report the number of women analysed
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unequal number of women in each treatment
group due to post-randomisation exclusions. Ex-
clusions included women who delivered < 30 min-
utes or > 4 hours after administration of study
agents
Tawfik 1982
Methods RCT: methods not clear.
Participants Setting: Egypt.
90 primiparous women with normal presentation and position and expected to deliver
normally
Interventions Intervention: pethidine 50 mg IM 4-5 hourly.
Comparison: TENS applied to back. The position arranged to suit the mother and
moved to lower abdomen if preferred
Both groups were given 10 mg diazepam IM. Both groups had artificial rupture of
membranes at 5 cm and oxytocin augmentation
Outcomes Pain intensity (scored as being: severe = 3; moderate = 2; mild = 1) - only measured
before intervention; pain relief scored (complete = 4, excellent = 3, good = 2, slight
(satisfactory) = 1) at 30 mins, 5 cm and at full cervical dilatation; patient’s opinion on
the technique - satisfaction (during whole period of delivery), scored as (excellent = 3,
good = 2, satisfactory = 1); Apgar score; side effects (drowsiness, nausea, vomiting)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly divided between 2 groups.”
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Tawfik 1982 (Continued)
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding (performance bias and detection
bias)
Women
High risk Not reported - but not feasible with nature of interventions
Blinding (performance bias and detection
bias)
Clinical staff
High risk Not reported - but not feasible with nature of interventions
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Not reported - but not feasible with nature of interventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent loss to follow-up.
Selective reporting (reporting bias) Unclear risk All outcomes described within the methods are reported
upon within the results. However, the study protocol was
not evaluated
Other bias Unclear risk Unbalanced groups; 35 in the intervention group and 55 in
the comparison group
Thakur 2004
Methods RCT.
Participants Setting: Indore, India.
300women in established labour attending for care in a hospital in India. The participants
were described as being predominantly from low socio-economic groups and from urban
areas
Inclusion criteria: term pregnancy (37-42 weeks), vertex presentation, cervical dilatation
3 cm or more with contractions
Exclusion criteria: previous uterine scar, malpresentation, multiple pregnancy, cephalo-
pelvic disproportion, antepartum haemorrhage, pre-eclampsia or othermedical disorders
Interventions Interventions group: TENS to back.
Comparison group 1: 100 mg intramuscular tramadol.
Comparison group 2: no intervention.
Outcomes Maternal pain score measured on a verbal response scale during labour “degree of anal-
gesia” (degree of pain relief: no relief, mild relief, moderate relief, complete relief - di-
chotomised as a percentage); mean time for onset and duration of analgesia; duration of
stages of labour; mode of delivery (normal, forceps, CS); mean Apgar score of neonates;
side effects for mothers
Notes
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Thakur 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomly allocated” but groups were of identi-
cal size with identical numbers of primiparous and multiparous
women in each group
Allocation concealment (selection bias) Unclear risk Method of randomisation not described.
Blinding (performance bias and detection
bias)
Women
High risk No blinding reported - but not possible due to nature of inter-
vention
Blinding (performance bias and detection
bias)
Clinical staff
High risk No blinding reported.
Blinding (performance bias and detection
bias)
Outcome assessor
High risk No blinding reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Apparently there was no loss to follow-up.
Selective reporting (reporting bias) Unclear risk All outcomes described within the methods are reported upon
within the results.However, the study protocol was not evaluated
Other bias Unclear risk Groups were unusually similar and it was not clear that there
had been stratification to achieve such balanced groups
Tharamas 1999
Methods RCT. 2-arm parallel groups.
Participants 200 nulliparous women in labour.
Inclusion criteria: at term (37-42 weeks) spontaneous labour, in active labour, vertex
presentation
Exclusions: age < 16 or > 35, weight < 50 or > 75 kg, infant birthweight estimated <
2500 or > 4000 g, medical or surgical complication or unable to understand VAS
Interventions Intervention group: IM buprenorphine 300 mcg.
Comparison group: IM pethidine 75 mg.
Outcomes Analgesic effect at 1, 2, 3, 4 hrs, side effects (nausea, drowsiness, use of antidote)
Notes Data extraction from translation notes.
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Tharamas 1999 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
Women
Low risk Treatment described as blinded.
Blinding (performance bias and detection
bias)
Clinical staff
Low risk Treatment described as blinded.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Unclear.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Denominators in tables not clear.
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unclear.
Tsui 2004
Methods RCT, 2-arm parallel group design.
Participants Setting: Hong Kong - hospital.
50women.Healthywomen in early active labour and requiring analgesia.Uncomplicated
singleton term pregnancy, cephalic presentation. Spontaneous and induced labour onset.
Excluded if epidural already requested
Parity: 3:2 nullip:multip ratio.
Interventions Experimental: IM pethidine 100 mg (N = 25).
Control: placebo (saline) (N = 25).
Single dose of study drug.
Rescue analgesia allowed after 30 min nitrous-oxide or epidural for women in pethidine
group and pethidine for women in placebo group
Outcomes Maternal outcomes: pain intensity at 15 and 30 min VAS (0-100), maternal assessment
of sedation at 15 and 30 min VAS (0-100), type of birth, additional analgesia required,
vomiting, maternal satisfaction at 30 min 5-point scale (1 = totally dissatisfied to 5 =
very satisfied). Neonatal outcomes: Apgar at 1 and 5 min, resuscitation and admission
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Tsui 2004 (Continued)
to SCBU
Notes Study terminated after 50 women recruited as interim analysis demonstrated benefit for
pethidine. Stratified by parity
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated in blocks of 10.
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque sealed envelopes.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind and women blind to contents
of syringe.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind and staff blind to contents of
syringe.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk States double blind and assessor blind to contents
of syringe
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women accounted for in the analysis.
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias High risk 20/25 women in pethidine group versus 12/25
women in placebo group had labour induced
which may affect maternal and neonatal outcomes
Viegas 1993
Methods RCT, 3-arm parallel group design.
Participants Setting: Singapore - hospital.
90 women. Women aged 18 to 35 years in active labour and requiring analgesia, cx 3-
5 cm, uncomplicated term pregnancy with uncomplicated birth expected, spontaneous
or induced labour onset. Excluded if preterm labour
Parity: 100% nullips.
Interventions Experimental: IM tramadol 50 mg (N = 30), tramadol 100 mg (N = 30)
Control: IM pethidine 75 mg (N = 30).
Single dose of study drug.
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Viegas 1993 (Continued)
Outcomes Maternal outcomes: pain relief at 10, 20, 30, 45 and 1 hour 4-point scale (0 = none, 1 =
insufficient, 2 = sufficient, 3 = complete pain relief ), type of birth, drowsiness, nausea,
vomiting. Neonatal outcomes: Apgar at 1 and 5 min, resuscitation and admission to
SCBU
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Low risk States double blind, identical syringes prepared
separately from clinical observer
Blinding (performance bias and detection
bias)
Clinical staff
Low risk States double blind, identical syringes prepared
separately from clinical observer
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk States double blind, identical syringes prepared
separately from clinical observer
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed.
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unclear.
Volikas 2001
Methods RCT, 2-arm parallel group design.
Participants Setting: hospital in Surrey, UK.
17 healthy women 36-40 weeks’ gestation requesting pethidine for pain relief in labour,
ASA I or II. Women with a contraindication to pethidine or remifentanil or requesting
epidural were excluded
Interventions Experimental: IV PCA remifentanil, 0.5 mcg bolus per kg (based on antenatal booking
weight) with 2 min lock-out, no hourly max
Control: IV PCA pethidine, 10 mg bolus, 5 min lock-out, 100 mg hourly max
All women were given 10 mg metoclopramide IV over 8 hrs.
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Volikas 2001 (Continued)
Outcomes Maternal: pain on 10 cmVAS recorded hourly; nausea recorded on a 10 cmVAS; itching;
BP pulse and resps
Neonate: 1 and 5 min Apgar scores.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described “randomly allocated”.
Allocation concealment (selection bias) Low risk “by selecting the next in a series of sealed envelopes
prepared by pharmacy.”
Blinding (performance bias and detection
bias)
Women
Low risk Women were described as blind.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk “One investigator selected the envelope and pre-
pared the PCA pump. the pump was covered so
that the other investigator, the observer, was un-
able to see which drug the woman was receiving.”
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up apparent although for some
outcomes it was not clear what the denominators
were
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Low risk None apparent.
Wahab 1988
Methods RCT. 4-arm parallel groups.
Participants Setting: hospital in Cairo, Egypt.
80 multiparous women at term (39-41 weeks), 19-27 years (parity 2-6), in the first stage
of labour following uncomplicated pregnancies, spontaneous labour
Women with respiratory or cardiac disease were excluded.
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Wahab 1988 (Continued)
Interventions Group 1: IM nalbuphine 0.13 mg/kg.
Group 2: IM butorphanol 0.16 mg/kg.
Group 3: IM pentazocine 0.4 mg/kg.
Group 4: IM placebo.
Outcomes Pain relief 0 = complete relief, 3 = no relief. Apgar score at 1 and 5 min. Maternal and
fetal blood gases
Notes Data were reported as means and have not been included in data tables. We describe
findings briefly in the text
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described “randomly divided”.
Allocation concealment (selection bias) Unclear risk Not described “four equal groups”.
Blinding (performance bias and detection
bias)
Women
Unclear risk Not clear. Placebo controlled, but not clear if women or
staff were aware of group assignment
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Unclear.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Unclear.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear.
Selective reporting (reporting bias) Unclear risk Not clear when randomisation took place and denomi-
nators in tables not clear
Other bias Unclear risk The equal division into groups suggests that there may
not have been true random allocation
Wheble 1988
Methods RCT, 2-arm parallel group design.
Participants Setting: UK - hospital.
47 women. Women in active labour and requiring analgesia, 37-42 weeks’ gestation,
singleton pregnancies with no known disorders, spontaneous or induced labour onset
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Parity: mixed.
Interventions Experimental: IM meptazinol (N = 17).
Control: IM pethidine (N = 17).
Study dose dependent on woman’s weight: 100 mg if weight < 70 kg, 150 mg if weight
≥ 70 kg. Additional analgesia at discretion of caregiver, either 2nd dose of study drug,
epidural or nitrous oxide, metoclorpromide as required for nausea and vomiting
Outcomes Maternal outcomes: type of birth, additional analgesia, epidural. Neonatal outcomes:
Apgar at 1 and 5 min, fetal heart rate changes
Notes Open non-randomised control arm.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk Described as double blind but methods not de-
scribed.
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk Described as double blind but methods not de-
scribed.
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Described as double blind but methods not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients analysed in an ITT analysis.
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Balanced at baseline for height, weight, age, socioe-
conomic group, gestation, cervical dilation, parity
and smoking
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Wilson 1986
Methods RCT, 2-arm parallel group design.
Participants Setting: UK - hospital.
80 women. Healthy women in active labour and requiring analgesia, ≥ 38 weeks’ gesta-
tion, uncomplicated pregnancy
Parity: 4 or less.
Interventions Experimental: IM nalbuphine 20 mg (N = 37). Control: IM pethidine 100 mg (N =
35). Additional doses of test drug allowed at intervals no less than 2 hrs if required to
a maximum of 3 doses. Epidural if analgesia inadequate at discretion of caregiver and
subsequently removed from trial
Outcomes Maternal outcomes: pain intensity at peak of contraction at 30, 60 and 90min (rated very
severe, severe, moderate, slight) and with VAS (0-100), type of birth, sleepiness, nausea
and vomiting. Neonatal outcomes: Apgar at 1 and 5 min, naloxone administration,
Scanlon score (neuro-behavioural score) at 2-4 and 24 hrs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Women
Unclear risk States double blind and study drugswere dispensed
in coded ampoules
Blinding (performance bias and detection
bias)
Clinical staff
Unclear risk States double blind and study drugswere dispensed
in coded ampoules
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 8/80 excluded from analyses due to inadequate
pain relief.
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Does not report actual number randomised per
group. Broadly comparable at baseline with respect
to physical and obstetric characteristics
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ARM: artificial rupture of the membranes
ASA: American Society of Anesthesiologists Classification
BMI: body mass index
BP: blood pressure
CS: caesarean section
CTG: cardiotocograph
cx: cervix
FGR: fetal growth restriction
FHR: fetal heart rate
GA: gestational age
IM: intramuscular
IOL: induction of labour
ITT: intention to treat
IV: intravenous
min: minutes
multips: multiparous women
MW: midwife
nullips: nulliparous women
PCA: patient controlled analgesia
PN: postnatal
primips: primiparous women
RCT: randomised controlled trial
resps: respirations
SC: subcutaneous
SCBU: special care baby unit
TENS: transcutaneous electrical nerve stimulation
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aiken 1971 This study compares the use of diazepam versus a placebo. Both groups had pethidine
Balcioglu 2007 In this study group allocation was by order of hospital admission (alternate allocation). Not an RCT
Balki 2007 In this study both groups received the same drug (remifentanil) by PCA. The focus of the study was on
variation in the bolus size versus variation in the background infusion rate. Studies that examine variation in
mode of administration will be considered in a separate related Cochrane review
Ballas 1976 There was no evidence that this study was an RCT. There were 3 study groups and all 3 received pethidine
(1 after 1-hour delay). The aim of the study was to monitor uterine activity over 60 minutes
Bare 1962 This study examined the effects of hydroxine hydrochloride, an antihistamine. None of the study groups
received an opioid analgesic drug
Bredow 1992 This study was not an RCT. Alternate allocation to groups.
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(Continued)
Brelje 1966 This was a quasi-randomised study with group allocation by month of birth. The aim of the study was to
look at hydroxine as an adjunct to pethidine. both study groups had pethidine
Busacca 1982 In this study 1 group received pethidine with promethazine and 1 received no treatment. As the opioid group
received a combination of drugs any differences between groups may have been due to the effect of the add-
on drug
Cahal 1960 This study had 3 groups: SC pethidine, SC benzethidine and SC flurethidine. We are not aware that, apart
from pethidine, these drugs are used any longer for pain relief in labour
Calderon 2006 In this study 1 group received IV remifentanil and 1 group received IM pethidine with haloperidol. With 1
group receiving an add-on drug it would not be possible to compare the effects of the 2 opioids
Callaghan 1966 In this study pethidine was compared with the use of a sedative. It was not clear that this was an RCT
Camann 1992 This study compared IV sufentanil with epidural analgesia. Epidural analgesia in labour is covered in a related
Cochrane review
Castro 2004 This study was for pain relief during second trimester labour for termination of pregnancy and so not for
pain relief for labour of childbirth
Cavanagh 1966 This study had 4 groups: pethidine IM, amileridine IM, pethidine + perphenazine IM and amileridine +
perphenazine IM. We are not aware that amileridine is used any longer in obstetric practice
Chang 1976 It was not clear that participants in this trial were all in labour. The aim of the study was to examine fetal
acid balance, with maternal and fetal blood sampling 30 and 60 minutes after administering the drugs. No
other outcomes were recorded
Cincadze 1978 Brief conference abstract. It was not clear that this was an RCT. We attempted to trace the authors for more
information without success
Cullhed 1961 This was not an RCT. Groups were divided into groups according to date of hospital attendance
Dan 1991 In this study 1 group received IV nalbuphine and the other pethidine with promethazine, as the pethidine
group had an add-on drug it is not possible to compare the 2 opioids
De Kornfeld 1964 This study was excluded for methodological reasons; there was extremely high attrition for some outcomes
(> 50%). SC pethidine and placebo were compared in this study; however, it appeared that the drugs were
administered very late in labour. Of 224 women included in the analysis, it appeared that more than half had
given birth within an hour of drug administration. There were data on pain relief for only approximately
103 women at 1 hour. Results were very difficult to interpret
De Lamerens 1964 All study groups received pethidine. The aim of the study was to examine the effects of tranquillisers as
adjuncts to analgesics
Eames 1964 This study had 2 groups: pethidine 100 mg IM and oxymorphone 1.5 mg IM. Oxymorphone is no longer
used for pain relief in labour
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El-Kerdawy 2010 This study compared opioids with epidural analgesia. Epidural analgesia in labour is covered in a related
Cochrane review
Eliot 1975 There was no evidence that there was random allocation in this study. There were 2 study groups and both
received pethidine, the aim of the study was to compare drugs administered as an adjunct to the opioid
analgesia (diazepam vs promazine)
Evron 2005 In this study 2 different drugs using different modes of administration were compared. IV pethidine (with
dummy PCA) was compared with PCA remifentanil (with dummy background IV infusion). With both the
drug and method being different in each arm of the trial results from this study are very difficult to interpret
Evron 2007 PCA IV pethidine was compared with epidural analgesia.
Evron 2008 In this study with 4 different treatment arms, 1 group received IV remifentanil, the remaining 3 received
epidural analgesia. Epidurals are covered in a separate Cochrane review
Gambling 1998 This study compared IV pethidine versus a combined spinal epidural
Ginosar 2003 Study examining IV versus epidural fentanyl.
Goodlin 1988 Entry in trials register. It is not clear that this study was completed. We attempted to contact the author and
searched for any published results relating to this trial without success
Grandjean 1979 Study examining IV versus epidural analgesia.
Greer 1988 The study evaluated the effects of the interventions on platelet function in the newborn
Hodgkinson 1978 In this study both randomised groups received pethidine. 1 group also received naloxone. A third, non-
randomised “matched” group received no narcotic drugs
Isenor 1993 In this study both groups received the same drug (pethidine). The focus of the study was on variation in
route of administration; IM was compared with PCA (IV) pethidine. Studies that examine variation in mode
of administration will be considered in a separate related Cochrane review
Kalaskar 2007 No results were reported in this brief abstract. We attempted to contact the author without success
Kaltreider 1967 Only women in preterm labour were recruited to this study. This study was excluded for methodological
reasons: there was no information about the number of women randomised and women who received any
additional non-study medications were excluded post randomisation. Under these circumstances interpreting
the findings of this study are very difficult
Krins 1969 Study participants were not women in labour
Li 1995 In this study 2 opioid drugs were compared (tramadol and dihydroetorphine hydrochloride). However, the
drugs were administered by different routes (sublingual versus oral) and results are therefore very difficult to
interpret
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MacVicar 1960 Not an RCT; consecutive allocation to groups. Study examining the sedative effects of drugs and their effects
on memory
Malkasian 1967 In this study both groups received pethidine. The focus of the trial was on the use of promethazine versus
hydroxyzine as add-on drugs
McDonald 1964 This study included 5 study arms and focused specifically on neonatal serum bilirubin, an outcome not
relevant to this review
McGrath 1992 A study examining epidural versus IV analgesia.
McInnes 2004 In this study both groups received the same drug (diamorphine) either by PCA or IM. Studies that examine
variation in mode of administration will be considered in a separate related Cochrane review
McQuitty 1967 This study focused on promethazine, promazine and propiomazine ad adjuncts to pethidine. All study groups
received pethidine
Moore 1974 It was not clear that this was a randomised trial. Women were paired and then allocated in sequence to 4
study arms
Morgan 2004 This was a pilot study reported as an abstract only and there was too little information on methods and
results to assess risk of bias and results did not include outcomes relevant to this review
Morris 1994 Study focusing on IV versus epidural fentanyl.
Nafisi 2006 Study comparing IV pethidine versus epidural.
Nikkola 2000 In this study women in the 2 arms of the trials were given different drugs with different routes of adminis-
tration. PCA IV fentanyl was compared with paracervical blockade; 10 ml 0.25% bupivacaine injected into
4 locations in the cervix
Overton 1992 This study comparing sublingual diamorphine with IM pethidine was reported in a brief abstract; no de-
nominators for study groups were provided. We attempted to contact the study author for more information
without success
Pandole 2003 In this study women received either IM tramadol or IM pethidine. It was not clear that this was an RCT
Polley 2000 This study compared IV vs epidural fentanyl (epidural analgesia is the subject of separate Cochrane reviews)
Posner 1960 In this study both groups received pethidine; the focus of the study was on a narcotic antagonist (levallorphan)
as an adjunct to pethidine
Powe 1962 All 3 groups in this study received pethidine. The aim of the study was to examine the effects of promethazine
and propiomazine as adjuncts to pethidine
Rabie 2006 This study compared the use of IV PCA remifentanil versus epidural
Ransom 1966 This study had 2 groups: pethidine 125 mg IM and oxymorphone 1.25 mg IM
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Rayburn 1989 In this study both groups received the same drug (pethidine) by PCA versus nurse administered (IV). Studies
that examine variation in mode of administration will be considered in a separate related Cochrane review
Rayburn 1991 In this study both groups received the same drug (fentanyl) 1 group by PCA and 1 nurse administered (IV).
Studies that examine variation in mode of administration will be considered in a separate related Cochrane
review
Roberts 1957 In this study a mood enhancing drug (methylpentonol) was compared with an analgesic (pethidine). The
outcome was not pain relief but fetal expiratory volume. There was no comparison of analgesic drugs in
labour. We are not aware that methylpentonol is any longer used during childbirth
Roberts 1960 In this study both groups received the same IM opioid analgesia (alphaprodine). The study examined the
effects of a narcotic antagonist (levallorphan) as an adjunct to the opioid
Robinson 1980 This study compared different ways of administering pethidine (IM vs IV); the IM group received an anti-
emetic the IV group didn’t. 386 women were randomised but there appears to have been serious attrition with
complete data for only approximately a third of women randomised. Attrition was mainly due to protocol
deviations. With these methodological problems findings from this study are very difficult to interpret
Ron 1984 Study examining the value of promethazine as an adjunct to pethidine. The study did include a placebo group
but the only result reported was maternal blood pressure ten minutes after injection of the drug/ placebo
Rowley 1963 This was a quasi-randomised study. The outcomes collected in this study were neonate bilirubin levels
Savage 1955 Quasi-randomised study with alternate allocation.
Sentnor 1966 This study had 4 groups: pethidine 50 mg, 75 mg or 100 mg IM, oxymorphone 0.75 mg, 1.125 mg or 1.
5 mg, pethidine + noroxymorphone IM and oxymorphone + noroxymorphone IM. Oxymorphone is no
longer used in clinical practice
Shahriari 2007 In this study IV remifentanil was compared with IM pethidine. As both the drug and the route were different
we excluded this study as results are difficult to interpret
Singh 2001 Not an RCT.
Solek-Pastuszka 2009 This study compared opioids with epidural analgesia. Epidural analgesia in labour is covered in a related
Cochrane review
Soontrapa 2002 This was a quasi-randomised study and allocation could be anticipated
Sosa 2004 This study focused on women with dystocia and the use of pethidine to promote progress in labour. Women
requiring pain relief were excluded
Spellacy 1966 All study groups received pethidine; the aim of the study was to look at the effects of adjuncts
Suvonnakote 1986 In this study comparing IM pethidine and IM tramadol the report states that the sample was randomly
selected, but there was no indication that there was random allocation to groups
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Taskin 1993 In this study the focus was on the rate of cervical dilatation rather than pain relief. The study was reported
in a brief abstract; we attempted to contact the authors for more information without success
Thurlow 2002 In this study 2 different drugs with different modes of administration were compared. IM pethidine (with
an antiemetic) was compared with PCA remifentanil. In view of the different modes of administration we
decided to exclude this study as results are very difficult to interpret
Tomlin 1965 It was not clear that the women included in this study were in labour; women were recruited in the third
trimester admitted to hospital following complications or “awaiting caesarean section or the birth of multiple
pregnancies”
Tournaire 1980 This study, otherwise eligible for the review, focused on the effect of pethidine on the frequency and intensity
of uterine contractions and the rate of cervical dilatation; no other outcomes were reported
Treisser 1981 This study did not focus on pain relief in labour; rather, it examined the effects of different drugs on progress
in labour for women with dystocia (oxytocin, chlorpromazine, ritodine and pethidine were compared)
Tripti 2006 Quasi-randomised study with alternate allocation.
Vavrinkova 2005 There was no evidence that this was an RCT.
Volmanen 2005 This study compares IV remifentanil with inhaled 50% nitrous oxide in a cross-over trial. Results were not
reported separately for the first stage of this trial
Volmanen 2008 This study compared IV remifentanil versus epidural analgesia
Von Vorherr 1963 This study focused on speeding up progress in labour. In this group study groups received oxytocin as well
as analgesics and women in the control arm received an higher dose of oxytocin
Walker 1992 In this study pethidine was compared with a NSAID ketorolac. Ketorolac is not used nowadays in obstetric
analgesia
Wan 1965 Both study groups received pethidine; the aim of the study was to look at the effects of a sedative as an
adjuvant therapy
Wiener 1979 In this study epidural analgesia was compared with IM pethidine. It was not clear that this was an RCT
Williams 1962 Both groups in this study received pethidine. The aim of the study was to examine the effects of a narcotic
antagonist (levallorphan) as an adjunct to pethidine
Wong 2005 This study is reported in a series of papers and conference abstracts. The study examined the use of an
intrathecal opioid as part of a combined spinal epidural compared to a systemic opioid. Epidural analgesia
is covered in a separate related Cochrane review
IM: intramuscular
IV: intravenous
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NSAID: non-steroidal anti-inflammatory drug
PCA: patient controlled analgesia
RCT: randomised controlled trial
SC: subcutaneous
Characteristics of ongoing studies [ordered by study ID]
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D A T A A N D A N A L Y S E S
Comparison 1. Pethidine 100 mg IM versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction at 30
minutes (number of women
satisfied or very satisfied)
1 50 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.38, 128.87]
2 Maternal pain relief good or fair
(1 hour)
1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.24, 2.47]
3 Pain relief at 30 minutes
(reduction in VAS of at least 40
mm)
1 50 Risk Ratio (M-H, Fixed, 95% CI) 25.0 [1.56, 400.54]
4 Additional analgesia 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.54, 0.94]
5 Epidural 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.14, 1.78]
6 Nausea and vomiting 2 166 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.65, 3.31]
7 Maternal sleepiness 2 166 Risk Ratio (M-H, Fixed, 95% CI) 4.67 [2.43, 8.95]
8 Assisted vaginal delivery 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.34, 2.19]
9 Caesarean section 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.29, 2.38]
10 Low Apgar score (≤ 7) at 1 and
5 minutes
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Low scores at 1 minute 2 166 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.52, 5.18]
10.2 Low scores at 5 minutes 1 50 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Neonatal resuscitation 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.45, 6.24]
12 Admission to NICU 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.12]
Comparison 2. Meptazinol versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain relief poor or
none (3-5 PN)
1 801 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.91, 1.12]
2 Pain intensity 4 or 5 on 5-point
scale (1 hour)
2 239 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.69, 1.80]
3 Additional analgesia required 2 233 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.88, 1.20]
4 Epidural 4 788 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.71, 1.29]
5 Nausea and vomiting 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Nausea 3 1590 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.95, 1.28]
5.2 Vomiting 3 1589 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.06, 1.47]
6 Maternal sleepiness 3 1590 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.28, 1.07]
7 Assisted vaginal delivery 3 1266 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.81, 1.22]
8 Caesarean section 3 1266 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.16, 2.00]
9 Fetal heart rate changes
(decelerations)
1 34 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.92, 1.64]
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10 Low Apgar score (≤ 7) at 1 and
5 minutes
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Low scores at 1 minute 4 662 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.50, 1.13]
10.2 Low scores at 5 minutes 3 616 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.05, 5.37]
11 Naloxone administration 1 998 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.77, 1.02]
11.1 < 36 weeks’ gestation 1 23 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.49, 1.89]
11.2 ≥ 36 weeks’ gestation 1 975 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.77, 1.02]
12 Neonatal resuscitation 2 1356 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.95, 1.05]
12.1 < 36 weeks’ gestation 1 23 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.69, 1.16]
12.2 ≥ 36 weeks’ gestation 2 1333 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.95, 1.05]
13 Admission to NICU 1 199 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.48, 1.63]
14 Breastfeeding problems 1 197 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.17, 3.30]
15 Apgar less than or equal to 7 at
1 minute
2 129 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.47, 1.67]
16 Neonatal resuscitation 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.26, 8.60]
Comparison 3. PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain score (measured 1 day after
delivery)
1 10 Mean Difference (IV, Fixed, 95% CI) -17.60 [-49.93, 14.
73]
2 Satisfied with mode of
administration (PCA IM)
1 10 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.71, 1.41]
3 Epidural 1 10 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.15, 59.89]
4 Nausea score in labour (rated 1
day after delivery)
1 10 Mean Difference (IV, Fixed, 95% CI) -8.0 [-48.70, 32.70]
5 Drowsiness score in labour (rated
1 day after delivery)
1 10 Mean Difference (IV, Fixed, 95% CI) 5.60 [-28.19, 39.39]
6 Naloxone administered 1 10 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.08, 11.93]
Comparison 4. Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global assessment of pain relief
at 24 hours
1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.67, 1.16]
2 Pain intensity at 1 hour
(moderate or severe)
1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.72, 1.01]
3 Additonal analgesia required 1 133 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.53, 3.40]
4 Epidural 1 133 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.72, 2.07]
5 Vomiting 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.17, 0.86]
6 Maternal sleepiness 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.52, 1.66]
7 Assisted vaginal delivery 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.46, 2.02]
8 Caesarean section 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.10, 2.76]
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9 Apgar < 7 at 1 minute 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.18, 0.91]
10 Apgar < 7 at 5 minutes 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.04, 3.27]
11 Neonatal resuscitation 1 133 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.73, 2.02]
12 Admission to NICU 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.21, 1.64]
Comparison 5. Tramadol versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain intensity: women with poor
pain relief
4 243 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [1.10, 2.21]
2 Additional analgesia required 3 295 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.60, 1.91]
3 Nausea and vomiting 6 454 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.34, 2.76]
4 Maternal sleepiness 5 409 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.33, 0.97]
5 Assisted vaginal delivery 3 260 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.12, 2.56]
6 Caesarean section 3 260 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.23, 2.18]
7 Low Apgar scores (≤ 7) at 1 and
5 minutes
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Low scores at 1 minute 2 250 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Low scores at 5 minutes 1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Neonatal resuscitation 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Neonatal respiratory distress 1 59 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [0.64, 7.89]
10 Admission to NICU 1 59 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [0.64, 7.89]
Comparison 6. Tramadol + triflupromazine versus pethidine + triflupromazine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nausea and vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Nausea 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.13, 5.25]
1.2 Vomiting 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.02, 9.35]
2 Maternal sleepiness 1 40 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [0.68, 12.12]
Comparison 7. Dihydrocodeine 50 mg IM versus pethidine 100 mg IM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain relief poor (1
hour)
1 138 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.64, 1.86]
2 Nausea and vomiting 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.40, 1.88]
3 Maternal sleepiness 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.43, 1.04]
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4 Apgar ≤ 7 at 1 minute 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.39, 0.84]
Comparison 8. Pentazocine IM versus pethidine IM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain relief (good or very good) at
delivery
2 253 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.92, 1.27]
2 Pain relief poor (partial, none or
worse)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 No add-on drugs 3 365 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.74, 2.05]
2.2 With promazine 1 85 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.66, 3.58]
3 Additional analgesia required 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Pentazocine 1 94 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.50, 1.65]
3.2 Pentazocine + promazine 1 85 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.73, 3.84]
4 Nausea and vomiting 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Nausea 3 391 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.24, 0.90]
4.2 Vomiting 1 73 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.27, 3.14]
5 Assisted vaginal delivery 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 No add-on drugs 1 94 Risk Ratio (M-H, Fixed, 95% CI) 5.22 [0.63, 42.97]
5.2 With promazine 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.23, 2.71]
6 Maternal sleepiness 3 391 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.89, 1.12]
7 Low Apgar score (≤ 7) at 1 and
5 minutes
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Low score at 1 minute 2 242 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.06, 32.97]
7.2 Low score at 5 minutes 1 62 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.01, 4.54]
Comparison 9. Pentazocine + promazine versus pethidine + promazine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Low Apgar score (≤ 7) at 1 and
5 minutes (with promazine)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Low score at 1 minute 1 66 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.07, 17.30]
1.2 Low score at 5 minutes 1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 8.88]
2 Naloxone administration
(neonatal)
1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.09, 2.53]
2.1 With promazine 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.09, 2.53]
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Comparison 10. Nalbuphine versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia at 24 hours; numbers
dissatisfied
1 72 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.55, 0.96]
2 Pain free 1 40 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.79, 45.42]
3 Pain intensity at 30 minutes:
women with severe pain
1 295 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.59, 1.26]
4 VAS at 60 minutes (at peak of
contraction)
1 72 Mean Difference (IV, Fixed, 95% CI) -8.0 [-18.55, 2.55]
5 Additional analgesia required 1 72 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.49, 3.27]
6 Epidural 1 307 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [0.55, 4.94]
7 Nausea and vomiting 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Nausea 1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.42, 0.91]
7.2 Vomiting 1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.22, 0.76]
7.3 Nausea and vomiting 1 72 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.18, 0.94]
8 Maternal sleepiness 1 72 Risk Ratio (M-H, Fixed, 95% CI) 3.78 [0.86, 16.60]
9 Assisted vaginal delivery 2 382 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.25, 3.85]
10 Caesarean section 1 310 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.12, 1.69]
11 Low Apgar score (≤ 7) at 1 and
5 minutes
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Low score at 1 minute 2 382 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.72, 1.95]
11.2 Low score at 5 minutes 1 72 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.04, 4.99]
12 Naloxone administration
(neonatal)
1 72 Risk Ratio (M-H, Fixed, 95% CI) 6.63 [0.35, 123.93]
13 Admission to NICU 1 299 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.61, 1.89]
14 Neonatal neurobehavioural
(Scanlon) 2-4 hours PN
1 72 Mean Difference (IV, Fixed, 95% CI) -3.70 [-6.14, -1.26]
Comparison 11. Phenazocine versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Epidural 1 212 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.58, 2.97]
2 Vomiting 1 212 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.20, 0.78]
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Comparison 12. Morphine versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain relief described as poor 1 90 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.56, 2.66]
2 Additional analgesia required 1 90 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.45, 2.89]
3 Nausea and vomiting 1 90 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.21, 4.69]
4 Maternal sleepiness 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.29, 1.23]
5 Apgar < 7 at 1 minute 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal resuscitation 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 13. Butorphanol versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional analgesia required 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.55, 1.45]
2 Nausea 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 4.04]
3 Vomiting 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.30]
4 Neonatal resuscitation 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.95]
5 Naloxone administration
(neonatal)
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.95]
Comparison 14. IM tramadol versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Anagesic effect described as
satisfactory (not clear when
measured)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.64, 190.53]
2 Mean blood loss at delivery (ml) 1 60 Mean Difference (IV, Fixed, 95% CI) 25.70 [-9.83, 61.23]
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Comparison 15. IM Avacan ® versus IM pentazocine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Further analgesia required
(nitrous oxide)
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.53, 1.63]
2 Further analgesia required
(pudendal-paracervical block)
1 160 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [1.16, 3.53]
3 Caesarean section 1 184 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.21, 1.84]
4 Low Apgar score (< 7) ”at birth” 1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.27, 1.26]
Comparison 16. IM pentazocine versus IM pethilorfan
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain relief (women NOT
obtaining pain relief ) at 1 hour
1 69 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.77, 1.95]
2 Additional analgesia required 1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.10, 2.71]
3 Assisted vaginal delivery 1 98 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.07, 16.19]
4 Apgar < 8 at 1 minute 1 82 Risk Ratio (M-H, Fixed, 95% CI) 5.71 [0.72, 45.39]
5 Apgar < 8 at 5 minutes 1 82 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 17. IV fentanyl versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain score (1 hour after drug
administration)
1 105 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.34, -0.06]
2 Mean doses of analgesia 1 105 Mean Difference (IV, Fixed, 95% CI) 0.40 [0.14, 0.66]
3 Nausea and/or vomiting 1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.17, 1.55]
4 Anti-emetic required 1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.52]
5 Maternal sedation 1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.00, 0.82]
6 Caesarean section 1 105 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.24, 5.40]
7 Apgar score < 7 at 1 and 5
minutes
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Low score at 1 minute 1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.23, 1.77]
7.2 Low score at 5 minutes 1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 9.12]
8 Naloxone administered 1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.02, 1.28]
9 Babies requiring resuscitation/
ventilatory support
1 105 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.46, 2.32]
10 Neurobehavioural score (1 - 2
hours after delivery)
1 105 Mean Difference (IV, Fixed, 95% CI) 1.30 [0.15, 2.45]
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11 Neurobehavioural score (2
hours - 24 hours)
1 105 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.42, 2.22]
Comparison 18. IV nalbuphine versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Caesarean section 1 28 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 95.61]
2 Apgar score < 7 at 1 and 5
minutes
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Low score at 1 minute 1 28 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 67.91]
2.2 Low score at 5 minutes 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 19. IV phenazocine versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Satisfaction with pain relief
(women with fair or poor
relief )
1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.48, 1.10]
2 Nausea with vomiting 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.08, 2.01]
3 Perinatal death 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Apgar score < 7 at 1 minute 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 20. IV butorphanol versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain relief score 1 80 Mean Difference (IV, Fixed, 95% CI) 0.67 [0.25, 1.09]
2 Pain score (1 hour after drug
administration)
1 80 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.02, -0.18]
3 Further analgesia (2nd dose)
required
1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.63, 1.45]
4 Epidural 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.30, 3.35]
5 Nausea and/or vomiting 1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.67]
6 Assisted vaginal delivery 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.3 [0.60, 2.83]
7 Caesarean section 1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.22, 2.89]
8 Apgar score < 7 at 1 and 5
minutes
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Low score at 1 minute 2 230 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.15, 1.61]
8.2 Low score at 5 minutes 2 230 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 15.77]
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Comparison 21. IV morphine versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Women satisfied with analgesia
(assessed 3 days postpartum)
1 141 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.78, 0.98]
2 Further dose of study analgesia
required
1 143 Risk Ratio (M-H, Fixed, 95% CI) 3.41 [1.90, 6.12]
3 Nausea and vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Nausea 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.14]
3.2 Vomiting 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 1.86]
4 Caesarean section 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 22. IV nisentil versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nausea and vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Nausea 1 395 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.33, 1.52]
1.2 Vomiting 1 395 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.22, 0.66]
2 Babies requiring
resuscitation/ventilatory
support
1 395 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.85, 4.63]
Comparison 23. IV fentanyl versus IV butorphanol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional analgesia required
(women requesting two or
more doses)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [1.05, 1.85]
2 Epidural 1 100 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [1.00, 4.02]
3 Matenal drowsiness (required
tactile rousing)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.64, 14.16]
4 Caesarean section 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.23, 2.81]
5 Apgar score < 7 at 5 minutes 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.39, 3.68]
6 Babies requiring ventilatory
support
1 100 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.62, 193.80]
7 Naloxone required 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [0.81, 3.80]
8 Neurobehavioural score at 2-4
hours
1 100 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.61, 1.61]
9 Neurobehavioural score at 24-36
hours
1 100 Mean Difference (IV, Fixed, 95% CI) -0.50 [-1.62, 0.62]
112Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 24. PCA pentazocine versus PCA pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain score in labour 1 23 Std. Mean Difference (IV, Fixed, 95% CI) -0.76 [-1.62, 0.09]
2 Pain relief rated as good one day
after birth
1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.51, 1.32]
3 Epidural 1 28 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.29, 7.65]
4 Nausea and vomiting 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.61]
5 Sedation 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.09]
6 Caesarean section 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.02, 8.07]
7 Apgar score < 7 at 5 minutes 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Breastfeeding at discharge 1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.85, 1.17]
Comparison 25. PCA remifentanil versus PCA pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain score in labour 2 122 Mean Difference (IV, Random, 95% CI) -8.59 [-27.61, 10.
44]
2 Women receiving other analgesia
(Entonox)
2 56 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.69, 1.08]
3 Epidural 2 122 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.20, 0.89]
4 Maternal sleepiness during
labour
1 105 Mean Difference (IV, Fixed, 95% CI) 0.40 [0.14, 0.66]
5 Nausea and vomiting 2 119 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.61, 1.49]
6 Assisted vaginal birth 2 97 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.46, 2.00]
7 Caesarean section 2 97 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [0.60, 5.46]
8 Apgar score < 7 at 5 minutes 1 17 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.16]
9 Naloxone administered 2 56 Risk Ratio (M-H, Fixed, 95% CI) 0.3 [0.01, 6.47]
10 Admission to NICU 1 17 Risk Ratio (M-H, Fixed, 95% CI) 0.3 [0.01, 6.47]
11 Satisfaction with childbirth
experience
1 68 Mean Difference (IV, Fixed, 95% CI) 1.10 [0.46, 1.74]
12 Neurobehavioural score (15
minutes post delivery)
1 56 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.93, 1.33]
13 Neurobehavioural score (2
hours post delivery)
1 56 Mean Difference (IV, Fixed, 95% CI) 0.60 [-0.66, 1.86]
113Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 26. PCA nalbuphine versus PCA pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain relief in labour measured
in the postnatal period (rated
good or excellent)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.88, 1.89]
2 Would use the same pain relief
again
1 59 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.79, 1.43]
3 Pain score in labour 1 60 Std. Mean Difference (IV, Fixed, 95% CI) -0.51 [-1.02, 0.00]
4 Women receiving other analgesia
(Entonox)
1 59 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.46, 1.48]
5 Nausea and vomiting 1 59 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.30, 1.54]
6 Apgar score < 7 at 5 minutes 1 41 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.02, 9.76]
Comparison 27. PCA fentanyl versus PCA alfentanil
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain relief described as adequate
(recorded after delivery)
1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.93, 2.60]
2 Pain score at 4-6 cm cervical
dilatation
1 21 Mean Difference (IV, Fixed, 95% CI) -12.80 [-32.12, 6.
52]
3 Nausea 1 23 Risk Ratio (M-H, Fixed, 95% CI) 2.73 [0.66, 11.30]
4 Caesarean section 1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.33, 8.03]
5 Naloxone required 1 24 Risk Ratio (M-H, Fixed, 95% CI) 2.36 [0.53, 10.55]
Comparison 28. PCA fentanyl versus PCA pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain score in labour 1 107 Mean Difference (IV, Fixed, 95% CI) -0.65 [-1.56, 0.26]
2 Epidural 1 107 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.21, 0.92]
3 Maternal sleepiness during
labour
1 107 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.25, 0.13]
4 Nausea and vomiting 1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.55, 1.37]
5 Assisted vaginal birth 1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.22, 1.49]
6 Caesarean section 1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.34]
7 Neurobehavioural score (15
minutes post delivery)
1 63 Mean Difference (IV, Fixed, 95% CI) -0.90 [-2.31, 0.51]
8 Neurobehavioural score (2 hours
post delivery)
1 64 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.95, 0.95]
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Comparison 29. Opioids versus TENS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia measured post
delivery (rated as good)
2 104 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.79, 1.92]
2 Maternal pain score measured
during labour
2 290 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.81, 1.61]
3 Drowsiness 2 290 Risk Ratio (M-H, Fixed, 95% CI) 8.96 [1.13, 71.07]
4 Nausea and vomiting 2 290 Risk Ratio (M-H, Fixed, 95% CI) 14.06 [1.96, 100.61]
5 Caesarean section 1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Assisted vaginal birth 1 200 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.85]
7 Fetal distress 1 200 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.85]
Analysis 1.1. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 1 Maternal satisfaction at 30
minutes (number of women satisfied or very satisfied).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 1 Maternal satisfaction at 30 minutes (number of women satisfied or very satisfied)
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 (1) 3/25 0/25 100.0 % 7.00 [ 0.38, 128.87 ]
Total (95% CI) 25 25 100.0 % 7.00 [ 0.38, 128.87 ]
Total events: 3 (Pethidine IM), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours pethidine
(1) Maternal satisfaction rated as 4 or 5 on rating scale 0-5 where 0 = very disatisfied to 5= very satisfied
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Analysis 1.2. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 2 Maternal pain relief good or
fair (1 hour).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 2 Maternal pain relief good or fair (1 hour)
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 42/58 24/58 100.0 % 1.75 [ 1.24, 2.47 ]
Total (95% CI) 58 58 100.0 % 1.75 [ 1.24, 2.47 ]
Total events: 42 (Pethidine IM), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours pethidine
Analysis 1.3. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 3 Pain relief at 30 minutes
(reduction in VAS of at least 40 mm).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 3 Pain relief at 30 minutes (reduction in VAS of at least 40 mm)
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 12/25 0/25 100.0 % 25.00 [ 1.56, 400.54 ]
Total (95% CI) 25 25 100.0 % 25.00 [ 1.56, 400.54 ]
Total events: 12 (Pethidine IM), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours pethidine
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Analysis 1.4. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 4 Additional analgesia.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 4 Additional analgesia
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 17/25 24/25 100.0 % 0.71 [ 0.54, 0.94 ]
Total (95% CI) 25 25 100.0 % 0.71 [ 0.54, 0.94 ]
Total events: 17 (Pethidine IM), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.5. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 5 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 5 Epidural
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 3/25 6/25 100.0 % 0.50 [ 0.14, 1.78 ]
Total (95% CI) 25 25 100.0 % 0.50 [ 0.14, 1.78 ]
Total events: 3 (Pethidine IM), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.6. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 6 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 6 Nausea and vomiting
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 10/58 8/58 94.1 % 1.25 [ 0.53, 2.94 ]
Tsui 2004 (1) 2/25 0/25 5.9 % 5.00 [ 0.25, 99.16 ]
Total (95% CI) 83 83 100.0 % 1.47 [ 0.65, 3.31 ]
Total events: 12 (Pethidine IM), 8 (Placebo)
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Figures for vomiting only
Analysis 1.7. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 7 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 7 Maternal sleepiness
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 26/58 6/58 66.7 % 4.33 [ 1.93, 9.74 ]
Tsui 2004 16/25 3/25 33.3 % 5.33 [ 1.77, 16.05 ]
Total (95% CI) 83 83 100.0 % 4.67 [ 2.43, 8.95 ]
Total events: 42 (Pethidine IM), 9 (Placebo)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.63 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 8 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 8 Assisted vaginal delivery
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 6/25 7/25 100.0 % 0.86 [ 0.34, 2.19 ]
Total (95% CI) 25 25 100.0 % 0.86 [ 0.34, 2.19 ]
Total events: 6 (Pethidine IM), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 9 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 9 Caesarean section
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 5/25 6/25 100.0 % 0.83 [ 0.29, 2.38 ]
Total (95% CI) 25 25 100.0 % 0.83 [ 0.29, 2.38 ]
Total events: 5 (Pethidine IM), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.10. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 10 Low Apgar score (≤ 7) at 1
and 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 10 Low Apgar score (≤ 7) at 1 and 5 minutes
Study or subgroup Pethidine IM Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low scores at 1 minute
Sliom 1970 33/58 13/58 2.54 [ 1.50, 4.31 ]
Tsui 2004 3/25 4/25 0.75 [ 0.19, 3.01 ]
Subtotal (95% CI) 83 83 1.64 [ 0.52, 5.18 ]
Total events: 36 (Pethidine IM), 17 (Placebo)
Heterogeneity: Tau2 = 0.46; Chi2 = 2.59, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.85 (P = 0.39)
2 Low scores at 5 minutes
Tsui 2004 0/25 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 25 25 0.0 [ 0.0, 0.0 ]
Total events: 0 (Pethidine IM), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 1.11. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 11 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 11 Neonatal resuscitation
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 5/25 3/25 100.0 % 1.67 [ 0.45, 6.24 ]
Total (95% CI) 25 25 100.0 % 1.67 [ 0.45, 6.24 ]
Total events: 5 (Pethidine IM), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.12. Comparison 1 Pethidine 100 mg IM versus placebo, Outcome 12 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 Pethidine 100 mg IM versus placebo
Outcome: 12 Admission to NICU
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 1/25 1/25 100.0 % 1.00 [ 0.07, 15.12 ]
Total (95% CI) 25 25 100.0 % 1.00 [ 0.07, 15.12 ]
Total events: 1 (Pethidine IM), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Meptazinol versus pethidine, Outcome 1 Maternal pain relief poor or none (3-5
PN).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 1 Maternal pain relief poor or none (3-5 PN)
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morrison 1987 (1) 255/394 260/407 100.0 % 1.01 [ 0.91, 1.12 ]
Total (95% CI) 394 407 100.0 % 1.01 [ 0.91, 1.12 ]
Total events: 255 (Meptazinol), 260 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
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Favours experimental Favours control
(1) Post partum assessment of analgesia 3-5 postpartum
Analysis 2.2. Comparison 2 Meptazinol versus pethidine, Outcome 2 Pain intensity 4 or 5 on 5-point scale
(1 hour).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 2 Pain intensity 4 or 5 on 5-point scale (1 hour)
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nel 1981 11/34 6/30 22.5 % 1.62 [ 0.68, 3.84 ]
Sheikh 1986 78/87 79/88 77.5 % 1.00 [ 0.90, 1.10 ]
Total (95% CI) 121 118 100.0 % 1.11 [ 0.69, 1.80 ]
Total events: 89 (Meptazinol), 85 (Pethidine)
Heterogeneity: Tau2 = 0.08; Chi2 = 1.77, df = 1 (P = 0.18); I2 =43%
Test for overall effect: Z = 0.43 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Meptazinol versus pethidine, Outcome 3 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 3 Additional analgesia required
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Osler 1987 (1) 79/100 76/99 97.4 % 1.03 [ 0.89, 1.19 ]
Wheble 1988 2/17 2/17 2.6 % 1.00 [ 0.16, 6.30 ]
Total (95% CI) 117 116 100.0 % 1.03 [ 0.88, 1.20 ]
Total events: 81 (Meptazinol), 78 (Pethidine)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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(1) For Osler 1987 additional analgesia relates to a pudendal, whereas for Wheble it relates to a second dose of study drug.
Analysis 2.4. Comparison 2 Meptazinol versus pethidine, Outcome 4 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 4 Epidural
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nicholas 1982 36/186 37/172 53.9 % 0.90 [ 0.60, 1.35 ]
Osler 1987 11/100 9/99 12.7 % 1.21 [ 0.52, 2.79 ]
Sheikh 1986 17/98 20/99 27.9 % 0.86 [ 0.48, 1.54 ]
Wheble 1988 6/17 4/17 5.6 % 1.50 [ 0.51, 4.38 ]
Total (95% CI) 401 387 100.0 % 0.96 [ 0.71, 1.29 ]
Total events: 70 (Meptazinol), 70 (Pethidine)
Heterogeneity: Chi2 = 1.20, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Meptazinol versus pethidine, Outcome 5 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 5 Nausea and vomiting
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Morrison 1987 189/513 169/522 73.5 % 1.14 [ 0.96, 1.35 ]
Nicholas 1982 39/186 39/172 17.8 % 0.92 [ 0.62, 1.37 ]
Sheikh 1986 24/98 20/99 8.7 % 1.21 [ 0.72, 2.05 ]
Subtotal (95% CI) 797 793 100.0 % 1.11 [ 0.95, 1.28 ]
Total events: 252 (Meptazinol), 228 (Pethidine)
Heterogeneity: Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
2 Vomiting
Morrison 1987 184/513 141/522 74.3 % 1.33 [ 1.11, 1.59 ]
Nicholas 1982 36/186 31/171 17.2 % 1.07 [ 0.69, 1.65 ]
Sheikh 1986 15/98 16/99 8.5 % 0.95 [ 0.50, 1.81 ]
Subtotal (95% CI) 797 792 100.0 % 1.25 [ 1.06, 1.47 ]
Total events: 235 (Meptazinol), 188 (Pethidine)
Heterogeneity: Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0071)
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Analysis 2.6. Comparison 2 Meptazinol versus pethidine, Outcome 6 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 6 Maternal sleepiness
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Morrison 1987 147/513 202/522 63.3 % 0.74 [ 0.62, 0.88 ]
Nicholas 1982 4/186 14/172 23.9 % 0.26 [ 0.09, 0.79 ]
Sheikh 1986 2/98 4/99 12.8 % 0.51 [ 0.09, 2.69 ]
Total (95% CI) 797 793 100.0 % 0.55 [ 0.28, 1.07 ]
Total events: 153 (Meptazinol), 220 (Pethidine)
Heterogeneity: Tau2 = 0.18; Chi2 = 3.57, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Meptazinol versus pethidine, Outcome 7 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 7 Assisted vaginal delivery
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morrison 1987 97/512 107/521 75.7 % 0.92 [ 0.72, 1.18 ]
Osler 1987 36/100 28/99 20.1 % 1.27 [ 0.85, 1.91 ]
Wheble 1988 6/17 6/17 4.3 % 1.00 [ 0.40, 2.48 ]
Total (95% CI) 629 637 100.0 % 1.00 [ 0.81, 1.22 ]
Total events: 139 (Meptazinol), 141 (Pethidine)
Heterogeneity: Chi2 = 1.76, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Meptazinol versus pethidine, Outcome 8 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 8 Caesarean section
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Morrison 1987 33/512 25/521 46.8 % 1.34 [ 0.81, 2.23 ]
Osler 1987 5/100 13/99 38.7 % 0.38 [ 0.14, 1.03 ]
Wheble 1988 0/17 5/17 14.6 % 0.09 [ 0.01, 1.53 ]
Total (95% CI) 629 637 100.0 % 0.56 [ 0.16, 2.00 ]
Total events: 38 (Meptazinol), 43 (Pethidine)
Heterogeneity: Tau2 = 0.84; Chi2 = 7.85, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Meptazinol versus pethidine, Outcome 9 Fetal heart rate changes
(decelerations).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 9 Fetal heart rate changes (decelerations)
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Boer 1987 16/17 13/17 100.0 % 1.23 [ 0.92, 1.64 ]
Total (95% CI) 17 17 100.0 % 1.23 [ 0.92, 1.64 ]
Total events: 16 (Meptazinol), 13 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Meptazinol versus pethidine, Outcome 10 Low Apgar score (≤ 7) at 1 and 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 10 Low Apgar score (≤ 7) at 1 and 5 minutes
Study or subgroup Meptazinol Pethidine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low scores at 1 minute
Nel 1981 (1) 3/35 3/36 1.03 [ 0.22, 4.76 ]
Nicholas 1982 (2) 15/186 18/172 0.77 [ 0.40, 1.48 ]
Osler 1987 (3) 15/100 20/99 0.74 [ 0.40, 1.37 ]
Wheble 1988 (4) 3/17 5/17 0.60 [ 0.17, 2.12 ]
Subtotal (95% CI) 338 324 0.76 [ 0.50, 1.13 ]
Total events: 36 (Meptazinol), 46 (Pethidine)
Heterogeneity: Chi2 = 0.29, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Low scores at 5 minutes
Nel 1981 0/35 0/35 0.0 [ 0.0, 0.0 ]
Nicholas 1982 0/181 0/166 0.0 [ 0.0, 0.0 ]
Osler 1987 (5) 1/100 2/99 0.50 [ 0.05, 5.37 ]
Subtotal (95% CI) 316 300 0.50 [ 0.05, 5.37 ]
Total events: 1 (Meptazinol), 2 (Pethidine)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
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(1) Nel = Apgar < 7
(2) Nicholas = Apgar < 7
(3) Osler <= 7
(4) Wheble Apgar < 7
(5) Osler Apgar =< 7
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Analysis 2.11. Comparison 2 Meptazinol versus pethidine, Outcome 11 Naloxone administration.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 11 Naloxone administration
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 < 36 weeks’ gestation
Morrison 1987 9/15 5/8 2.8 % 0.96 [ 0.49, 1.89 ]
Subtotal (95% CI) 15 8 2.8 % 0.96 [ 0.49, 1.89 ]
Total events: 9 (Meptazinol), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
2 ≥ 36 weeks’ gestation
Morrison 1987 198/479 231/496 97.2 % 0.89 [ 0.77, 1.02 ]
Subtotal (95% CI) 479 496 97.2 % 0.89 [ 0.77, 1.02 ]
Total events: 198 (Meptazinol), 231 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 494 504 100.0 % 0.89 [ 0.77, 1.02 ]
Total events: 207 (Meptazinol), 236 (Pethidine)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 2.12. Comparison 2 Meptazinol versus pethidine, Outcome 12 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 12 Neonatal resuscitation
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 < 36 weeks’ gestation
Morrison 1987 13/15 8/8 2.3 % 0.89 [ 0.69, 1.16 ]
Subtotal (95% CI) 15 8 2.3 % 0.89 [ 0.69, 1.16 ]
Total events: 13 (Experimental), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 ≥ 36 weeks’ gestation
Morrison 1987 429/479 441/496 92.6 % 1.01 [ 0.96, 1.05 ]
Nicholas 1982 (1) 21/186 23/172 5.1 % 0.84 [ 0.49, 1.47 ]
Subtotal (95% CI) 665 668 97.7 % 1.00 [ 0.95, 1.05 ]
Total events: 450 (Experimental), 464 (Control)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 680 676 100.0 % 1.00 [ 0.95, 1.05 ]
Total events: 463 (Experimental), 472 (Control)
Heterogeneity: Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 0.66, df = 1 (P = 0.42), I2 =0.0%
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(1) Nicholas = apnoea interpreted as requirement for resuscitation
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Analysis 2.13. Comparison 2 Meptazinol versus pethidine, Outcome 13 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 13 Admission to NICU
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Osler 1987 16/100 18/99 100.0 % 0.88 [ 0.48, 1.63 ]
Total (95% CI) 100 99 100.0 % 0.88 [ 0.48, 1.63 ]
Total events: 16 (Meptazinol), 18 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Meptazinol versus pethidine, Outcome 14 Breastfeeding problems.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 14 Breastfeeding problems
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sheikh 1986 3/98 4/99 100.0 % 0.76 [ 0.17, 3.30 ]
Total (95% CI) 98 99 100.0 % 0.76 [ 0.17, 3.30 ]
Total events: 3 (Meptazinol), 4 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Meptazinol versus pethidine, Outcome 15 Apgar less than or equal to 7 at 1
minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 15 Apgar less than or equal to 7 at 1 minute
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Boer 1987 3/17 4/17 25.2 % 0.75 [ 0.20, 2.86 ]
Jackson 1983 11/47 12/48 74.8 % 0.94 [ 0.46, 1.91 ]
Total (95% CI) 64 65 100.0 % 0.89 [ 0.47, 1.67 ]
Total events: 14 (Experimental), 16 (Control)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Meptazinol versus pethidine, Outcome 16 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 Meptazinol versus pethidine
Outcome: 16 Neonatal resuscitation
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jackson 1983 3/50 2/50 100.0 % 1.50 [ 0.26, 8.60 ]
Total (95% CI) 50 50 100.0 % 1.50 [ 0.26, 8.60 ]
Total events: 3 (Meptazinol), 2 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 1 Pain score
(measured 1 day after delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 3 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 1 Pain score (measured 1 day after delivery)
Study or subgroup Meptazinol Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Li 1988 5 60.2 (29) 5 77.8 (22.8) 100.0 % -17.60 [ -49.93, 14.73 ]
Total (95% CI) 5 5 100.0 % -17.60 [ -49.93, 14.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 2 Satisfied with
mode of administration (PCA IM).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 3 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 2 Satisfied with mode of administration (PCA IM)
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 1988 5/5 5/5 100.0 % 1.00 [ 0.71, 1.41 ]
Total (95% CI) 5 5 100.0 % 1.00 [ 0.71, 1.41 ]
Total events: 5 (Meptazinol), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 3 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 3 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 3 Epidural
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 1988 1/5 0/5 100.0 % 3.00 [ 0.15, 59.89 ]
Total (95% CI) 5 5 100.0 % 3.00 [ 0.15, 59.89 ]
Total events: 1 (Meptazinol), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 3.4. Comparison 3 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 4 Nausea score in
labour (rated 1 day after delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 3 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 4 Nausea score in labour (rated 1 day after delivery)
Study or subgroup Meptazinol Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Li 1988 5 30.6 (28.7) 5 38.6 (36.5) 100.0 % -8.00 [ -48.70, 32.70 ]
Total (95% CI) 5 5 100.0 % -8.00 [ -48.70, 32.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 3.5. Comparison 3 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 5 Drowsiness score
in labour (rated 1 day after delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 3 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 5 Drowsiness score in labour (rated 1 day after delivery)
Study or subgroup Meptazinol Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Li 1988 (1) 5 57.4 (38.4) 5 51.8 (3.4) 100.0 % 5.60 [ -28.19, 39.39 ]
Total (95% CI) 5 5 100.0 % 5.60 [ -28.19, 39.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
(1) SD in pethidine group as reported in published paper (extremely small)
Analysis 3.6. Comparison 3 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 6 Naloxone
administered.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 3 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 6 Naloxone administered
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 1988 1/5 1/5 100.0 % 1.00 [ 0.08, 11.93 ]
Total (95% CI) 5 5 100.0 % 1.00 [ 0.08, 11.93 ]
Total events: 1 (Meptazinol), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 1 Global assessment of pain relief at 24 hours.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 1 Global assessment of pain relief at 24 hours
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 (1) 37/65 44/68 100.0 % 0.88 [ 0.67, 1.16 ]
Total (95% CI) 65 68 100.0 % 0.88 [ 0.67, 1.16 ]
Total events: 37 (Diamorphine cotherapy IM), 44 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Pain relief as rated as poor or fair
Analysis 4.2. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 2 Pain intensity at 1 hour (moderate or severe).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 2 Pain intensity at 1 hour (moderate or severe)
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 48/65 59/68 100.0 % 0.85 [ 0.72, 1.01 ]
Total (95% CI) 65 68 100.0 % 0.85 [ 0.72, 1.01 ]
Total events: 48 (Diamorphine cotherapy IM), 59 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 4.3. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 3 Additonal analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 3 Additonal analgesia required
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 9/65 7/68 100.0 % 1.35 [ 0.53, 3.40 ]
Total (95% CI) 65 68 100.0 % 1.35 [ 0.53, 3.40 ]
Total events: 9 (Diamorphine cotherapy IM), 7 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 4.4. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 4 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 4 Epidural
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 (1) 21/65 18/68 100.0 % 1.22 [ 0.72, 2.07 ]
Total (95% CI) 65 68 100.0 % 1.22 [ 0.72, 2.07 ]
Total events: 21 (Diamorphine cotherapy IM), 18 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) 2nd dose of study drug
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Analysis 4.5. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 5 Vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 5 Vomiting
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 (1) 7/65 19/68 100.0 % 0.39 [ 0.17, 0.86 ]
Total (95% CI) 65 68 100.0 % 0.39 [ 0.17, 0.86 ]
Total events: 7 (Diamorphine cotherapy IM), 19 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) 1 hour post-adminstration
Analysis 4.6. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 6 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 6 Maternal sleepiness
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 (1) 16/65 18/68 100.0 % 0.93 [ 0.52, 1.66 ]
Total (95% CI) 65 68 100.0 % 0.93 [ 0.52, 1.66 ]
Total events: 16 (Diamorphine cotherapy IM), 18 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Moderately drowsy or asleep at 60 minutes post-injection
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Analysis 4.7. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 7 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 7 Assisted vaginal delivery
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 11/65 12/68 100.0 % 0.96 [ 0.46, 2.02 ]
Total (95% CI) 65 68 100.0 % 0.96 [ 0.46, 2.02 ]
Total events: 11 (Diamorphine cotherapy IM), 12 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 4.8. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 8 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 8 Caesarean section
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 2/65 4/68 100.0 % 0.52 [ 0.10, 2.76 ]
Total (95% CI) 65 68 100.0 % 0.52 [ 0.10, 2.76 ]
Total events: 2 (Diamorphine cotherapy IM), 4 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 4.9. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 9 Apgar < 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 9 Apgar < 7 at 1 minute
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 7/65 18/68 100.0 % 0.41 [ 0.18, 0.91 ]
Total (95% CI) 65 68 100.0 % 0.41 [ 0.18, 0.91 ]
Total events: 7 (Diamorphine cotherapy IM), 18 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 4.10. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 10 Apgar < 7 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 10 Apgar < 7 at 5 minutes
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 1/65 3/68 100.0 % 0.35 [ 0.04, 3.27 ]
Total (95% CI) 65 68 100.0 % 0.35 [ 0.04, 3.27 ]
Total events: 1 (Diamorphine cotherapy IM), 3 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 4.11. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 11 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 11 Neonatal resuscitation
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 22/65 19/68 100.0 % 1.21 [ 0.73, 2.02 ]
Total (95% CI) 65 68 100.0 % 1.21 [ 0.73, 2.02 ]
Total events: 22 (Diamorphine cotherapy IM), 19 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 4.12. Comparison 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine,
Outcome 12 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 Diamorphine + prochloprerazine versus pethidine + prochloprerazine
Outcome: 12 Admission to NICU
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 5/65 9/68 100.0 % 0.58 [ 0.21, 1.64 ]
Total (95% CI) 65 68 100.0 % 0.58 [ 0.21, 1.64 ]
Total events: 5 (Diamorphine cotherapy IM), 9 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 5.1. Comparison 5 Tramadol versus pethidine, Outcome 1 Pain intensity: women with poor pain
relief.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 1 Pain intensity: women with poor pain relief
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bitsch 1980 9/23 3/22 10.0 % 2.87 [ 0.89, 9.23 ]
Keskin 2003 (1) 21/23 13/25 40.8 % 1.76 [ 1.18, 2.61 ]
Prasertsawat 1986 (2) 10/45 9/45 29.5 % 1.11 [ 0.50, 2.47 ]
Viegas 1993 (3) 7/30 6/30 19.7 % 1.17 [ 0.44, 3.06 ]
Total (95% CI) 121 122 100.0 % 1.56 [ 1.10, 2.21 ]
Total events: 47 (Tramadol IM), 31 (Pethidine IM)
Heterogeneity: Chi2 = 2.42, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Keskin 4 or 5 at 60 mins; Bitsch 5-10 mins post-admin
(2) Prasertsawat Poor response after 1st dose.
(3) Viegas none or insufficient relief
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Analysis 5.2. Comparison 5 Tramadol versus pethidine, Outcome 2 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 2 Additional analgesia required
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bitsch 1980 16/23 17/22 0.90 [ 0.63, 1.28 ]
Khooshideh 2009 0/80 0/80 0.0 [ 0.0, 0.0 ]
Prasertsawat 1986 11/45 7/45 1.57 [ 0.67, 3.69 ]
Total (95% CI) 148 147 1.07 [ 0.60, 1.91 ]
Total events: 27 (Tramadol IM), 24 (Pethidine IM)
Heterogeneity: Tau2 = 0.10; Chi2 = 1.86, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 5.3. Comparison 5 Tramadol versus pethidine, Outcome 3 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 3 Nausea and vomiting
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bitsch 1980 0/23 6/22 9.0 % 0.07 [ 0.00, 1.24 ]
Husslein 1987 (1) 2/20 2/20 14.3 % 1.00 [ 0.16, 6.42 ]
Keskin 2003 (2) 9/30 1/29 13.3 % 8.70 [ 1.18, 64.41 ]
Khooshideh 2009 12/80 28/80 24.0 % 0.43 [ 0.23, 0.78 ]
Prasertsawat 1986 (3) 10/45 3/45 19.2 % 3.33 [ 0.98, 11.32 ]
Viegas 1993 (4) 4/30 7/30 20.1 % 0.57 [ 0.19, 1.75 ]
Total (95% CI) 228 226 100.0 % 0.97 [ 0.34, 2.76 ]
Total events: 37 (Tramadol IM), 47 (Pethidine IM)
(4) Viegas vomiting 3/30 Tramadol 100 mg and 7/30 Pethidine. Nausea in FP.
(Continued . . . )
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(. . . Continued)
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 1.09; Chi2 = 17.89, df = 5 (P = 0.003); I2 =72%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Husslein is nausea only or vomiting only as the data are identical
(2) Keskin: nausea at 60 mins - vomiting 1 case in pathidine group.
(3) nausea - vomiting in 2/45 tramadol and 2/45 pethidine.
(4) Viegas vomiting 3/30 Tramadol 100 mg and 7/30 Pethidine. Nausea in FP.
Analysis 5.4. Comparison 5 Tramadol versus pethidine, Outcome 4 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 4 Maternal sleepiness
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Husslein 1987 6/20 10/20 17.9 % 0.60 [ 0.27, 1.34 ]
Keskin 2003 (1) 16/30 14/29 23.7 % 1.10 [ 0.67, 1.83 ]
Khooshideh 2009 23/80 64/80 26.4 % 0.36 [ 0.25, 0.52 ]
Prasertsawat 1986 10/45 15/45 20.0 % 0.67 [ 0.34, 1.32 ]
Viegas 1993 3/30 10/30 12.0 % 0.30 [ 0.09, 0.98 ]
Total (95% CI) 205 204 100.0 % 0.57 [ 0.33, 0.97 ]
Total events: 58 (Tramadol IM), 113 (Pethidine IM)
Heterogeneity: Tau2 = 0.24; Chi2 = 14.15, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Keskin - assessed at 60 mins.
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Analysis 5.5. Comparison 5 Tramadol versus pethidine, Outcome 5 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 5 Assisted vaginal delivery
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Husslein 1987 0/20 1/20 33.3 % 0.33 [ 0.01, 7.72 ]
Khooshideh 2009 0/80 2/80 55.6 % 0.20 [ 0.01, 4.10 ]
Viegas 1993 1/30 0/30 11.1 % 3.00 [ 0.13, 70.83 ]
Total (95% CI) 130 130 100.0 % 0.56 [ 0.12, 2.56 ]
Total events: 1 (Tramadol IM), 3 (Pethidine IM)
Heterogeneity: Chi2 = 1.63, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 5.6. Comparison 5 Tramadol versus pethidine, Outcome 6 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 6 Caesarean section
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Husslein 1987 0/20 0/20 0.0 [ 0.0, 0.0 ]
Khooshideh 2009 4/80 5/80 0.80 [ 0.22, 2.87 ]
Viegas 1993 1/30 2/30 0.50 [ 0.05, 5.22 ]
Total (95% CI) 130 130 0.71 [ 0.23, 2.18 ]
Total events: 5 (Tramadol IM), 7 (Pethidine IM)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 5.7. Comparison 5 Tramadol versus pethidine, Outcome 7 Low Apgar scores (≤ 7) at 1 and 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 7 Low Apgar scores (≤ 7) at 1 and 5 minutes
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low scores at 1 minute
Khooshideh 2009 0/80 0/80 0.0 [ 0.0, 0.0 ]
Prasertsawat 1986 0/45 0/45 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 125 125 0.0 [ 0.0, 0.0 ]
Total events: 0 (Tramadol IM), 0 (Pethidine IM)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
2 Low scores at 5 minutes
Khooshideh 2009 0/80 0/80 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 80 80 0.0 [ 0.0, 0.0 ]
Total events: 0 (Tramadol IM), 0 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 5.8. Comparison 5 Tramadol versus pethidine, Outcome 8 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 8 Neonatal resuscitation
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 0/45 0/45 0.0 [ 0.0, 0.0 ]
Total (95% CI) 45 45 0.0 [ 0.0, 0.0 ]
Total events: 0 (Tramadol IM), 0 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 5.9. Comparison 5 Tramadol versus pethidine, Outcome 9 Neonatal respiratory distress.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 9 Neonatal respiratory distress
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keskin 2003 7/30 3/29 100.0 % 2.26 [ 0.64, 7.89 ]
Total (95% CI) 30 29 100.0 % 2.26 [ 0.64, 7.89 ]
Total events: 7 (Tramadol IM), 3 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 5.10. Comparison 5 Tramadol versus pethidine, Outcome 10 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 Tramadol versus pethidine
Outcome: 10 Admission to NICU
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keskin 2003 7/30 3/29 100.0 % 2.26 [ 0.64, 7.89 ]
Total (95% CI) 30 29 100.0 % 2.26 [ 0.64, 7.89 ]
Total events: 7 (Tramadol IM), 3 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 6.1. Comparison 6 Tramadol + triflupromazine versus pethidine + triflupromazine, Outcome 1
Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 Tramadol + triflupromazine versus pethidine + triflupromazine
Outcome: 1 Nausea and vomiting
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Kainz 1992 (1) 2/22 2/18 100.0 % 0.82 [ 0.13, 5.25 ]
Subtotal (95% CI) 22 18 100.0 % 0.82 [ 0.13, 5.25 ]
Total events: 2 (Tramadol IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
2 Vomiting
Kainz 1992 0/18 1/22 100.0 % 0.40 [ 0.02, 9.35 ]
Subtotal (95% CI) 18 22 100.0 % 0.40 [ 0.02, 9.35 ]
Total events: 0 (Tramadol IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
0.01 0.1 1 10 100
Favours experimental Favours control
(1) assessment at 60 minutes
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Analysis 6.2. Comparison 6 Tramadol + triflupromazine versus pethidine + triflupromazine, Outcome 2
Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 Tramadol + triflupromazine versus pethidine + triflupromazine
Outcome: 2 Maternal sleepiness
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kainz 1992 7/22 2/18 100.0 % 2.86 [ 0.68, 12.12 ]
Total (95% CI) 22 18 100.0 % 2.86 [ 0.68, 12.12 ]
Total events: 7 (Tramadol IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 7.1. Comparison 7 Dihydrocodeine 50 mg IM versus pethidine 100 mg IM, Outcome 1 Maternal
pain relief poor (1 hour).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 7 Dihydrocodeine 50 mg IM versus pethidine 100 mg IM
Outcome: 1 Maternal pain relief poor (1 hour)
Study or subgroup Dihydrocodeine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 24/80 16/58 100.0 % 1.09 [ 0.64, 1.86 ]
Total (95% CI) 80 58 100.0 % 1.09 [ 0.64, 1.86 ]
Total events: 24 (Dihydrocodeine IM), 16 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 7.2. Comparison 7 Dihydrocodeine 50 mg IM versus pethidine 100 mg IM, Outcome 2 Nausea and
vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 7 Dihydrocodeine 50 mg IM versus pethidine 100 mg IM
Outcome: 2 Nausea and vomiting
Study or subgroup Dihydrocodeine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 12/80 10/58 100.0 % 0.87 [ 0.40, 1.88 ]
Total (95% CI) 80 58 100.0 % 0.87 [ 0.40, 1.88 ]
Total events: 12 (Dihydrocodeine IM), 10 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 7.3. Comparison 7 Dihydrocodeine 50 mg IM versus pethidine 100 mg IM, Outcome 3 Maternal
sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 7 Dihydrocodeine 50 mg IM versus pethidine 100 mg IM
Outcome: 3 Maternal sleepiness
Study or subgroup Dihydrocodeine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 24/80 26/58 100.0 % 0.67 [ 0.43, 1.04 ]
Total (95% CI) 80 58 100.0 % 0.67 [ 0.43, 1.04 ]
Total events: 24 (Dihydrocodeine IM), 26 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 7.4. Comparison 7 Dihydrocodeine 50 mg IM versus pethidine 100 mg IM, Outcome 4 Apgar ≤ 7 at
1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 7 Dihydrocodeine 50 mg IM versus pethidine 100 mg IM
Outcome: 4 Apgar ≤ 7 at 1 minute
Study or subgroup Dihydrocodeine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 26/80 33/58 100.0 % 0.57 [ 0.39, 0.84 ]
Total (95% CI) 80 58 100.0 % 0.57 [ 0.39, 0.84 ]
Total events: 26 (Dihydrocodeine IM), 33 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0046)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 8.1. Comparison 8 Pentazocine IM versus pethidine IM, Outcome 1 Pain relief (good or very good)
at delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 Pentazocine IM versus pethidine IM
Outcome: 1 Pain relief (good or very good) at delivery
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Borglin 1971 74/91 65/89 81.5 % 1.11 [ 0.95, 1.31 ]
Mowat 1970 (1) 13/34 16/39 18.5 % 0.93 [ 0.53, 1.65 ]
Total (95% CI) 125 128 100.0 % 1.08 [ 0.92, 1.27 ]
Total events: 87 (Pentazocine IM), 81 (Pethidine IM)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours control Favours experimental
(1) Obtained relief after 1st injection.
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Analysis 8.2. Comparison 8 Pentazocine IM versus pethidine IM, Outcome 2 Pain relief poor (partial, none
or worse).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 Pentazocine IM versus pethidine IM
Outcome: 2 Pain relief poor (partial, none or worse)
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 No add-on drugs
Duncan 1969 (1) 77/83 73/77 42.6 % 0.98 [ 0.90, 1.06 ]
Levy 1971 (2) 14/38 9/45 23.2 % 1.84 [ 0.90, 3.77 ]
Moore 1970 (3) 33/65 23/57 34.2 % 1.26 [ 0.85, 1.87 ]
Subtotal (95% CI) 186 179 100.0 % 1.23 [ 0.74, 2.05 ]
Total events: 124 (Pentazocine IM), 105 (Pethidine IM)
Heterogeneity: Tau2 = 0.16; Chi2 = 11.59, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 0.81 (P = 0.42)
2 With promazine
Refstad 1980 11/43 7/42 100.0 % 1.53 [ 0.66, 3.58 ]
Subtotal (95% CI) 43 42 100.0 % 1.53 [ 0.66, 3.58 ]
Total events: 11 (Pentazocine IM), 7 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
0.01 0.1 1 10 100
Favours experimental Favours control
(1) After 1st injection only.
(2) Unclear when pain assessed but following first dose.
(3) Severe pain at 60 minutes.
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Analysis 8.3. Comparison 8 Pentazocine IM versus pethidine IM, Outcome 3 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 Pentazocine IM versus pethidine IM
Outcome: 3 Additional analgesia required
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pentazocine
Mowat 1970 (1) 14/46 16/48 100.0 % 0.91 [ 0.50, 1.65 ]
Subtotal (95% CI) 46 48 100.0 % 0.91 [ 0.50, 1.65 ]
Total events: 14 (Pentazocine IM), 16 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
2 Pentazocine + promazine
Refstad 1980 (2) 12/43 7/42 100.0 % 1.67 [ 0.73, 3.84 ]
Subtotal (95% CI) 43 42 100.0 % 1.67 [ 0.73, 3.84 ]
Total events: 12 (Pentazocine IM), 7 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Additional doses of study drug.
(2) 2nd dose of study drug
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Analysis 8.4. Comparison 8 Pentazocine IM versus pethidine IM, Outcome 4 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 Pentazocine IM versus pethidine IM
Outcome: 4 Nausea and vomiting
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Borglin 1971 1/91 1/89 4.3 % 0.98 [ 0.06, 15.40 ]
Moore 1970 (1) 7/73 15/65 67.8 % 0.42 [ 0.18, 0.96 ]
Mowat 1970 (2) 3/34 7/39 27.9 % 0.49 [ 0.14, 1.75 ]
Subtotal (95% CI) 198 193 100.0 % 0.46 [ 0.24, 0.90 ]
Total events: 11 (Pentazocine IM), 23 (Pethidine IM)
Heterogeneity: Chi2 = 0.36, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
2 Vomiting
Mowat 1970 (3) 4/34 5/39 100.0 % 0.92 [ 0.27, 3.14 ]
Subtotal (95% CI) 34 39 100.0 % 0.92 [ 0.27, 3.14 ]
Total events: 4 (Pentazocine IM), 5 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Nausea or vomiting
(2) After 1st injection.
(3) After 1st injection.
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Analysis 8.5. Comparison 8 Pentazocine IM versus pethidine IM, Outcome 5 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 Pentazocine IM versus pethidine IM
Outcome: 5 Assisted vaginal delivery
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No add-on drugs
Mowat 1970 5/46 1/48 100.0 % 5.22 [ 0.63, 42.97 ]
Subtotal (95% CI) 46 48 100.0 % 5.22 [ 0.63, 42.97 ]
Total events: 5 (Pentazocine IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
2 With promazine
Refstad 1980 4/43 5/42 100.0 % 0.78 [ 0.23, 2.71 ]
Subtotal (95% CI) 43 42 100.0 % 0.78 [ 0.23, 2.71 ]
Total events: 4 (Pentazocine IM), 5 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 8.6. Comparison 8 Pentazocine IM versus pethidine IM, Outcome 6 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 Pentazocine IM versus pethidine IM
Outcome: 6 Maternal sleepiness
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Borglin 1971 (1) 82/91 80/89 62.7 % 1.00 [ 0.91, 1.11 ]
Moore 1970 21/73 19/65 15.6 % 0.98 [ 0.58, 1.66 ]
Mowat 1970 (2) 26/34 30/39 21.7 % 0.99 [ 0.77, 1.28 ]
Total (95% CI) 198 193 100.0 % 1.00 [ 0.89, 1.12 ]
Total events: 129 (Pentazocine IM), 129 (Pethidine IM)
Heterogeneity: Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Borglin 1971 - Sedating and relaxing effects
(2) After 1st injection
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Analysis 8.7. Comparison 8 Pentazocine IM versus pethidine IM, Outcome 7 Low Apgar score (≤ 7) at 1 and
5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 Pentazocine IM versus pethidine IM
Outcome: 7 Low Apgar score (≤ 7) at 1 and 5 minutes
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low score at 1 minute
Borglin 1971 6/91 1/89 55.6 % 5.87 [ 0.72, 47.76 ]
Levy 1971 (1) 0/29 2/33 44.4 % 0.23 [ 0.01, 4.54 ]
Subtotal (95% CI) 120 122 100.0 % 1.39 [ 0.06, 32.97 ]
Total events: 6 (Pentazocine IM), 3 (Pethidine IM)
Heterogeneity: Tau2 = 3.56; Chi2 = 3.04, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.20 (P = 0.84)
2 Low score at 5 minutes
Levy 1971 (2) 0/29 2/33 100.0 % 0.23 [ 0.01, 4.54 ]
Subtotal (95% CI) 29 33 100.0 % 0.23 [ 0.01, 4.54 ]
Total events: 0 (Pentazocine IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Apgar is for babies that had 1 dose only and does not include data for 1st dose of women who had 2 doses
(2) Apgar is for babies that had 1 dose only and does not include data for 1st dose of women who had 2 doses
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Analysis 9.1. Comparison 9 Pentazocine + promazine versus pethidine + promazine, Outcome 1 Low Apgar
score (≤ 7) at 1 and 5 minutes (with promazine).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 Pentazocine + promazine versus pethidine + promazine
Outcome: 1 Low Apgar score (≤ 7) at 1 and 5 minutes (with promazine)
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low score at 1 minute
Refstad 1980 (1) 1/31 1/35 100.0 % 1.13 [ 0.07, 17.30 ]
Subtotal (95% CI) 31 35 100.0 % 1.13 [ 0.07, 17.30 ]
Total events: 1 (Pentazocine IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2 Low score at 5 minutes
Refstad 1980 (2) 0/31 1/35 100.0 % 0.38 [ 0.02, 8.88 ]
Subtotal (95% CI) 31 35 100.0 % 0.38 [ 0.02, 8.88 ]
Total events: 0 (Pentazocine IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
0.01 0.1 1 10 100
Favours experimental Favours control
(1) After 1 dose only
(2) After 1st dose only
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Analysis 9.2. Comparison 9 Pentazocine + promazine versus pethidine + promazine, Outcome 2 Naloxone
administration (neonatal).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 Pentazocine + promazine versus pethidine + promazine
Outcome: 2 Naloxone administration (neonatal)
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 With promazine
Refstad 1980 2/43 4/42 100.0 % 0.49 [ 0.09, 2.53 ]
Total (95% CI) 43 42 100.0 % 0.49 [ 0.09, 2.53 ]
Total events: 2 (Pentazocine IM), 4 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 10.1. Comparison 10 Nalbuphine versus pethidine, Outcome 1 Maternal satisfaction with analgesia
at 24 hours; numbers dissatisfied.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 1 Maternal satisfaction with analgesia at 24 hours; numbers dissatisfied
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1986 (1) 23/37 30/35 100.0 % 0.73 [ 0.55, 0.96 ]
Total (95% CI) 37 35 100.0 % 0.73 [ 0.55, 0.96 ]
Total events: 23 (Nalbuphine IM), 30 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Rated as minimally effective.
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Analysis 10.2. Comparison 10 Nalbuphine versus pethidine, Outcome 2 Pain free.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 2 Pain free
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mitterschiffthaler 1991 (1) 6/20 1/20 100.0 % 6.00 [ 0.79, 45.42 ]
Total (95% CI) 20 20 100.0 % 6.00 [ 0.79, 45.42 ]
Total events: 6 (Nalbuphine IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
(1) Unclear when pain assessed
Analysis 10.3. Comparison 10 Nalbuphine versus pethidine, Outcome 3 Pain intensity at 30 minutes:
women with severe pain.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 3 Pain intensity at 30 minutes: women with severe pain
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lardizabal 1999 37/149 42/146 100.0 % 0.86 [ 0.59, 1.26 ]
Total (95% CI) 149 146 100.0 % 0.86 [ 0.59, 1.26 ]
Total events: 37 (Nalbuphine IM), 42 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 10.4. Comparison 10 Nalbuphine versus pethidine, Outcome 4 VAS at 60 minutes (at peak of
contraction).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 4 VAS at 60 minutes (at peak of contraction)
Study or subgroup Nalbuphine IM Pethidine IM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wilson 1986 37 66 (24.9) 35 74 (20.7) 100.0 % -8.00 [ -18.55, 2.55 ]
Total (95% CI) 37 35 100.0 % -8.00 [ -18.55, 2.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 10.5. Comparison 10 Nalbuphine versus pethidine, Outcome 5 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 5 Additional analgesia required
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1986 (1) 8/37 6/35 100.0 % 1.26 [ 0.49, 3.27 ]
Total (95% CI) 37 35 100.0 % 1.26 [ 0.49, 3.27 ]
Total events: 8 (Nalbuphine IM), 6 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) 2nd dose of study drug
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Analysis 10.6. Comparison 10 Nalbuphine versus pethidine, Outcome 6 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 6 Epidural
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lardizabal 1999 8/151 5/156 100.0 % 1.65 [ 0.55, 4.94 ]
Total (95% CI) 151 156 100.0 % 1.65 [ 0.55, 4.94 ]
Total events: 8 (Nalbuphine IM), 5 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 10.7. Comparison 10 Nalbuphine versus pethidine, Outcome 7 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 7 Nausea and vomiting
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Lardizabal 1999 30/147 51/154 100.0 % 0.62 [ 0.42, 0.91 ]
Subtotal (95% CI) 147 154 100.0 % 0.62 [ 0.42, 0.91 ]
Total events: 30 (Nalbuphine IM), 51 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
2 Vomiting
Lardizabal 1999 12/147 31/154 100.0 % 0.41 [ 0.22, 0.76 ]
Subtotal (95% CI) 147 154 100.0 % 0.41 [ 0.22, 0.76 ]
Total events: 12 (Nalbuphine IM), 31 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
0.01 0.1 1 10 100
Favours experimental Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 Nausea and vomiting
Wilson 1986 6/37 14/35 100.0 % 0.41 [ 0.18, 0.94 ]
Subtotal (95% CI) 37 35 100.0 % 0.41 [ 0.18, 0.94 ]
Total events: 6 (Nalbuphine IM), 14 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 10.8. Comparison 10 Nalbuphine versus pethidine, Outcome 8 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 8 Maternal sleepiness
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1986 (1) 8/37 2/35 100.0 % 3.78 [ 0.86, 16.60 ]
Total (95% CI) 37 35 100.0 % 3.78 [ 0.86, 16.60 ]
Total events: 8 (Nalbuphine IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Excessive sedation
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Analysis 10.9. Comparison 10 Nalbuphine versus pethidine, Outcome 9 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 9 Assisted vaginal delivery
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lardizabal 1999 13/152 9/158 72.5 % 1.50 [ 0.66, 3.41 ]
Wilson 1986 1/37 3/35 27.5 % 0.32 [ 0.03, 2.89 ]
Total (95% CI) 189 193 100.0 % 0.98 [ 0.25, 3.85 ]
Total events: 14 (Nalbuphine IM), 12 (Pethidine IM)
Heterogeneity: Tau2 = 0.50; Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 10.10. Comparison 10 Nalbuphine versus pethidine, Outcome 10 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 10 Caesarean section
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lardizabal 1999 3/152 7/158 100.0 % 0.45 [ 0.12, 1.69 ]
Total (95% CI) 152 158 100.0 % 0.45 [ 0.12, 1.69 ]
Total events: 3 (Nalbuphine IM), 7 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 10.11. Comparison 10 Nalbuphine versus pethidine, Outcome 11 Low Apgar score (≤ 7) at 1 and 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 11 Low Apgar score (≤ 7) at 1 and 5 minutes
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low score at 1 minute
Lardizabal 1999 16/152 10/158 29.8 % 1.66 [ 0.78, 3.55 ]
Wilson 1986 (1) 26/37 24/35 70.2 % 1.02 [ 0.75, 1.39 ]
Subtotal (95% CI) 189 193 100.0 % 1.18 [ 0.72, 1.95 ]
Total events: 42 (Nalbuphine IM), 34 (Pethidine IM)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.77, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.66 (P = 0.51)
2 Low score at 5 minutes
Wilson 1986 1/37 2/35 100.0 % 0.47 [ 0.04, 4.99 ]
Subtotal (95% CI) 37 35 100.0 % 0.47 [ 0.04, 4.99 ]
Total events: 1 (Nalbuphine IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Apgar modified: minus colour score
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Analysis 10.12. Comparison 10 Nalbuphine versus pethidine, Outcome 12 Naloxone administration
(neonatal).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 12 Naloxone administration (neonatal)
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1986 3/37 0/35 100.0 % 6.63 [ 0.35, 123.93 ]
Total (95% CI) 37 35 100.0 % 6.63 [ 0.35, 123.93 ]
Total events: 3 (Nalbuphine IM), 0 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 10.13. Comparison 10 Nalbuphine versus pethidine, Outcome 13 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 13 Admission to NICU
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lardizabal 1999 21/148 20/151 100.0 % 1.07 [ 0.61, 1.89 ]
Total (95% CI) 148 151 100.0 % 1.07 [ 0.61, 1.89 ]
Total events: 21 (Nalbuphine IM), 20 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 10.14. Comparison 10 Nalbuphine versus pethidine, Outcome 14 Neonatal neurobehavioural
(Scanlon) 2-4 hours PN.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 Nalbuphine versus pethidine
Outcome: 14 Neonatal neurobehavioural (Scanlon) 2-4 hours PN
Study or subgroup Nalbuphine IM Pethidine IM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wilson 1986 (1) 37 21.6 (4.9) 35 25.3 (5.6) 100.0 % -3.70 [ -6.14, -1.26 ]
Total (95% CI) 37 35 100.0 % -3.70 [ -6.14, -1.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0029)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
(1) Lower scores on Scanlon scale = poorer outcome
Analysis 11.1. Comparison 11 Phenazocine versus pethidine, Outcome 1 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 11 Phenazocine versus pethidine
Outcome: 1 Epidural
Study or subgroup Phenazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Grant 1970 12/107 9/105 100.0 % 1.31 [ 0.58, 2.97 ]
Total (95% CI) 107 105 100.0 % 1.31 [ 0.58, 2.97 ]
Total events: 12 (Phenazocine IM), 9 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 11.2. Comparison 11 Phenazocine versus pethidine, Outcome 2 Vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 11 Phenazocine versus pethidine
Outcome: 2 Vomiting
Study or subgroup Phenazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Grant 1970 10/107 25/105 100.0 % 0.39 [ 0.20, 0.78 ]
Total (95% CI) 107 105 100.0 % 0.39 [ 0.20, 0.78 ]
Total events: 10 (Phenazocine IM), 25 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0072)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 12.1. Comparison 12 Morphine versus pethidine, Outcome 1 Pain relief described as poor.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 Morphine versus pethidine
Outcome: 1 Pain relief described as poor
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 (1) 11/45 9/45 100.0 % 1.22 [ 0.56, 2.66 ]
Total (95% CI) 45 45 100.0 % 1.22 [ 0.56, 2.66 ]
Total events: 11 (Morphine IM), 9 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Poor response after 1st dose.
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Analysis 12.2. Comparison 12 Morphine versus pethidine, Outcome 2 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 Morphine versus pethidine
Outcome: 2 Additional analgesia required
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 (1) 8/45 7/45 100.0 % 1.14 [ 0.45, 2.89 ]
Total (95% CI) 45 45 100.0 % 1.14 [ 0.45, 2.89 ]
Total events: 8 (Morphine IM), 7 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) 2nd dose of study drug but half initial amount
Analysis 12.3. Comparison 12 Morphine versus pethidine, Outcome 3 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 Morphine versus pethidine
Outcome: 3 Nausea and vomiting
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 (1) 3/45 3/45 100.0 % 1.00 [ 0.21, 4.69 ]
Total (95% CI) 45 45 100.0 % 1.00 [ 0.21, 4.69 ]
Total events: 3 (Morphine IM), 3 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Prasertsawat nausea - vomiting in 1/45 morphine and 2/45 pethidine.
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Analysis 12.4. Comparison 12 Morphine versus pethidine, Outcome 4 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 Morphine versus pethidine
Outcome: 4 Maternal sleepiness
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 9/45 15/45 100.0 % 0.60 [ 0.29, 1.23 ]
Total (95% CI) 45 45 100.0 % 0.60 [ 0.29, 1.23 ]
Total events: 9 (Morphine IM), 15 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 12.5. Comparison 12 Morphine versus pethidine, Outcome 5 Apgar < 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 Morphine versus pethidine
Outcome: 5 Apgar < 7 at 1 minute
Study or subgroup Morphine IM Pethidine IM Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 0/45 0/45 0.0 [ 0.0, 0.0 ]
Total (95% CI) 45 45 0.0 [ 0.0, 0.0 ]
Total events: 0 (Morphine IM), 0 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 12.6. Comparison 12 Morphine versus pethidine, Outcome 6 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 Morphine versus pethidine
Outcome: 6 Neonatal resuscitation
Study or subgroup Morphine IM Pethidine IM Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 0/45 0/45 0.0 [ 0.0, 0.0 ]
Total (95% CI) 45 45 0.0 [ 0.0, 0.0 ]
Total events: 0 (Morphine IM), 0 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 13.1. Comparison 13 Butorphanol versus pethidine, Outcome 1 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 Butorphanol versus pethidine
Outcome: 1 Additional analgesia required
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 17/40 19/40 100.0 % 0.89 [ 0.55, 1.45 ]
Total (95% CI) 40 40 100.0 % 0.89 [ 0.55, 1.45 ]
Total events: 17 (Butorphanol IM), 19 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) 2nd dose of study drug
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Analysis 13.2. Comparison 13 Butorphanol versus pethidine, Outcome 2 Nausea.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 Butorphanol versus pethidine
Outcome: 2 Nausea
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 0/40 2/40 100.0 % 0.20 [ 0.01, 4.04 ]
Total (95% CI) 40 40 100.0 % 0.20 [ 0.01, 4.04 ]
Total events: 0 (Butorphanol IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Unclear when assessed
Analysis 13.3. Comparison 13 Butorphanol versus pethidine, Outcome 3 Vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 Butorphanol versus pethidine
Outcome: 3 Vomiting
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 1/40 2/40 100.0 % 0.50 [ 0.05, 5.30 ]
Total (95% CI) 40 40 100.0 % 0.50 [ 0.05, 5.30 ]
Total events: 1 (Butorphanol IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Unclear when assessed
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Analysis 13.4. Comparison 13 Butorphanol versus pethidine, Outcome 4 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 Butorphanol versus pethidine
Outcome: 4 Neonatal resuscitation
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 0/40 1/40 100.0 % 0.33 [ 0.01, 7.95 ]
Total (95% CI) 40 40 100.0 % 0.33 [ 0.01, 7.95 ]
Total events: 0 (Butorphanol IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) received 2 doses of pethidine (40 mg x 2)
Analysis 13.5. Comparison 13 Butorphanol versus pethidine, Outcome 5 Naloxone administration
(neonatal).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 Butorphanol versus pethidine
Outcome: 5 Naloxone administration (neonatal)
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 0/40 1/40 100.0 % 0.33 [ 0.01, 7.95 ]
Total (95% CI) 40 40 100.0 % 0.33 [ 0.01, 7.95 ]
Total events: 0 (Butorphanol IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) received 2 doses of pethidine (40 mg x 2)
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Analysis 14.1. Comparison 14 IM tramadol versus no treatment, Outcome 1 Anagesic effect described as
satisfactory (not clear when measured).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 14 IM tramadol versus no treatment
Outcome: 1 Anagesic effect described as satisfactory (not clear when measured)
Study or subgroup Tramadol No analgesia Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 1994 5/30 0/30 100.0 % 11.00 [ 0.64, 190.53 ]
Total (95% CI) 30 30 100.0 % 11.00 [ 0.64, 190.53 ]
Total events: 5 (Tramadol), 0 (No analgesia)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours no analgesia Favours tramadol
Analysis 14.2. Comparison 14 IM tramadol versus no treatment, Outcome 2 Mean blood loss at delivery
(ml).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 14 IM tramadol versus no treatment
Outcome: 2 Mean blood loss at delivery (ml)
Study or subgroup Tramadol No analgesia
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Li 1994 30 160.7 (78.8) 30 135 (60.4) 100.0 % 25.70 [ -9.83, 61.23 ]
Total (95% CI) 30 30 100.0 % 25.70 [ -9.83, 61.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours tramadol Favours no analgesia
173Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 15.1. Comparison 15 IM Avacan ® versus IM pentazocine, Outcome 1 Further analgesia required
(nitrous oxide).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 15 IM Avacan versus IM pentazocine
Outcome: 1 Further analgesia required (nitrous oxide)
Study or subgroup Avacan Pentazocine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamann 1972 18/81 19/79 100.0 % 0.92 [ 0.53, 1.63 ]
Total (95% CI) 81 79 100.0 % 0.92 [ 0.53, 1.63 ]
Total events: 18 (Avacan), 19 (Pentazocine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours Avacan Favours pentazocine
Analysis 15.2. Comparison 15 IM Avacan ® versus IM pentazocine, Outcome 2 Further analgesia required
(pudendal-paracervical block).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 15 IM Avacan versus IM pentazocine
Outcome: 2 Further analgesia required (pudendal-paracervical block)
Study or subgroup Avacan Pentazocine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamann 1972 29/81 14/79 100.0 % 2.02 [ 1.16, 3.53 ]
Total (95% CI) 81 79 100.0 % 2.02 [ 1.16, 3.53 ]
Total events: 29 (Avacan), 14 (Pentazocine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.013)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Avacan Favours pentazocine
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Analysis 15.3. Comparison 15 IM Avacan ® versus IM pentazocine, Outcome 3 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 15 IM Avacan versus IM pentazocine
Outcome: 3 Caesarean section
Study or subgroup Avacan Pentazocine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamann 1972 (1) 5/92 8/92 100.0 % 0.63 [ 0.21, 1.84 ]
Total (95% CI) 92 92 100.0 % 0.63 [ 0.21, 1.84 ]
Total events: 5 (Avacan), 8 (Pentazocine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Avacan Favours pentazocine
(1) Denominators not clear (women having CS were excluded from analyses in study report).
Analysis 15.4. Comparison 15 IM Avacan ® versus IM pentazocine, Outcome 4 Low Apgar score (< 7) “at
birth”.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 15 IM Avacan versus IM pentazocine
Outcome: 4 Low Apgar score (< 7) ”at birth”
Study or subgroup Avacan Pentazocine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamann 1972 9/81 15/79 100.0 % 0.59 [ 0.27, 1.26 ]
Total (95% CI) 81 79 100.0 % 0.59 [ 0.27, 1.26 ]
Total events: 9 (Avacan), 15 (Pentazocine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Avacan Favours pentazocine
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Analysis 16.1. Comparison 16 IM pentazocine versus IM pethilorfan, Outcome 1 Pain relief (women NOT
obtaining pain relief) at 1 hour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 16 IM pentazocine versus IM pethilorfan
Outcome: 1 Pain relief (women NOT obtaining pain relief) at 1 hour
Study or subgroup Pentazocine Pethilorfan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 (1) 18/32 17/37 100.0 % 1.22 [ 0.77, 1.95 ]
Total (95% CI) 32 37 100.0 % 1.22 [ 0.77, 1.95 ]
Total events: 18 (Pentazocine), 17 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) After 1st dose only
Analysis 16.2. Comparison 16 IM pentazocine versus IM pethilorfan, Outcome 2 Additional analgesia
required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 16 IM pentazocine versus IM pethilorfan
Outcome: 2 Additional analgesia required
Study or subgroup Pentazocine Pethilorfan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 (1) 2/48 4/50 100.0 % 0.52 [ 0.10, 2.71 ]
Total (95% CI) 48 50 100.0 % 0.52 [ 0.10, 2.71 ]
Total events: 2 (Pentazocine), 4 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) 2nd dose of study drug
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Analysis 16.3. Comparison 16 IM pentazocine versus IM pethilorfan, Outcome 3 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 16 IM pentazocine versus IM pethilorfan
Outcome: 3 Assisted vaginal delivery
Study or subgroup Pentazocine Pethilorfan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 1/48 1/50 100.0 % 1.04 [ 0.07, 16.19 ]
Total (95% CI) 48 50 100.0 % 1.04 [ 0.07, 16.19 ]
Total events: 1 (Pentazocine), 1 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 16.4. Comparison 16 IM pentazocine versus IM pethilorfan, Outcome 4 Apgar < 8 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 16 IM pentazocine versus IM pethilorfan
Outcome: 4 Apgar < 8 at 1 minute
Study or subgroup Pentazocine Pethilorfan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 6/42 1/40 100.0 % 5.71 [ 0.72, 45.39 ]
Total (95% CI) 42 40 100.0 % 5.71 [ 0.72, 45.39 ]
Total events: 6 (Pentazocine), 1 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 16.5. Comparison 16 IM pentazocine versus IM pethilorfan, Outcome 5 Apgar < 8 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 16 IM pentazocine versus IM pethilorfan
Outcome: 5 Apgar < 8 at 5 minutes
Study or subgroup Pentazocine Pethilorfan Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 0/42 0/40 0.0 [ 0.0, 0.0 ]
Total (95% CI) 42 40 0.0 [ 0.0, 0.0 ]
Total events: 0 (Pentazocine), 0 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 17.1. Comparison 17 IV fentanyl versus IV pethidine, Outcome 1 Pain score (1 hour after drug
administration).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 1 Pain score (1 hour after drug administration)
Study or subgroup Experimental Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rayburn 1989a (1) 49 5.9 (0.4) 56 6.1 (0.3) 100.0 % -0.20 [ -0.34, -0.06 ]
Total (95% CI) 49 56 100.0 % -0.20 [ -0.34, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0042)
Test for subgroup differences: Not applicable
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(1) Pain score at 4-7cm dilatation (SD/SE not clear)
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Analysis 17.2. Comparison 17 IV fentanyl versus IV pethidine, Outcome 2 Mean doses of analgesia.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 2 Mean doses of analgesia
Study or subgroup Experimental Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rayburn 1989a 49 2.3 (0.8) 56 1.9 (0.5) 100.0 % 0.40 [ 0.14, 0.66 ]
Total (95% CI) 49 56 100.0 % 0.40 [ 0.14, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
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Analysis 17.3. Comparison 17 IV fentanyl versus IV pethidine, Outcome 3 Nausea and/or vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 3 Nausea and/or vomiting
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 4/49 9/56 100.0 % 0.51 [ 0.17, 1.55 ]
Total (95% CI) 49 56 100.0 % 0.51 [ 0.17, 1.55 ]
Total events: 4 (Experimental), 9 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 17.4. Comparison 17 IV fentanyl versus IV pethidine, Outcome 4 Anti-emetic required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 4 Anti-emetic required
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 0/49 6/56 100.0 % 0.09 [ 0.01, 1.52 ]
Total (95% CI) 49 56 100.0 % 0.09 [ 0.01, 1.52 ]
Total events: 0 (Experimental), 6 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Not applicable
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Analysis 17.5. Comparison 17 IV fentanyl versus IV pethidine, Outcome 5 Maternal sedation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 5 Maternal sedation
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 0/49 11/56 100.0 % 0.05 [ 0.00, 0.82 ]
Total (95% CI) 49 56 100.0 % 0.05 [ 0.00, 0.82 ]
Total events: 0 (Experimental), 11 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
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Analysis 17.6. Comparison 17 IV fentanyl versus IV pethidine, Outcome 6 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 6 Caesarean section
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 3/49 3/56 100.0 % 1.14 [ 0.24, 5.40 ]
Total (95% CI) 49 56 100.0 % 1.14 [ 0.24, 5.40 ]
Total events: 3 (Experimental), 3 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 17.7. Comparison 17 IV fentanyl versus IV pethidine, Outcome 7 Apgar score < 7 at 1 and 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 7 Apgar score < 7 at 1 and 5 minutes
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low score at 1 minute
Rayburn 1989a 5/49 9/56 100.0 % 0.63 [ 0.23, 1.77 ]
Subtotal (95% CI) 49 56 100.0 % 0.63 [ 0.23, 1.77 ]
Total events: 5 (Experimental), 9 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
2 Low score at 5 minutes
Rayburn 1989a 0/49 1/56 100.0 % 0.38 [ 0.02, 9.12 ]
Subtotal (95% CI) 49 56 100.0 % 0.38 [ 0.02, 9.12 ]
Total events: 0 (Experimental), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 17.8. Comparison 17 IV fentanyl versus IV pethidine, Outcome 8 Naloxone administered.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 8 Naloxone administered
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 1/49 7/56 100.0 % 0.16 [ 0.02, 1.28 ]
Total (95% CI) 49 56 100.0 % 0.16 [ 0.02, 1.28 ]
Total events: 1 (Experimental), 7 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Not applicable
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Analysis 17.9. Comparison 17 IV fentanyl versus IV pethidine, Outcome 9 Babies requiring resuscitation/
ventilatory support.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 9 Babies requiring resuscitation/ ventilatory support
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 9/49 10/56 100.0 % 1.03 [ 0.46, 2.32 ]
Total (95% CI) 49 56 100.0 % 1.03 [ 0.46, 2.32 ]
Total events: 9 (Experimental), 10 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 17.10. Comparison 17 IV fentanyl versus IV pethidine, Outcome 10 Neurobehavioural score (1 - 2
hours after delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 10 Neurobehavioural score (1 - 2 hours after delivery)
Study or subgroup Experimental Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rayburn 1989a 49 33.2 (2.9) 56 31.9 (3.1) 100.0 % 1.30 [ 0.15, 2.45 ]
Total (95% CI) 49 56 100.0 % 1.30 [ 0.15, 2.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 17.11. Comparison 17 IV fentanyl versus IV pethidine, Outcome 11 Neurobehavioural score (2
hours - 24 hours).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IV fentanyl versus IV pethidine
Outcome: 11 Neurobehavioural score (2 hours - 24 hours)
Study or subgroup Experimental Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rayburn 1989a 49 35.7 (3.4) 56 34.8 (3.5) 100.0 % 0.90 [ -0.42, 2.22 ]
Total (95% CI) 49 56 100.0 % 0.90 [ -0.42, 2.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 18.1. Comparison 18 IV nalbuphine versus IV pethidine, Outcome 1 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 18 IV nalbuphine versus IV pethidine
Outcome: 1 Caesarean section
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giannina 1995 2/14 0/14 100.0 % 5.00 [ 0.26, 95.61 ]
Total (95% CI) 14 14 100.0 % 5.00 [ 0.26, 95.61 ]
Total events: 2 (Experimental), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 18.2. Comparison 18 IV nalbuphine versus IV pethidine, Outcome 2 Apgar score < 7 at 1 and 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 18 IV nalbuphine versus IV pethidine
Outcome: 2 Apgar score < 7 at 1 and 5 minutes
Study or subgroup Experimental Pethidine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low score at 1 minute
Giannina 1995 1/14 0/14 3.00 [ 0.13, 67.91 ]
Subtotal (95% CI) 14 14 3.00 [ 0.13, 67.91 ]
Total events: 1 (Experimental), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Low score at 5 minutes
Giannina 1995 0/14 0/14 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 14 14 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
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Analysis 19.1. Comparison 19 IV phenazocine versus IV pethidine, Outcome 1 Satisfaction with pain relief
(women with fair or poor relief).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 19 IV phenazocine versus IV pethidine
Outcome: 1 Satisfaction with pain relief (women with fair or poor relief)
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olson 1964 26/97 36/97 100.0 % 0.72 [ 0.48, 1.10 ]
Total (95% CI) 97 97 100.0 % 0.72 [ 0.48, 1.10 ]
Total events: 26 (Experimental), 36 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 19.2. Comparison 19 IV phenazocine versus IV pethidine, Outcome 2 Nausea with vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 19 IV phenazocine versus IV pethidine
Outcome: 2 Nausea with vomiting
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olson 1964 2/97 5/97 100.0 % 0.40 [ 0.08, 2.01 ]
Total (95% CI) 97 97 100.0 % 0.40 [ 0.08, 2.01 ]
Total events: 2 (Experimental), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 19.3. Comparison 19 IV phenazocine versus IV pethidine, Outcome 3 Perinatal death.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 19 IV phenazocine versus IV pethidine
Outcome: 3 Perinatal death
Study or subgroup Experimental Pethidine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olson 1964 0/97 0/97 0.0 [ 0.0, 0.0 ]
Total (95% CI) 97 97 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 19.4. Comparison 19 IV phenazocine versus IV pethidine, Outcome 4 Apgar score < 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 19 IV phenazocine versus IV pethidine
Outcome: 4 Apgar score < 7 at 1 minute
Study or subgroup Experimental Pethidine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 0/97 0/97 0.0 [ 0.0, 0.0 ]
Total (95% CI) 97 97 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 20.1. Comparison 20 IV butorphanol versus IV pethidine, Outcome 1 Pain relief score.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV butorphanol versus IV pethidine
Outcome: 1 Pain relief score
Study or subgroup Experimental Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Quilligan 1980 40 1.7 (1.01) 40 1.03 (0.89) 100.0 % 0.67 [ 0.25, 1.09 ]
Total (95% CI) 40 40 100.0 % 0.67 [ 0.25, 1.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P = 0.0016)
Test for subgroup differences: Not applicable
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Analysis 20.2. Comparison 20 IV butorphanol versus IV pethidine, Outcome 2 Pain score (1 hour after drug
administration).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV butorphanol versus IV pethidine
Outcome: 2 Pain score (1 hour after drug administration)
Study or subgroup Experimental Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Quilligan 1980 40 2.1 (1.01) 40 2.7 (0.89) 100.0 % -0.60 [ -1.02, -0.18 ]
Total (95% CI) 40 40 100.0 % -0.60 [ -1.02, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
Test for subgroup differences: Not applicable
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Analysis 20.3. Comparison 20 IV butorphanol versus IV pethidine, Outcome 3 Further analgesia (2nd dose)
required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV butorphanol versus IV pethidine
Outcome: 3 Further analgesia (2nd dose) required
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Quilligan 1980 23/50 24/50 100.0 % 0.96 [ 0.63, 1.45 ]
Total (95% CI) 50 50 100.0 % 0.96 [ 0.63, 1.45 ]
Total events: 23 (Experimental), 24 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 20.4. Comparison 20 IV butorphanol versus IV pethidine, Outcome 4 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV butorphanol versus IV pethidine
Outcome: 4 Epidural
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 5/100 5/100 100.0 % 1.00 [ 0.30, 3.35 ]
Total (95% CI) 100 100 100.0 % 1.00 [ 0.30, 3.35 ]
Total events: 5 (Experimental), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 20.5. Comparison 20 IV butorphanol versus IV pethidine, Outcome 5 Nausea and/or vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV butorphanol versus IV pethidine
Outcome: 5 Nausea and/or vomiting
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 0/100 12/100 100.0 % 0.04 [ 0.00, 0.67 ]
Total (95% CI) 100 100 100.0 % 0.04 [ 0.00, 0.67 ]
Total events: 0 (Experimental), 12 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
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Analysis 20.6. Comparison 20 IV butorphanol versus IV pethidine, Outcome 6 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV butorphanol versus IV pethidine
Outcome: 6 Assisted vaginal delivery
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 13/100 10/100 100.0 % 1.30 [ 0.60, 2.83 ]
Total (95% CI) 100 100 100.0 % 1.30 [ 0.60, 2.83 ]
Total events: 13 (Experimental), 10 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 20.7. Comparison 20 IV butorphanol versus IV pethidine, Outcome 7 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV butorphanol versus IV pethidine
Outcome: 7 Caesarean section
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 4/100 5/100 100.0 % 0.80 [ 0.22, 2.89 ]
Total (95% CI) 100 100 100.0 % 0.80 [ 0.22, 2.89 ]
Total events: 4 (Experimental), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 20.8. Comparison 20 IV butorphanol versus IV pethidine, Outcome 8 Apgar score < 7 at 1 and 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV butorphanol versus IV pethidine
Outcome: 8 Apgar score < 7 at 1 and 5 minutes
Study or subgroup Experimental Pethidine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low score at 1 minute
Hodgkinson 1979 3/100 7/100 0.43 [ 0.11, 1.61 ]
Nelson 2005 1/15 1/15 1.00 [ 0.07, 14.55 ]
Subtotal (95% CI) 115 115 0.50 [ 0.15, 1.61 ]
Total events: 4 (Experimental), 8 (Pethidine)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
2 Low score at 5 minutes
Hodgkinson 1979 1/100 1/100 1.00 [ 0.06, 15.77 ]
Nelson 2005 0/15 0/15 0.0 [ 0.0, 0.0 ]
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(. . . Continued)
Study or subgroup Experimental Pethidine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 115 115 1.00 [ 0.06, 15.77 ]
Total events: 1 (Experimental), 1 (Pethidine)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
0.01 0.1 1 10 100
Favours experimental Favours pethidine
Analysis 21.1. Comparison 21 IV morphine versus IV pethidine, Outcome 1 Women satisfied with analgesia
(assessed 3 days postpartum).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV morphine versus IV pethidine
Outcome: 1 Women satisfied with analgesia (assessed 3 days postpartum)
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Campbell 1961 60/72 66/69 100.0 % 0.87 [ 0.78, 0.98 ]
Total (95% CI) 72 69 100.0 % 0.87 [ 0.78, 0.98 ]
Total events: 60 (Experimental), 66 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 21.2. Comparison 21 IV morphine versus IV pethidine, Outcome 2 Further dose of study analgesia
required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV morphine versus IV pethidine
Outcome: 2 Further dose of study analgesia required
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Campbell 1961 38/72 11/71 100.0 % 3.41 [ 1.90, 6.12 ]
Total (95% CI) 72 71 100.0 % 3.41 [ 1.90, 6.12 ]
Total events: 38 (Experimental), 11 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 4.10 (P = 0.000041)
Test for subgroup differences: Not applicable
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Analysis 21.3. Comparison 21 IV morphine versus IV pethidine, Outcome 3 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV morphine versus IV pethidine
Outcome: 3 Nausea and vomiting
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Olofsson 1996 1/10 6/10 100.0 % 0.17 [ 0.02, 1.14 ]
Subtotal (95% CI) 10 10 100.0 % 0.17 [ 0.02, 1.14 ]
Total events: 1 (Experimental), 6 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.068)
2 Vomiting
Olofsson 1996 1/10 4/10 100.0 % 0.25 [ 0.03, 1.86 ]
Subtotal (95% CI) 10 10 100.0 % 0.25 [ 0.03, 1.86 ]
Total events: 1 (Experimental), 4 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
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Analysis 21.4. Comparison 21 IV morphine versus IV pethidine, Outcome 4 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV morphine versus IV pethidine
Outcome: 4 Caesarean section
Study or subgroup Experimental Pethidine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olofsson 1996 0/10 0/10 0.0 [ 0.0, 0.0 ]
Total (95% CI) 10 10 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 22.1. Comparison 22 IV nisentil versus IV pethidine, Outcome 1 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 22 IV nisentil versus IV pethidine
Outcome: 1 Nausea and vomiting
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Gillam 1958 10/185 16/210 100.0 % 0.71 [ 0.33, 1.52 ]
Subtotal (95% CI) 185 210 100.0 % 0.71 [ 0.33, 1.52 ]
Total events: 10 (Experimental), 16 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
2 Vomiting
Gillam 1958 (1) 15/185 45/210 100.0 % 0.38 [ 0.22, 0.66 ]
Subtotal (95% CI) 185 210 100.0 % 0.38 [ 0.22, 0.66 ]
Total events: 15 (Experimental), 45 (Pethidine)
(1) Both groups also received scopolamine
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Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00053)
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(1) Both groups also received scopolamine
Analysis 22.2. Comparison 22 IV nisentil versus IV pethidine, Outcome 2 Babies requiring
resuscitation/ventilatory support.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 22 IV nisentil versus IV pethidine
Outcome: 2 Babies requiring resuscitation/ventilatory support
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gillam 1958 14/185 8/210 100.0 % 1.99 [ 0.85, 4.63 ]
Total (95% CI) 185 210 100.0 % 1.99 [ 0.85, 4.63 ]
Total events: 14 (Experimental), 8 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 23.1. Comparison 23 IV fentanyl versus IV butorphanol, Outcome 1 Additional analgesia required
(women requesting two or more doses).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV fentanyl versus IV butorphanol
Outcome: 1 Additional analgesia required (women requesting two or more doses)
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 39/50 28/50 100.0 % 1.39 [ 1.05, 1.85 ]
Total (95% CI) 50 50 100.0 % 1.39 [ 1.05, 1.85 ]
Total events: 39 (Fentanyl), 28 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 23.2. Comparison 23 IV fentanyl versus IV butorphanol, Outcome 2 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV fentanyl versus IV butorphanol
Outcome: 2 Epidural
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 18/50 9/50 100.0 % 2.00 [ 1.00, 4.02 ]
Total (95% CI) 50 50 100.0 % 2.00 [ 1.00, 4.02 ]
Total events: 18 (Fentanyl), 9 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
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Analysis 23.3. Comparison 23 IV fentanyl versus IV butorphanol, Outcome 3 Matenal drowsiness (required
tactile rousing).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV fentanyl versus IV butorphanol
Outcome: 3 Matenal drowsiness (required tactile rousing)
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 6/50 2/50 100.0 % 3.00 [ 0.64, 14.16 ]
Total (95% CI) 50 50 100.0 % 3.00 [ 0.64, 14.16 ]
Total events: 6 (Fentanyl), 2 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 23.4. Comparison 23 IV fentanyl versus IV butorphanol, Outcome 4 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV fentanyl versus IV butorphanol
Outcome: 4 Caesarean section
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 4/50 5/50 100.0 % 0.80 [ 0.23, 2.81 ]
Total (95% CI) 50 50 100.0 % 0.80 [ 0.23, 2.81 ]
Total events: 4 (Fentanyl), 5 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 23.5. Comparison 23 IV fentanyl versus IV butorphanol, Outcome 5 Apgar score < 7 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV fentanyl versus IV butorphanol
Outcome: 5 Apgar score < 7 at 5 minutes
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 6/50 5/50 100.0 % 1.20 [ 0.39, 3.68 ]
Total (95% CI) 50 50 100.0 % 1.20 [ 0.39, 3.68 ]
Total events: 6 (Fentanyl), 5 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 23.6. Comparison 23 IV fentanyl versus IV butorphanol, Outcome 6 Babies requiring ventilatory
support.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV fentanyl versus IV butorphanol
Outcome: 6 Babies requiring ventilatory support
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 5/50 0/50 100.0 % 11.00 [ 0.62, 193.80 ]
Total (95% CI) 50 50 100.0 % 11.00 [ 0.62, 193.80 ]
Total events: 5 (Fentanyl), 0 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 23.7. Comparison 23 IV fentanyl versus IV butorphanol, Outcome 7 Naloxone required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV fentanyl versus IV butorphanol
Outcome: 7 Naloxone required
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 14/50 8/50 100.0 % 1.75 [ 0.81, 3.80 ]
Total (95% CI) 50 50 100.0 % 1.75 [ 0.81, 3.80 ]
Total events: 14 (Fentanyl), 8 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 23.8. Comparison 23 IV fentanyl versus IV butorphanol, Outcome 8 Neurobehavioural score at 2-4
hours.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV fentanyl versus IV butorphanol
Outcome: 8 Neurobehavioural score at 2-4 hours
Study or subgroup Fentanyl Butorphanol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Atkinson 1994 50 28.4 (3.7) 50 28.4 (4.5) 100.0 % 0.0 [ -1.61, 1.61 ]
Total (95% CI) 50 50 100.0 % 0.0 [ -1.61, 1.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 23.9. Comparison 23 IV fentanyl versus IV butorphanol, Outcome 9 Neurobehavioural score at 24-
36 hours.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV fentanyl versus IV butorphanol
Outcome: 9 Neurobehavioural score at 24-36 hours
Study or subgroup Fentanyl Butorphanol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Atkinson 1994 50 31.7 (2.9) 50 32.2 (2.8) 100.0 % -0.50 [ -1.62, 0.62 ]
Total (95% CI) 50 50 100.0 % -0.50 [ -1.62, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 24.1. Comparison 24 PCA pentazocine versus PCA pethidine, Outcome 1 Pain score in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 PCA pentazocine versus PCA pethidine
Outcome: 1 Pain score in labour
Study or subgroup Experimental Pethidine
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Erskine 1985 (1) 11 4.2 (1.98) 12 5.65 (1.68) 100.0 % -0.76 [ -1.62, 0.09 ]
Total (95% CI) 11 12 100.0 % -0.76 [ -1.62, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Not applicable
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Analysis 24.2. Comparison 24 PCA pentazocine versus PCA pethidine, Outcome 2 Pain relief rated as good
one day after birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 PCA pentazocine versus PCA pethidine
Outcome: 2 Pain relief rated as good one day after birth
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 9/14 11/14 100.0 % 0.82 [ 0.51, 1.32 ]
Total (95% CI) 14 14 100.0 % 0.82 [ 0.51, 1.32 ]
Total events: 9 (Experimental), 11 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Favours pethidine Favours experimental
Analysis 24.3. Comparison 24 PCA pentazocine versus PCA pethidine, Outcome 3 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 PCA pentazocine versus PCA pethidine
Outcome: 3 Epidural
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 3/14 2/14 100.0 % 1.50 [ 0.29, 7.65 ]
Total (95% CI) 14 14 100.0 % 1.50 [ 0.29, 7.65 ]
Total events: 3 (Experimental), 2 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 24.4. Comparison 24 PCA pentazocine versus PCA pethidine, Outcome 4 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 PCA pentazocine versus PCA pethidine
Outcome: 4 Nausea and vomiting
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 0/14 5/15 100.0 % 0.10 [ 0.01, 1.61 ]
Total (95% CI) 14 15 100.0 % 0.10 [ 0.01, 1.61 ]
Total events: 0 (Experimental), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 24.5. Comparison 24 PCA pentazocine versus PCA pethidine, Outcome 5 Sedation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 PCA pentazocine versus PCA pethidine
Outcome: 5 Sedation
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 0/14 2/15 100.0 % 0.21 [ 0.01, 4.09 ]
Total (95% CI) 14 15 100.0 % 0.21 [ 0.01, 4.09 ]
Total events: 0 (Experimental), 2 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 24.6. Comparison 24 PCA pentazocine versus PCA pethidine, Outcome 6 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 PCA pentazocine versus PCA pethidine
Outcome: 6 Caesarean section
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 0/14 1/15 100.0 % 0.36 [ 0.02, 8.07 ]
Total (95% CI) 14 15 100.0 % 0.36 [ 0.02, 8.07 ]
Total events: 0 (Experimental), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 24.7. Comparison 24 PCA pentazocine versus PCA pethidine, Outcome 7 Apgar score < 7 at 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 PCA pentazocine versus PCA pethidine
Outcome: 7 Apgar score < 7 at 5 minutes
Study or subgroup Experimental Pethidine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 0/14 0/15 0.0 [ 0.0, 0.0 ]
Total (95% CI) 14 15 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 24.8. Comparison 24 PCA pentazocine versus PCA pethidine, Outcome 8 Breastfeeding at
discharge.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 PCA pentazocine versus PCA pethidine
Outcome: 8 Breastfeeding at discharge
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 11/11 12/12 100.0 % 1.00 [ 0.85, 1.17 ]
Total (95% CI) 11 12 100.0 % 1.00 [ 0.85, 1.17 ]
Total events: 11 (Experimental), 12 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 25.1. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 1 Pain score in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 1 Pain score in labour
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Douma 2010 52 4.56 (2.4) 53 6.61 (2.3) 68.8 % -2.05 [ -2.95, -1.15 ]
Volikas 2001 9 28 (28) 8 51 (25) 31.2 % -23.00 [ -48.19, 2.19 ]
Total (95% CI) 61 61 100.0 % -8.59 [ -27.61, 10.44 ]
Heterogeneity: Tau2 = 136.73; Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 25.2. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 2 Women receiving other
analgesia (Entonox).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 2 Women receiving other analgesia (Entonox)
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blair 2005 18/20 19/19 79.0 % 0.90 [ 0.76, 1.07 ]
Volikas 2001 4/9 5/8 21.0 % 0.71 [ 0.29, 1.76 ]
Total (95% CI) 29 27 100.0 % 0.86 [ 0.69, 1.08 ]
Total events: 22 (Experimental), 24 (Pethidine)
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 25.3. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 3 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 3 Epidural
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 7/52 18/53 94.4 % 0.40 [ 0.18, 0.87 ]
Volikas 2001 1/9 1/8 5.6 % 0.89 [ 0.07, 12.00 ]
Total (95% CI) 61 61 100.0 % 0.42 [ 0.20, 0.89 ]
Total events: 8 (Remifentanil), 19 (Pethidine)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.024)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 25.4. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 4 Maternal sleepiness
during labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 4 Maternal sleepiness during labour
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 52 1.85 (0.8) 53 1.45 (0.5) 100.0 % 0.40 [ 0.14, 0.66 ]
Total (95% CI) 52 53 100.0 % 0.40 [ 0.14, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0022)
Test for subgroup differences: Not applicable
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Analysis 25.5. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 5 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 5 Nausea and vomiting
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 20/51 23/51 97.8 % 0.87 [ 0.55, 1.37 ]
Volikas 2001 (1) 2/9 0/8 2.2 % 4.50 [ 0.25, 81.76 ]
Total (95% CI) 60 59 100.0 % 0.95 [ 0.61, 1.49 ]
Total events: 22 (Remifentanil), 23 (Pethidine)
Heterogeneity: Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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(1) Anti-emetic required
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Analysis 25.6. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 6 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 6 Assisted vaginal birth
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 10/45 8/35 81.0 % 0.97 [ 0.43, 2.20 ]
Volikas 2001 2/9 2/8 19.0 % 0.89 [ 0.16, 4.93 ]
Total (95% CI) 54 43 100.0 % 0.96 [ 0.46, 2.00 ]
Total events: 12 (Remifentanil), 10 (Pethidine)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 25.7. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 7 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 7 Caesarean section
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 7/45 3/35 76.1 % 1.81 [ 0.51, 6.52 ]
Volikas 2001 2/9 1/8 23.9 % 1.78 [ 0.20, 16.10 ]
Total (95% CI) 54 43 100.0 % 1.81 [ 0.60, 5.46 ]
Total events: 9 (Remifentanil), 4 (Pethidine)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 25.8. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 8 Apgar score < 7 at 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 8 Apgar score < 7 at 5 minutes
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Volikas 2001 0/9 3/8 100.0 % 0.13 [ 0.01, 2.16 ]
Total (95% CI) 9 8 100.0 % 0.13 [ 0.01, 2.16 ]
Total events: 0 (Experimental), 3 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 25.9. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 9 Naloxone administered.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 9 Naloxone administered
Study or subgroup Experimental Pethidine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blair 2005 0/20 0/19 0.0 [ 0.0, 0.0 ]
Volikas 2001 0/9 1/8 0.30 [ 0.01, 6.47 ]
Total (95% CI) 29 27 0.30 [ 0.01, 6.47 ]
Total events: 0 (Experimental), 1 (Pethidine)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 25.10. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 10 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 10 Admission to NICU
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Volikas 2001 0/9 1/8 100.0 % 0.30 [ 0.01, 6.47 ]
Total (95% CI) 9 8 100.0 % 0.30 [ 0.01, 6.47 ]
Total events: 0 (Experimental), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 25.11. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 11 Satisfaction with
childbirth experience.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 11 Satisfaction with childbirth experience
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 38 8.1 (1.1) 30 7 (1.5) 100.0 % 1.10 [ 0.46, 1.74 ]
Total (95% CI) 38 30 100.0 % 1.10 [ 0.46, 1.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.37 (P = 0.00076)
Test for subgroup differences: Not applicable
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Analysis 25.12. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 12 Neurobehavioural
score (15 minutes post delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 12 Neurobehavioural score (15 minutes post delivery)
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 31 37 (2.2) 25 36.8 (2.1) 100.0 % 0.20 [ -0.93, 1.33 ]
Total (95% CI) 31 25 100.0 % 0.20 [ -0.93, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 25.13. Comparison 25 PCA remifentanil versus PCA pethidine, Outcome 13 Neurobehavioural
score (2 hours post delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 PCA remifentanil versus PCA pethidine
Outcome: 13 Neurobehavioural score (2 hours post delivery)
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 30 37.8 (2) 26 37.2 (2.7) 100.0 % 0.60 [ -0.66, 1.86 ]
Total (95% CI) 30 26 100.0 % 0.60 [ -0.66, 1.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 26.1. Comparison 26 PCA nalbuphine versus PCA pethidine, Outcome 1 Pain relief in labour
measured in the postnatal period (rated good or excellent).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 26 PCA nalbuphine versus PCA pethidine
Outcome: 1 Pain relief in labour measured in the postnatal period (rated good or excellent)
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 22/30 17/30 100.0 % 1.29 [ 0.88, 1.89 ]
Total (95% CI) 30 30 100.0 % 1.29 [ 0.88, 1.89 ]
Total events: 22 (Experimental), 17 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 26.2. Comparison 26 PCA nalbuphine versus PCA pethidine, Outcome 2 Would use the same pain
relief again.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 26 PCA nalbuphine versus PCA pethidine
Outcome: 2 Would use the same pain relief again
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 23/30 21/29 100.0 % 1.06 [ 0.79, 1.43 ]
Total (95% CI) 30 29 100.0 % 1.06 [ 0.79, 1.43 ]
Total events: 23 (Experimental), 21 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 26.3. Comparison 26 PCA nalbuphine versus PCA pethidine, Outcome 3 Pain score in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 26 PCA nalbuphine versus PCA pethidine
Outcome: 3 Pain score in labour
Study or subgroup Experimental Pethidine
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frank 1987 (1) 30 2.1 (0.774) 30 2.5 (0.774) 100.0 % -0.51 [ -1.02, 0.00 ]
Total (95% CI) 30 30 100.0 % -0.51 [ -1.02, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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(1) SD estimated from P value 0.05
Analysis 26.4. Comparison 26 PCA nalbuphine versus PCA pethidine, Outcome 4 Women receiving other
analgesia (Entonox).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 26 PCA nalbuphine versus PCA pethidine
Outcome: 4 Women receiving other analgesia (Entonox)
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 12/30 14/29 100.0 % 0.83 [ 0.46, 1.48 ]
Total (95% CI) 30 29 100.0 % 0.83 [ 0.46, 1.48 ]
Total events: 12 (Experimental), 14 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 26.5. Comparison 26 PCA nalbuphine versus PCA pethidine, Outcome 5 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 26 PCA nalbuphine versus PCA pethidine
Outcome: 5 Nausea and vomiting
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 7/30 10/29 100.0 % 0.68 [ 0.30, 1.54 ]
Total (95% CI) 30 29 100.0 % 0.68 [ 0.30, 1.54 ]
Total events: 7 (Experimental), 10 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 26.6. Comparison 26 PCA nalbuphine versus PCA pethidine, Outcome 6 Apgar score < 7 at 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 26 PCA nalbuphine versus PCA pethidine
Outcome: 6 Apgar score < 7 at 5 minutes
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 (1) 0/18 1/23 100.0 % 0.42 [ 0.02, 9.76 ]
Total (95% CI) 18 23 100.0 % 0.42 [ 0.02, 9.76 ]
Total events: 0 (Experimental), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours pethidine
(1) Those babies delivered within 4 hrs of medication only
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Analysis 27.1. Comparison 27 PCA fentanyl versus PCA alfentanil, Outcome 1 Pain relief described as
adequate (recorded after delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 PCA fentanyl versus PCA alfentanil
Outcome: 1 Pain relief described as adequate (recorded after delivery)
Study or subgroup Fentanyl Alfentanil Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morley-Forster 2000 10/11 7/12 100.0 % 1.56 [ 0.93, 2.60 ]
Total (95% CI) 11 12 100.0 % 1.56 [ 0.93, 2.60 ]
Total events: 10 (Fentanyl), 7 (Alfentanil)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.090)
Test for subgroup differences: Not applicable
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Analysis 27.2. Comparison 27 PCA fentanyl versus PCA alfentanil, Outcome 2 Pain score at 4-6 cm cervical
dilatation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 PCA fentanyl versus PCA alfentanil
Outcome: 2 Pain score at 4-6 cm cervical dilatation
Study or subgroup Fentanyl Alfentanil
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Morley-Forster 2000 11 54.9 (24.9) 10 67.7 (20.2) 100.0 % -12.80 [ -32.12, 6.52 ]
Total (95% CI) 11 10 100.0 % -12.80 [ -32.12, 6.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 27.3. Comparison 27 PCA fentanyl versus PCA alfentanil, Outcome 3 Nausea.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 PCA fentanyl versus PCA alfentanil
Outcome: 3 Nausea
Study or subgroup Fentanyl Alfentanil Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morley-Forster 2000 5/11 2/12 100.0 % 2.73 [ 0.66, 11.30 ]
Total (95% CI) 11 12 100.0 % 2.73 [ 0.66, 11.30 ]
Total events: 5 (Fentanyl), 2 (Alfentanil)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 27.4. Comparison 27 PCA fentanyl versus PCA alfentanil, Outcome 4 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 PCA fentanyl versus PCA alfentanil
Outcome: 4 Caesarean section
Study or subgroup Fentanyl Alfentanil Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morley-Forster 2000 3/11 2/12 100.0 % 1.64 [ 0.33, 8.03 ]
Total (95% CI) 11 12 100.0 % 1.64 [ 0.33, 8.03 ]
Total events: 3 (Fentanyl), 2 (Alfentanil)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 27.5. Comparison 27 PCA fentanyl versus PCA alfentanil, Outcome 5 Naloxone required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 PCA fentanyl versus PCA alfentanil
Outcome: 5 Naloxone required
Study or subgroup Fentanyl Alfentanil Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morley-Forster 2000 4/11 2/13 100.0 % 2.36 [ 0.53, 10.55 ]
Total (95% CI) 11 13 100.0 % 2.36 [ 0.53, 10.55 ]
Total events: 4 (Fentanyl), 2 (Alfentanil)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 28.1. Comparison 28 PCA fentanyl versus PCA pethidine, Outcome 1 Pain score in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA fentanyl versus PCA pethidine
Outcome: 1 Pain score in labour
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 54 5.96 (2.5) 53 6.61 (2.3) 100.0 % -0.65 [ -1.56, 0.26 ]
Total (95% CI) 54 53 100.0 % -0.65 [ -1.56, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 28.2. Comparison 28 PCA fentanyl versus PCA pethidine, Outcome 2 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA fentanyl versus PCA pethidine
Outcome: 2 Epidural
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 8/54 18/53 100.0 % 0.44 [ 0.21, 0.92 ]
Total (95% CI) 54 53 100.0 % 0.44 [ 0.21, 0.92 ]
Total events: 8 (Fentanyl), 18 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 28.3. Comparison 28 PCA fentanyl versus PCA pethidine, Outcome 3 Maternal sleepiness during
labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA fentanyl versus PCA pethidine
Outcome: 3 Maternal sleepiness during labour
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 54 1.39 (0.5) 53 1.45 (0.5) 100.0 % -0.06 [ -0.25, 0.13 ]
Total (95% CI) 54 53 100.0 % -0.06 [ -0.25, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 28.4. Comparison 28 PCA fentanyl versus PCA pethidine, Outcome 4 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA fentanyl versus PCA pethidine
Outcome: 4 Nausea and vomiting
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 20/51 23/51 100.0 % 0.87 [ 0.55, 1.37 ]
Total (95% CI) 51 51 100.0 % 0.87 [ 0.55, 1.37 ]
Total events: 20 (Fentanyl), 23 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 28.5. Comparison 28 PCA fentanyl versus PCA pethidine, Outcome 5 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA fentanyl versus PCA pethidine
Outcome: 5 Assisted vaginal birth
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 6/46 8/35 100.0 % 0.57 [ 0.22, 1.49 ]
Total (95% CI) 46 35 100.0 % 0.57 [ 0.22, 1.49 ]
Total events: 6 (Fentanyl), 8 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 28.6. Comparison 28 PCA fentanyl versus PCA pethidine, Outcome 6 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA fentanyl versus PCA pethidine
Outcome: 6 Caesarean section
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 1/46 3/35 100.0 % 0.25 [ 0.03, 2.34 ]
Total (95% CI) 46 35 100.0 % 0.25 [ 0.03, 2.34 ]
Total events: 1 (Fentanyl), 3 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 28.7. Comparison 28 PCA fentanyl versus PCA pethidine, Outcome 7 Neurobehavioural score (15
minutes post delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA fentanyl versus PCA pethidine
Outcome: 7 Neurobehavioural score (15 minutes post delivery)
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 38 35.9 (3.6) 25 36.8 (2.1) 100.0 % -0.90 [ -2.31, 0.51 ]
Total (95% CI) 38 25 100.0 % -0.90 [ -2.31, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 28.8. Comparison 28 PCA fentanyl versus PCA pethidine, Outcome 8 Neurobehavioural score (2
hours post delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA fentanyl versus PCA pethidine
Outcome: 8 Neurobehavioural score (2 hours post delivery)
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 38 36.7 (3.2) 26 37.2 (2.7) 100.0 % -0.50 [ -1.95, 0.95 ]
Total (95% CI) 38 26 100.0 % -0.50 [ -1.95, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 29.1. Comparison 29 Opioids versus TENS, Outcome 1 Maternal satisfaction with analgesia
measured post delivery (rated as good).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 Opioids versus TENS
Outcome: 1 Maternal satisfaction with analgesia measured post delivery (rated as good)
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Neumark 1978 2/5 2/9 7.2 % 1.80 [ 0.35, 9.16 ]
Tawfik 1982 28/55 15/35 92.8 % 1.19 [ 0.75, 1.89 ]
Total (95% CI) 60 44 100.0 % 1.23 [ 0.79, 1.92 ]
Total events: 30 (Opioids), 17 (TENS)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 29.2. Comparison 29 Opioids versus TENS, Outcome 2 Maternal pain score measured during
labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 Opioids versus TENS
Outcome: 2 Maternal pain score measured during labour
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tawfik 1982 38/55 17/35 38.5 % 1.42 [ 0.97, 2.09 ]
Thakur 2004 70/100 70/100 61.5 % 1.00 [ 0.83, 1.20 ]
Total (95% CI) 155 135 100.0 % 1.15 [ 0.81, 1.61 ]
Total events: 108 (Opioids), 87 (TENS)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.76, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 29.3. Comparison 29 Opioids versus TENS, Outcome 3 Drowsiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 Opioids versus TENS
Outcome: 3 Drowsiness
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tawfik 1982 9/55 0/35 54.9 % 12.21 [ 0.73, 203.45 ]
Thakur 2004 2/100 0/100 45.1 % 5.00 [ 0.24, 102.85 ]
Total (95% CI) 155 135 100.0 % 8.96 [ 1.13, 71.07 ]
Total events: 11 (Opioids), 0 (TENS)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
Test for subgroup differences: Not applicable
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Analysis 29.4. Comparison 29 Opioids versus TENS, Outcome 4 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 Opioids versus TENS
Outcome: 4 Nausea and vomiting
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tawfik 1982 6/55 0/35 54.9 % 8.36 [ 0.49, 143.87 ]
Thakur 2004 10/100 0/100 45.1 % 21.00 [ 1.25, 353.58 ]
Total (95% CI) 155 135 100.0 % 14.06 [ 1.96, 100.61 ]
Total events: 16 (Opioids), 0 (TENS)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0085)
Test for subgroup differences: Not applicable
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Analysis 29.5. Comparison 29 Opioids versus TENS, Outcome 5 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 Opioids versus TENS
Outcome: 5 Caesarean section
Study or subgroup Opioids TENS Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thakur 2004 0/100 0/100 0.0 [ 0.0, 0.0 ]
Total (95% CI) 100 100 0.0 [ 0.0, 0.0 ]
Total events: 0 (Opioids), 0 (TENS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 29.6. Comparison 29 Opioids versus TENS, Outcome 6 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 Opioids versus TENS
Outcome: 6 Assisted vaginal birth
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thakur 2004 2/100 0/100 100.0 % 5.00 [ 0.24, 102.85 ]
Total (95% CI) 100 100 100.0 % 5.00 [ 0.24, 102.85 ]
Total events: 2 (Opioids), 0 (TENS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 29.7. Comparison 29 Opioids versus TENS, Outcome 7 Fetal distress.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 Opioids versus TENS
Outcome: 7 Fetal distress
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thakur 2004 2/100 0/100 100.0 % 5.00 [ 0.24, 102.85 ]
Total (95% CI) 100 100 100.0 % 5.00 [ 0.24, 102.85 ]
Total events: 2 (Opioids), 0 (TENS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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WH A T ’ S N E W
Last assessed as up-to-date: 6 July 2011.
Date Event Description
21 June 2011 New search has been performed Search updated. We have included data from three new studies (Douma 2010;
Tawfik 1982; Thakur 2004). These changes have not altered the conclusions of
the review
New outcome added - see Differences between protocol and review.
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 9, 2010
C O N T R I B U T I O N S O F A U T H O R S
Roz Ullman and Therese Dowswell drafted the protocol. Roz Ullman, Lesley Smith, Ethel Burns and Therese Dowswell assessed studies
for eligibility, carried out data extraction and analysis, and drafted the text of the review. Rintaro Mori carried out data extraction and
commented on drafts.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• (TD) The University of Liverpool, UK.
External sources
• (TD) National Institute for Health Research, UK.
NIHR NHS Cochrane Collaboration Programme Grant Scheme award for NHS-prioritised centrally-managed, pregnancy and
childbirth systematic reviews:CPGS02
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The Background section of the review has been updated and amended since publication of the protocol. Two new review authors that
joined the team at the review stage (L Smith and E Burns) considered that it was important to make these amendments.
The focus of some of the reports we identified using the search strategy was on the route of administration, rather than on the
effectiveness of opioids compared with placebo or other opioids. That is, in several trials, women in both arms received the same opioid
and the same dose but the drug was given by a different route (e.g. intravenous (staff administered) versus patient-controlled analgesia,
or intramuscular versus intravenous). Although in the original protocol we had specified that we would examine different routes, in
retrospect we thought that including such comparisons would add several more potentially large sections to the review (each report
requiring a different comparison) and would throw little light on the main review questions: whether opioids are effective for pain relief
in labour without causing unpleasant side effects or harm to mothers and babies. Studies focusing on route of administration will be
examined in the future in a separate, related Cochrane review.
This review is one of a series of reviews to be included in an overview of reviews examining methods of pain management in labour (in
development). It has been updated to follow the generic protocol developed in 2011 for reviews contributing to the overview (Jones
2011a), as a result of which we have added a new comparison (opioids versus TENS).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Analgesia,Obstetrical [∗methods]; Analgesics,Opioid [∗administration&dosage; adverse effects]; Injections, Intramuscular; Injections,
Intravenous; Labor Pain [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
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